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A B S T R A C T
Background
Electronic cigarettes (ECs) are handheld electronic vaping devices which produce an aerosol formed by heating an e-liquid. Some people
who smoke use ECs to stop or reduce smoking, but some organizations, advocacy groups and policymakers have discouraged this, citing
lack of evidence of eIicacy and safety. People who smoke, healthcare providers and regulators want to know if ECs can help people quit
and if they are safe to use for this purpose. This is an update of a review first published in 2014.
Objectives
To examine the eIectiveness, tolerability, and safety of using electronic cigarettes (ECs) to help people who smoke achieve long-term
smoking abstinence.
Search methods
We searched the Cochrane Tobacco Addiction Group's Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, Embase, and PsycINFO to 1 February 2021, together with reference-checking and contact with study authors.
Selection criteria
We included randomized controlled trials (RCTs) and randomized cross-over trials in which people who smoke were randomized to an
EC or control condition. We also included uncontrolled intervention studies in which all participants received an EC intervention. To be
included, studies had to report abstinence from cigarettes at six months or longer and/or data on adverse events (AEs) or other markers
of safety at one week or longer.
Data collection and analysis
We followed standard Cochrane methods for screening and data extraction. Our primary outcome measures were abstinence from smoking
aOer at least six months follow-up, adverse events (AEs), and serious adverse events (SAEs). Secondary outcomes included changes in
carbon monoxide, blood pressure, heart rate, blood oxygen saturation, lung function, and levels of known carcinogens/toxicants. We used
a fixed-eIect Mantel-Haenszel model to calculate the risk ratio (RR) with a 95% confidence interval (CI) for dichotomous outcomes. For
continuous outcomes, we calculated mean diIerences. Where appropriate, we pooled data from these studies in meta-analyses.
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Main results
We included 56 completed studies, representing 12,804 participants, of which 29 were RCTs. Six of the 56 included studies were new to this
review update. Of the included studies, we rated five (all contributing to our main comparisons) at low risk of bias overall, 41 at high risk
overall (including the 25 non-randomized studies), and the remainder at unclear risk.
There was moderate-certainty evidence, limited by imprecision, that quit rates were higher in people randomized to nicotine EC than in
those randomized to nicotine replacement therapy (NRT) (risk ratio (RR) 1.69, 95% confidence interval (CI) 1.25 to 2.27; I2 = 0%; 3 studies,
1498 participants). In absolute terms, this might translate to an additional four successful quitters per 100 (95% CI 2 to 8). There was low-
certainty evidence (limited by very serious imprecision) that the rate of occurrence of AEs was similar) (RR 0.98, 95% CI 0.80 to 1.19; I2 = 0%;
2 studies, 485 participants). SAEs occurred rarely, with no evidence that their frequency diIered between nicotine EC and NRT, but very
serious imprecision led to low certainty in this finding (RR 1.37, 95% CI 0.77 to 2.41: I2 = n/a; 2 studies, 727 participants).
There was moderate-certainty evidence, again limited by imprecision, that quit rates were higher in people randomized to nicotine EC
than to non-nicotine EC (RR 1.70, 95% CI 1.03 to 2.81; I2 = 0%; 4 studies, 1057 participants). In absolute terms, this might again lead to an
additional four successful quitters per 100 (95% CI 0 to 11). These trials mainly used older EC with relatively low nicotine delivery. There was
moderate-certainty evidence of no diIerence in the rate of AEs between these groups (RR 1.01, 95% CI 0.91 to 1.11; I2 = 0%; 3 studies, 601
participants). There was insuIicient evidence to determine whether rates of SAEs diIered between groups, due to very serious imprecision
(RR 0.60, 95% CI 0.15 to 2.44; I2 = n/a; 4 studies, 494 participants).
Compared to behavioral support only/no support, quit rates were higher for participants randomized to nicotine EC (RR 2.70, 95% CI 1.39
to 5.26; I2 = 0%; 5 studies, 2561 participants). In absolute terms this represents an increase of seven per 100 (95% CI 2 to 17). However, this
finding was of very low certainty, due to issues with imprecision and risk of bias. There was no evidence that the rate of SAEs diIered, but
some evidence that non-serious AEs were more common in people randomized to nicotine EC (AEs: RR 1.22, 95% CI 1.12 to 1.32; I2 = 41%,
low certainty; 4 studies, 765 participants; SAEs: RR 1.17, 95% CI 0.33 to 4.09; I2 = 5%; 6 studies, 1011 participants, very low certainty).
Data from non-randomized studies were consistent with RCT data. The most commonly reported AEs were throat/mouth irritation,
headache, cough, and nausea, which tended to dissipate with continued use. Very few studies reported data on other outcomes or
comparisons and hence evidence for these is limited, with confidence intervals oOen encompassing clinically significant harm and benefit.
Authors' conclusions
There is moderate-certainty evidence that ECs with nicotine increase quit rates compared to ECs without nicotine and compared to NRT.
Evidence comparing nicotine EC with usual care/no treatment also suggests benefit, but is less certain. More studies are needed to confirm
the size of eIect, particularly when using modern EC products. Confidence intervals were for the most part wide for data on AEs, SAEs and
other safety markers, though evidence indicated no diIerence in AEs between nicotine and non-nicotine ECs. Overall incidence of SAEs
was low across all study arms. We did not detect any clear evidence of harm from nicotine EC, but longest follow-up was two years and
the overall number of studies was small.
The evidence is limited mainly by imprecision due to the small number of RCTs, oOen with low event rates. Further RCTs are underway.
To ensure the review continues to provide up-to-date information, this review is now a living systematic review. We run searches monthly,
with the review updated when relevant new evidence becomes available. Please refer to the Cochrane Database of Systematic Reviews for
the review's current status.
P L A I N   L A N G U A G E   S U M M A R Y
Can electronic cigarettes help people stop smoking, and do they have any unwanted e5ects when used for this purpose?
What are electronic cigarettes?
Electronic cigarettes (e-cigarettes) are handheld devices that work by heating a liquid that usually contains nicotine and flavorings. E-
cigarettes allow you to inhale nicotine in a vapor rather than smoke. Because they do not burn tobacco, e-cigarettes do not expose users
to the same levels of toxins that we know can cause smoking-related diseases in people who use conventional cigarettes.
Using an e-cigarette is known as 'vaping'. Many people use e-cigarettes to help them to stop smoking tobacco.
Why we did this Cochrane Review
Stopping smoking lowers your risk of getting lung cancer and other diseases. Many people find it diIicult to quit. We wanted to find out if
using e-cigarettes could help people to stop smoking, and if people using them for this purpose experienced any unwanted eIects.
What did we do?
We searched for studies that looked at the use of e-cigarettes to help people stop smoking.
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We looked for randomized controlled trials, in which the treatments people received were decided at random. This type of study usually
gives the most reliable evidence about the eIects of a treatment. We also looked for studies in which everyone received an e-cigarette
treatment.
We were interested in finding out:
· how many people stopped smoking for at least six months; and
· how many people had unwanted eIects, reported on for at least one week.
Search date: We included evidence published up to 1st February 2021.
What we found
We found 56 studies in 12,804 adults who smoked. The studies compared e-cigarettes with:
· nicotine replacement therapy, such as patches or gum;
· varenicline (a medicine to help people stop smoking);
· nicotine-free e-cigarettes;
· behavioral support, such as advice or counseling; or
· no support, for stopping smoking.
Most studies took place in the USA (24 studies), the UK (9), and Italy (7).
What are the results of our review?
More people probably stop smoking for at least six months using nicotine e-cigarettes than using nicotine replacement therapy (3 studies,
1498 people), or nicotine-free e-cigarettes (4 studies, 1057 people).
Nicotine e-cigarettes may help more people to stop smoking than no support or behavioral support only (5 studies, 2561 people).
For every 100 people using nicotine e-cigarettes to stop smoking, 10 or 11 might successfully stop, compared with only six of 100 people
using nicotine-replacement therapy or nicotine-free e-cigarettes, or four of 100 people having no support or behavioral support only.
We are uncertain if there is a diIerence between how many unwanted eIects occur using nicotine e-cigarettes compared with nicotine
replacement therapy, no support or behavioral support only.   There was some evidence that non-serious unwanted eIects were more
common in groups receiving nicotine e-cigarettes compared to no support  or behavioral support only. Similar low numbers of unwanted
eIects, including serious unwanted eIects, were reported for other comparisons. There is probably no diIerence in how many non-serious
unwanted eIects occur in people using nicotine e-cigarettes compared to non-nicotine e-cigarettes.
The unwanted eIects reported most oOen with nicotine e-cigarettes were throat or mouth irritation, headache, cough and feeling sick.
These eIects reduced over time as people continued using nicotine e-cigarettes.
How reliable are these results?
Our results are based on a small number of studies, and in some the measured data varied widely.
We are moderately confident that nicotine e-cigarettes help more people to stop smoking than nicotine replacement therapy or nicotine-
free e-cigarettes. However, these results might change if further evidence becomes available.
We are less confident about how nicotine e-cigarettes compare with no support, or behavioral support, to stop smoking.
Most of our results for the unwanted eIects are likely to change when more evidence becomes available.
Key messages
Nicotine e-cigarettes probably do help people to stop smoking for at least six months. They probably work better than nicotine replacement
therapy and nicotine-free e-cigarettes.
They may work better than no support, or behavioral support alone, and they may not be associated with serious unwanted eIects.
However, we need more, reliable evidence to be confident about the eIects of e-cigarettes, particularly the eIects of newer types of e-
cigarettes that have better nicotine delivery.
Electronic cigarettes for smoking cessation (Review)

































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Nicotine EC compared to NRT for smoking cessation
Nicotine EC compared to NRT for smoking cessation
Patient or population: People who smoke
Setting: New Zealand, UK, USA
Intervention: Nicotine EC
Comparison: NRT
Anticipated absolute effects* (95% CI)Outcomes










Study populationSmoking cessation at 6 months to 1 year









Study populationAdverse events at 4 weeks to 6 months









Study populationSerious adverse events at 4 weeks to 1 year











on the one study in
which events were
reported
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI). For cessation, the assumed risk in the control group is based on assumed quit rates for NRT assuming receipt of limited behavioral stop-smoking support (as
per Hartmann-Boyce 2018a). The assumed risk for adverse events and serious adverse events is a weighted mean average of quit rates across control groups in contributing
studies.
CI: Confidence interval; RCT: randomized controlled trial; RR: Risk ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different



























































































































Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
aDowngraded one level due to imprecision; small number of events (< 300 overall).
bDowngraded two levels due to imprecision; confidence intervals encompass clinically-important harm as well as clinically important benefit.
 
 
Summary of findings 2.   Nicotine EC compared to non-nicotine EC for smoking cessation
Nicotine EC compared to non-nicotine EC for smoking cessation
Patient or population: People who smoke cigarettes
Setting: Canada, Italy, New Zealand, UK, USA
Intervention: Nicotine EC
Comparison: Non-nicotine EC
Anticipated absolute effects* (95% CI)Outcomes
Risk with non-
nicotine EC










Study populationSmoking cessation at 6-12 months









Study populationAdverse events at 1 week to 6 months









Study populationSerious adverse events at 1 week to 1 year











the one study in
which events were
reported
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI). For cessation, the assumed risk in the control group is based on receipt of moderate-intensity behavioral stop-smoking support. The assumed risk for adverse
events and serious adverse events is a weighted mean average of quit rates across control groups in contributing studies.
CI: Confidence interval; RCT: randomized controlled trial; RR: Risk ratio



























































































































High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
aNot downgraded for risk of bias. One of three studies considered high risk of bias; removing this study increased the direction of the eIect in favor of the intervention.
bDowngraded one level due to imprecision; confidence intervals incorporate no clinically-significant diIerence as well as clinically-significant benefit.
cDowngraded one level due to imprecision: though confidence intervals are narrow, only 3 studies with 601 participants contribute data.
dDowngraded two levels due to imprecision: confidence intervals encompass clinically-significant harm as well as clinically-significant benefit.
 
 
Summary of findings 3.   Nicotine EC compared to behavioral support only/no support for smoking cessation
Nicotine EC compared to behavioral support only/no support for smoking cessation
Patient or population: People who smoke
Setting: Canada, Italy, UK, USA
Intervention: Nicotine EC
Comparison: Behavioral support only/no support














Study populationSmoking cessation at 6 to 12 months









Study populationAdverse events at 12 weeks to 6 months









Study populationSerious adverse events at 4 weeks to 6
months
Assessed via self-report and medical
records








































































































































*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI). For cessation, the assumed risk in the control group is based on receipt of limited stop-smoking support. The assumed risk for adverse events and serious ad-
verse events is a weighted mean average of quit rates across control groups in contributing studies.
CI: Confidence interval; RCT: randomized controlled trial; RR: Risk ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
aDowngraded two levels due to risk of bias. Due to lack of blinding and diIerential support between arms, judged to be at high risk of bias.
bDowngraded one level due to imprecision; although confidence intervals are consistent with clinically- important diIerence, event count is very low (< 100).
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B A C K G R O U N D
Throughout this review, we discuss (1) conventional cigarettes and;
(2) electronic cigarettes, defined as handheld electronic vaping
devices that produce aerosol for inhalation formed by heating an
e-liquid. In this review, all mention of smoking, smoking cessation,
cigarette use, smoke intake, etc. concern combustible tobacco
cigarettes. When the text concerns electronic cigarettes we use the
abbreviation 'ECs'. EC users are sometimes described as vapers,
and EC use as vaping. We refer to ECs that do not contain nicotine
as non-nicotine ECs; these can also be conceptualized as placebo
ECs, but we are using the term non-nicotine EC, as they can be
conceptualized as an intervention in themselves. This review does
not address the use of vaping devices to inhale substances other
than nicotine, such as cannabis.
Description of the condition
Stopping smoking is associated with large health benefits. Despite
most people who smoke wanting to quit, many find it diIicult
to succeed in the long term. Almost half who try to quit without
support will not manage to stop for even a week, and fewer than five
per cent remain abstinent at one year aOer quitting (Hughes 2004).
Behavioral support and medications such as nicotine patches or
gum increase the chances of quitting through providing nicotine to
help alleviate withdrawal symptoms, but even with this additional
support long-term quit rates remain low (Cahill 2016; Hartmann-
Boyce 2018b; Hartmann-Boyce 2019). One of the limitations of
current treatments is that, despite substituting nicotine delivery,
none adequately addresses the sensory, behavioral and social
aspects of smoking that ex-smokers miss when they stop smoking
(e.g. holding a cigarette in their hands, taking a puI, enjoyment of
smoking, feeling part of a group). ECs may oIer a way to overcome
this limitation (Notley 2018b).
There is no doubt that people become dependent on tobacco, and
find it diIicult to stop smoking, primarily because of nicotine and
its actions on the brain's reward system (Balfour 2004). However,
other factors also contribute to tobacco dependence (Benowitz
2010; Rose 2006). Sensory and behavioral cues provide additional
reinforcement of smoking behavior (Rose 1993; Rose 2000) and
over time become almost as rewarding as nicotine. There are
several lines of evidence to support this. Firstly, people who smoke
appear to have a preference for cigarette smoke compared to
other forms of nicotine delivery. This is partly related to the speed
of nicotine delivery through smoke inhalation. However, even
when nicotine is administered intravenously it does not provide
the same level of satisfaction or reward as smoking (Rose 2000;
Westman 1996). Secondly, the local sensory eIects of smoking
(e.g. the ‘scratch’ in the back of the throat) may be important for
enjoyment and reward. Numbing the sensations of cigarette smoke
by anaesthetizing the upper and lower respiratory tract leads to
less enjoyment of smoking (Rose 1985). Conversely, products that
mimic the sensory eIects of smoking on the mouth and throat
(such as citric acid, black pepper, and ascorbic acid) reduce craving
and some withdrawal symptoms, at least in the short term (Levin
1993; Rose 1994; Westman 1995).  Thirdly, very low nicotine content
cigarettes (VLNCs) which have a very low content of nicotine (e.g.
0.08 mg instead of the normal 1 mg) and so have negligible or no
central eIects, have also been investigated for their role in aiding
smoking cessation (Przulj 2013). Despite delivering low levels of
nicotine, VLNCs are satisfying over the initial few days of abstinence
from nicotine (Donny 2007; Donny 2015; Pickworth 1999; Rose
2000). They also reduce tobacco withdrawal symptoms, including
urges to smoke and low mood (Barrett 2010; Donny 2009; McRobbie
2016; Perkins 2010; Rose 2000), and have been shown to improve
long-term continuous abstinence rates in one study (Walker 2012).
Social aspects of smoking, such as feeling part of a like-minded
group, or including smoking behavior as part of one's social identity
are also key elements of cigarette smoking that people who smoke
report to be key aspects of cigarette dependence (Notley 2018a).
Considering the other factors that contribute to tobacco
dependence, there is interest in developing smoking-cessation
products that would not only help relieve the unpleasant eIects of
nicotine withdrawal but would also act as an eIective substitute for
smoking behavior and the rituals and sensations that accompany
smoking, without the health risks associated with the inhalation of
tobacco smoke. Until recently the only pharmaceutical treatments
available that had some of these characteristics were the nicotine
inhalator and nicotine oral spray. However, these do not have
greater cessation eIicacy than the other nicotine replacement
therapy (NRT) products (Hajek 1999; Hartmann-Boyce 2018a).
This may in part be due to the considerable eIort (e.g. 20
minutes of continuous puIing) needed to provide nicotine blood
concentrations consistent with other NRTs (Schneider 2001).
Adherence to correct use of the inhalator is low compared to other
NRTs (Hajek 1999). It is therefore possible that any advantage of
sensorimotor replacement is diminished by low nicotine delivery
and limited similarities between inhalator use and sensations of
smoking (Bullen 2010). A nicotine inhaler using pressurized air has
recently been approved as a smoking cessation aid in the UK. The
nicotine delivery is substantially lower than from cigarettes, and
also lower than from the nicotine inhalator (Romeu 2020).
Description of the intervention
ECs are electronic vaping devices that are handheld and produce
an aerosol formed by heating an e-liquid, designed for inhalation
by the user (E-cigarette ontology 2021). The e-liquid, usually
comprising propylene glycol and glycerol, with or without nicotine
and flavors, is stored in disposable or refillable cartridges or a
reservoir or 'pod'. The commonly-used term for this aerosol is
vapor, which we use throughout the review. In many countries, ECs
are marketed as consumer products. Although routes are in place
for licensing them as a medicine in some areas, no country yet has
a licensed, medicinal EC.
ECs provide sensations similar to smoking a cigarette. They provide
taste and throat sensations that are closer to smoking than those
provided by the nicotine inhalator (Barbeau 2013). The vapor that
looks like tobacco smoke is only visible when the user exhales aOer
drawing on the mouthpiece, not when the device is being held. In
qualitative studies users report a sense of shared identity with other
users, similar to tobacco smoking identity, and also report pleasure
and enjoyment of use, suggesting that ECs may be viewed less as
a medical cessation aid but rather as an acceptable alternative to
tobacco smoking (Cox 2017; Notley 2018a).
There are many diIerent brands and models of EC available.
Variation exists both in the device ('product') and consumable
(e-liquid used). There is a wide variation in the composition
of e-liquids (nicotine content, flavors and other components)
(Goniewicz 2012; Goniewicz 2014), with some users choosing to mix
their own e-liquids (Cox 2019b). Initial studies showed that early
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models of EC delivered very low amounts of nicotine to naïve users
(Bullen 2010; Eissenberg 2010; Vansickel 2010). Later studies that
have measured nicotine pharmacokinetics in both experienced and
naïve EC users have found that some EC users can achieve blood
nicotine levels similar to those achieved with smoking, albeit more
slowly, and that their ability to do so oOen improves over time
(Hajek 2015b; Vansickel 2012; Vansickel 2013; Yingst 2019a; Yingst
2019b).
Early on in their development, ECs looked like cigarettes and
used disposable cartridges. These models were oOen called 'cig-a-
likes'. The nicotine delivery from these products was low, and even
the modern versions of EC devices that use pre-filled cartridges,
generally produced by the tobacco industry, for the most part have
only low nicotine delivery (Hajek 2017). The later refillable, or 'tank',
products have a larger battery and a transparent container that
users fill with an e-liquid of their choice, and usually provide faster
and more eIicient nicotine delivery, allow a wider choice of flavors
and nicotine concentrations, and are typically used by experienced
vapers who manage to switch to vaping completely (ASH 2019;
Dawkins 2013b; Farsalinos 2014). Observational evidence suggests
people who smoke are more likely to successfully quit using tank
models than with cig-a-likes (Chen 2016; Hitchman 2015). EC types
are also oOen grouped by 'generation': first-generation devices are
typically cig-a-likes; second-generation devices are usually tank
models, sometimes referred to as 'vape pens'; and third-generation
devices are tank models which, unlike second-generation devices,
allow users to adjust the power (wattage) level of the product (see
NCSCT EC briefing for further information and images of diIerent
product types). More recently, smaller 'pod' devices, such as Juul,
appeared that use nicotine salt. This nicotine formulation reduces
irritant eIects and allows the delivery of higher nicotine levels that
closely mimic the pharmacokinetic profile of nicotine delivery from
cigarettes, despite the low battery power of the device (Hajek 2020).
Juul has now become the most popular EC in the USA (Huang 2019).
The EU Tobacco Products Directive (European Parliament 2014)
does not allow sales of e-liquids with nicotine content higher than
20 mg/ml, and so the US version of Juul (59 mg/nl nicotine) is not
available within the EU (Huang 2019; Talih 2020).
The diIerent device types (cig-a-like, refillable and pods using
high nicotine content salts) may diIer significantly in their
eIicacy in helping people who smoke to quit, as they diIer in
delivery of nicotine, the active ingredient. Nicotine itself, when
delivered through mechanisms and doses similar to that delivered
in traditional NRT, is not considered harmful (Hartmann-Boyce
2018a). The safety profile of the diIerent types of EC may be
similar as they use the same constituents, although within the
generic range of EC types, there is some evidence to suggest EC
providing less nicotine may pose higher risks. This is because low-
nicotine delivery devices need to be puIed with higher intensity
to provide users with the nicotine levels that they seek, and
more intensive puIing is accompanied by increased inhalation
of potential toxicants (Dawkins 2016; Dawkins 2018; Smets 2019).
Throughout this review we refer to a nicotine-containing EC as
‘nicotine EC’ and to nicotine-free EC as 'non-nicotine EC', which can
also be considered 'placebo EC'. The 'placebo' comparison is a test
just of the nicotine eIect and not of the potential sensorimotor or
behavioral and social replacement that the EC may provide.
There is no one agreed classification system for EC devices, and
product development has moved so quickly that the definitions
used within trials of the devices tested may no longer be necessarily
fit for purpose. In this review, the definitions used are based on
those drawn from the included trials. We currently label three
diIerent types of EC as 'cartridges' for devices with disposable
cartridges and - typically, but not always - low nicotine delivery (e.g.
cig-a-likes); refillable ECs for devices that vapers fill with their own
choice of e-liquids; and pods for the small devices that use nicotine
salts. We may review this categorization system in future versions
of the review as new trials and devices emerge.
Why it is important to do this review
Since ECs appeared on the market in 2006 there has been a steady
increase in their use. In the UK the ASH 2019 survey found 19.4%
of the adult population have ever tried vaping, but only 7.2% were
current vapers. EC use remains slightly more common among men
compared with women, although the diIerence is small. EC use
is most prevalent in current (19.9%) and former (11.6%) smokers.
Less than one per cent of never-smokers report regular EC use.
Prevalence data from the USA in 2019 showed that 4.4% of adults
were current EC users (Du 2020). Data from lower-income countries
suggest similar levels of EC use and awareness (Besaratinia 2019;
Jiang 2016; Palipudi 2016).
Particular concern has been raised about the increased use of EC in
young people, especially among never-smokers. Data for 2019 from
Canada, England, and the USA show regular use (≥ 20 days in the
last 30 days) among 16- to 19-year-olds to be 5.7%, 2.7% and 6.7%,
respectively. There appear to be some regional diIerences in the
change in the prevalence of EC use. For example, in North America
the rates of regular EC use among 16- to 19-year-old never-smokers
has significantly increased between 2017 and 2019, compared to
England where there has not been any significant change (0.2%
to 0.3%) (Hammond 2020). However, as with adults, regular use
is greatest among those who are also smoking and lowest among
never-smokers (1.0%, 0.3%, and 1.8% for Canada, England and
USA, respectively).
Regulatory approaches being used for ECs currently vary widely,
from no regulation to partial and complete bans (McNeill 2021).
Within the USA, for example, the Food and Drug Administration
(FDA) has classified them as tobacco products and there are a
range of laws that include prohibition of EC use indoors, require
retailers to have a license to sell, and prohibit sales to minors.
Laws prohibiting sales to minors apply nationwide, but other laws
vary by state (Du 2020). The European Union includes ECs in
their Tobacco Products Directive, except where therapeutic claims
are made or in instances where they contain over 20 mg/nl of
nicotine, when they will require medicines authorization (European
Parliament 2014).
Categorical statements about the toxicity of ECs are not possible
because of the large number of devices and liquids available and
the frequent addition of new products to the market. In 2019, cases
of severe lung injury associated with EC use were reported in the
USA, and by February 2020 there were around 2800 hospitalized
cases or deaths (CDC 2020). This illness was termed E-cigarette
or Vaping-Associated Lung Injury (EVALI) and caused concern
throughout the world (Hall 2020), and a negative change in people's
perception of the risks of EC use compared to smoking (Tattan-Birch
2020). These cases were somewhat at odds with data from trials
and cohort studies, and it was later found that these injuries were
related to use of tetrahydrocannabinol (THC)-containing EC, and in
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particular THC products adulterated with vitamin E acetate (Blount
2020; Hartnett 2020). Among those brands of nicotine EC that have
been tested, levels of toxins have been found to be substantially
lower than in cigarettes (Hajek 2014; McNeill 2021). Long-term
eIects beyond 12 months are unknown, although based on what
is known about liquid and vapor constituents and patterns of use,
a report from the UK's Royal College of Physicians has concluded
that using an EC is likely to be considerably safer than smoking
(RCP 2016). The US National Academies of Sciences, Engineering,
and Medicine (NASEM) concluded that ECs are likely to be far less
harmful than continuing to smoke cigarettes, with the caveat that
the long-term health eIects of e-cigarette use are not yet known
(NASEM 2018).
Despite general acknowledgement that EC use exposes the user to
fewer toxicants and at lower levels than smoking cigarettes (McNeill
2021; NASEM 2018; RCP 2016), there remains some hesitancy in
making these products available to people who smoke as a harm
reduction tool or smoking cessation aid (e.g. McDonald 2020). Lack
of quality control measures, possible harms of second-hand EC
vapor inhalation, concerns that the products may be a gateway to
smoking initiation or may prolong continued dual-use of tobacco,
concerns that ECs may undermine smoke-free legislation if used
in smoke-free spaces, concerns about the involvement of the
tobacco industry, and concerns that the long-term eIects of EC
use on health are not yet known are oOen cited. Recently, a report
from the US Preventive Services Taskforce concluded "that the
current evidence is insuIicient to assess the balance of benefits and
harms of electronic cigarettes (e-cigarettes) for tobacco cessation
in adults" (USPFTS 2021). However, others suggest that potential
benefits outweigh potential disadvantages (Farsalinos 2014; Hajek
2014; McNeill 2021; NASEM 2018; RCP 2016).
People who smoke, healthcare providers and regulators are
interested to know if ECs can help smokers quit and if it is safe
to use them to do so. In particular, healthcare providers have an
urgent need to know what they should recommend for people who
want to stop smoking. The largest health gains are achieved from
stopping smoking completely, as opposed to reducing cigarette
consumption, and as such this review focuses on the eIectiveness
of ECs in aiding smoking cessation.
This review was first published in 2014, and updated in 2016 and
2020.
Following the publication of the 2020 update of this review, we
are maintaining  it as a living systematic review (Brooker 2019).
This means we are continually running searches and incorporating
new evidence into the review. For more information about the
living systematic review methods being used, see Appendix 1. A
living systematic review approach is appropriate for this review,
for three reasons. First, the review addresses an important public
health issue; the role of ECs in enabling people who smoke to
stop smoking, with potential for substantial ongoing individual and
societal benefits if eIective. Secondly, there remains uncertainty
in the existing evidence; more studies are needed to confirm the
degree of benefit for diIerent comparisons and product types, and
there is considerable uncertainty about adverse events and other
markers of safety. Thirdly, we are aware of multiple ongoing trials
on this topic that are likely to have an important impact on the
conclusions of the review.
O B J E C T I V E S
To examine the safety, tolerability and eIectiveness of using
electronic cigarettes (ECs) to help people who smoke achieve long-
term smoking abstinence.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We include randomized controlled trials (RCTs) and randomized
cross-over trials in which people who smoke are randomized to
ECs or to a control condition. RCTs are the best available primary
evidence, but the continued paucity of RCTs in this area requires
that we also include uncontrolled intervention studies in which all
participants are given an EC intervention.
We include studies regardless of their publication status or
language of publication.
Types of participants
People defined as currently smoking cigarettes at enrolment into
the studies. Participants could be motivated or unmotivated to quit.
Types of interventions
Any type of EC or intervention intended to promote EC use
for smoking cessation, including studies which did not measure
smoking cessation but provided ECs with the instruction they be
used as a complete substitute for cigarette use. ECs may or may not
contain nicotine.
Types of comparators
We compare nicotine ECs with non-nicotine ECs, ECs versus
alternative smoking cessation aids, including NRT or no
intervention, and ECs added to standard smoking cessation
treatment (behavioral or pharmacological or both) with standard
treatment alone.
Types of outcome measures
Primary outcomes
• Cessation at the longest follow-up point, at least six months
from the start of the intervention, measured on an intention-to-
treat basis using the strictest definition of abstinence, preferring
biochemically-validated results where reported
• Number of participants reporting adverse events or serious
adverse events at one week or longer (as defined by study
authors)
Secondary outcomes
Changes in the following measures at one week or longer:
• Carbon monoxide (CO), as measured through breath or blood
• Blood pressure
• Heart rate
• Blood oxygen saturation
• Lung function measures
• Known toxins/carcinogens, as measured through blood or urine
(toxicant names and abbreviations are listed in Appendix 2)
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Studies had to report one of the primary or secondary outcomes
above to be eligible for inclusion.
Search methods for identification of studies
Electronic searches
For this update we searched the following databases on 1st
February 2021:
• Cochrane Tobacco Addiction Group Specialized Register
• Cochrane Central Register of Controlled Trials (CENTRAL)
• MEDLINE (OVID SP)
• Embase (OVID SP)
• PsycINFO (OVID SP)
• ClinicalTrials.gov
• WHO International Clinical Trials Registry Platform (ICTRP:
www.who.int/ictrp/en/)
At the time of the search, the Register included the results of
searches of the Cochrane Central Register of Controlled trials
(CENTRAL), issue 1, 2021; MEDLINE (via OVID) to update 20210104;
Embase (via OVID) to week 202101; PsycINFO (via OVID) to update
20201228. See the Tobacco Addiction Group website for full search
strategies and a list of other resources searched.
For the first version of the review we also searched CINAHL (EBSCO
Host) (2004 to July 2014). We did not search this database from
2016 onwards as it did not contribute additional search results to
the first version of the review. The search terms were broad and
included e-cig$ OR elect$ cigar$ OR electronic nicotine. The search
for the 2016 update added the terms vape or vaper or vapers or
vaping. The 2020 searches added further terms, including the MESH
heading 'Electronic Nicotine Delivery Systems' and terms to limit
by study design. Our search strategy for MEDLINE (Ovid SP) is listed
in Appendix 3. The previously-used search strategy is shown in
Appendix 4. The search date parameters of the original searches
were limited to 2004 to the present, due to the fact that ECs were
not available before 2004.
Searching other resources
We searched the reference lists of eligible studies found in the
literature search and contacted authors of known trials and other
published EC studies.
Data collection and analysis
Selection of studies
Two review authors (for this update from: JHB, NL, CN, RB,
PH, NR, ARB, HMR) independently prescreened all titles and
abstracts obtained from the search, using a screening checklist, and
then independently screened full-text versions of the potentially
relevant papers for inclusion. We resolved any disagreements by
discussion or with a third review author.
Data extraction and management
Two review authors (for this update from: CN, ARB, AT, HMR)
extracted data from the included studies using a pre-piloted data
extraction form, and checked them against each other. We resolved
any disagreements by discussion or with a third review author. We
extracted data on:
• Author
• Date and place of publication
• Study dates
• Study design
• Inclusion and exclusion criteria
• Setting
• Summary of study participant characteristics
• Summary of intervention and control conditions
• Number of participants in each arm
• Smoking cessation outcomes
• Type of biochemical validation (if any)
• Adverse events (AEs), serious adverse events (SAEs), and
relevant biomarkers
• Assessment time points
• Study funding source
• Author declarations of interest
• Risk of bias in the domains specified below
• Additional comments
We adopted a broad focus to detect a variety of adverse events.
One review author (JHB) then entered the data into Review
Manager 2020 soOware for analyses, and another checked them (AB
for this update).
Assessment of risk of bias in included studies
Two review authors (for this update from: CN, ARB, AT, HMR)
independently assessed the risks of bias for each included
study, using the Cochrane 'Risk of bias' Tool v1 (Higgins 2011).
This approach uses a domain-based evaluation that addresses
seven diIerent areas: random sequence generation; allocation
concealment; blinding of participants and providers; blinding
of outcome assessment; incomplete outcome data; selective
outcome reporting; and other potential sources of bias. We
assigned a grade (low, high, or unclear) for risk of bias for each
domain. We resolved disagreements by discussion or by consulting
a third review author.
Specific considerations about judgments for individual domains in
this review are outlined below:
• Random sequence generation/allocation concealment: We
rated all non-randomized studies at high risk in these domains;
• Blinding of participants and personnel: We did not evaluate
this domain for non-randomized studies, as we considered it
not to be applicable. For randomized studies which did not use
blinding, we considered studies to be at low risk in this domain
if the intervention was compared to an active control of similar
intensity, as we judged performance bias to be unlikely in this
circumstance. If studies were unblinded and the comparator
group was a minimal-intervention control or of lower intensity
than the intervention group, we considered the study to be at
high risk of bias in this domain;
• Following standard methods of the Cochrane Tobacco Addiction
Review Group, we considered studies to be at low risk of
detection bias (blinding of outcome assessment) if our primary
outcome was objectively measured or if the intensity of
intervention was similar between groups, or both. For studies
where cessation was measured, our judgment was based on
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whether cessation was biochemically verified. For other studies,
we judged this domain based on adverse or serious adverse
events;
• Again following standard methods of the Cochrane Tobacco
Addiction Group, we rated studies at high risk of attrition bias if
loss to follow-up was greater than 50% overall or if there was a
diIerence in follow-up rates of more than 20% between study
arms.
We judged studies to be at high risk of bias overall if they were rated
at high risk in at least one domain, and at low risk of bias overall if
they were judged to be at low risk across all domains evaluated. We
judged the remaining studies to be at unclear risk of bias overall.
Measures of treatment e5ect
We analyzed dichotomous data by calculating the risk ratio (RR).
For cessation, we calculated the RR as ((number of events in
intervention condition/intervention denominator) / (number of
events in control condition/control denominator)) with a 95%
confidence interval (CI), using data at the longest follow-up period
reported.
We analyzed continuous data (other measures of tobacco exposure)
by comparing the diIerence between the mean change from
baseline to follow-up in the intervention and comparator groups.
For outcomes other than cessation where data were reported at
multiple time points, we used data at the longest follow-up point at
which ECs were still being provided.
Unit of analysis issues
In the case of trials with multiple arms, we do not combine data
between arms unless this is the way it has been presented by study
authors. We note in our analyses where this is the case.
For all but one study, the unit of assignment was the individual.
Dawkins 2020 assigned condition based on homeless support
service; this was a small pilot study with very few events and hence
we judged clustering to have very little impact on our overall result.
If larger cluster-randomized trials are eligible in the future, we will
assess whether study authors have adjusted for this clustering, and
whether this had an impact on the overall result. When clustering
appears to have had little impact on the results, we will use
unadjusted quit-rate data; however when clustering does appear to
have an impact on results, we will adjust for this using the intraclass
correlation (ICC).
For randomized cross-over trials, we report results at the end of
the first assignment period where available and where suIiciently
long to meet our inclusion criteria for outcomes. All other outcomes
from randomized cross-over trials are reported narratively. We
oIer a narrative synthesis of data from non-randomized studies,
and where possible use eIect direction plots as described in the
Cochrane Handbook (Higgins 2021).
Dealing with missing data
For smoking cessation, we used a conservative approach, as
is standard for the Cochrane Tobacco Addiction Group, treating
participants with missing data as still smoking. We based the
proportion of people aIected by adverse events on the number of
people available for follow-up, and not the number randomized.
For other outcomes, we use complete-case data and do not attempt
to impute missing values.
Assessment of heterogeneity
We assessed the clinical and methodological diversity between
studies to guide our decision as to whether data should be pooled.
We were also guided by the degree of statistical heterogeneity,
assessed by calculating the I2 statistic (Higgins 2003), and
considering a value greater than 50% as evidence of substantial
heterogeneity. We did not present pooled results where I2 values
exceeded 75%.
Assessment of reporting biases
Reporting bias can be  assessed using funnel plots, where 10 or
more RCTs contribute to an outcome. However, there are currently
insuIicient studies to support this approach.
Data synthesis
We provide a narrative summary of the included studies. Where
appropriate, we have pooled data from these studies in meta-
analyses. For dichotomous data, we used a fixed-eIect Mantel-
Haenszel model to calculate the RR with a 95% confidence interval,
in accord with the standard methods of the Cochrane Tobacco
Addiction Group for cessation studies.
For continuous outcomes, we pooled mean diIerences (or
standardized mean diIerences for studies using diIerent measures
for the same construct), using the inverse variance approach (also
with a 95% CI).
Subgroup analysis and investigation of heterogeneity
We had planned to undertake subgroup analyses to investigate
diIerences between studies, such as:
• Intensity of behavioral support used;
• Type of EC (cartridge; refillable; pod);
• Instructions for EC use (e.g. study provision, length of provision,
whether participants had a role in product choice);
• Type of participants (e.g. experience of EC use).
However, there were too few studies to conduct such analyses.
Should further studies become available in future, we will follow
this approach. For safety outcomes, we present subgroups by
length of follow-up for descriptive purposes.
In the absence of suIicient data for subgroup analyses on EC type,
in the text we specify the type of nicotine EC when reporting pooled
results for cessation.
Sensitivity analysis
We conducted sensitivity analyses to detect whether pooled results
were sensitive to the removal of studies judged to be at high risk of
bias.
Summary of findings and assessment of the certainty of the
evidence
Following standard Cochrane methodology, we created 'Summary
of findings' tables for our three main comparisons using GRADEpro
GDT: nicotine EC versus non-nicotine EC; nicotine EC versus NRT;
and nicotine EC versus behavioral support only/no support. We
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selected these comparisons a priori as being the most clinically
relevant. In the 'Summary of findings' tables, we present data on
our primary outcomes (cessation, adverse events, serious adverse
events) for these main comparisons. Also following standard
Cochrane methodology, we used the five GRADE considerations
(study limitations, consistency of eIect, imprecision, indirectness
and publication bias) to assess the certainty of the body of evidence
for each outcome, and to draw conclusions about the certainty of
evidence within the text of the review.
R E S U L T S
Description of studies
Results of the search
For this update, our bibliographic database searches identified
825 non-duplicate records (Figure 1). We screened all records
and retrieved the full-text papers of 100 potentially relevant
articles. AOer screening and checking the full-text of 100 papers,
we included 26  records, representing six studies new for this
update (Czoli 2019; Ikonomidis 2020; Ozga-Hess 2019; Pulvers
2020; Scheibein 2020; Yingst 2020), nine new articles linked to
studies already identified, and 11 new references to ongoing studies
(see Characteristics of ongoing studies). Secondary study reports,
commentaries, and correspondence relating to included studies
are linked to studies in the reference section. Figure 2, Figure 3 and
Figure 4 present PRISMA flow charts for previous versions of this
review.
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Figure 1.   2021 update flow diagram
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Figure 1.   (Continued)
 
 
Figure 2.   2020 update flow diagram
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Figure 3.   2016 update flow diagram
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Figure 4.   2014 flow diagram
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Included studies
In total, we include 56 studies, six new included studies and
50 eligible included studies identified in previous versions of
the review. Key features of the included studies are summarized
below. Further details on each included study can be found in the
Characteristics of included studies tables.
Participants
The 56 included studies represented 12,804 participants. Twenty-
four studies were conducted in the USA, nine were conducted
in the UK, seven in Italy, three in Greece, two each in Australia,
New Zealand, and Canada, and one each in Belgium, Ireland,
Poland, the Republic of Korea, South Africa, Switzerland, and
Turkey. All studies were conducted in adults who smoke. Seventeen
studies exclusively recruited participants who were not motivated
to quit smoking, and 29 studies exclusively recruited participants
motivated to quit; motivation was not specified for the other
studies. Eighteen studies recruited from specific population
groups; these included six studies which recruited participants
based on physical health condition (heart attack, cancer, HIV,
periodontitis, awaiting surgery), three studies which recruited
participants with serious mental illness, and three studies which
recruited participants in treatment or having recently completed
treatment for alcohol or other drug use. Two studies recruited
people accessing homeless centres or using supported temporary
accomodation. One study each recruited: people aged 55 or older,
young adults, and black and latinx participants.
Interventions and comparators
All but one study provided nicotine EC, either alone (50 studies)
or in conjunction with NRT or varenicline (five studies). One study
recruited dual users at baseline, and instructed them to continue
using their own EC devices (Czoli 2019). In two studies where
nicotine EC was provided on its own, nicotine levels were judged
to be so low as to be clinically comparable to non-nicotine EC (Lee
2019; Van Staden 2013); we include these studies in non-nicotine
EC comparisons. Eight studies compared nicotine EC with non-
nicotine EC, 16 studies compared nicotine EC to behavioral support
only or to no support, and eight studies compared nicotine EC
to NRT. One study directly compared a cig-a-like with a refillable
(tank) device (Yingst 2020). Results from these studies are reported
by comparison in EIects of interventions. Further details on the
intervention and comparator groups (where applicable) for each
study can be found in the Characteristics of included studies tables.
Where reported in the primary research publications, details on the
devices tested can also be found in the Characteristics of included
studies tables. Of the studies with suIicient data with which to
judge, 26 used cartridge devices (only one of which had high
nicotine delivery), 21 used refillable devices, three used both types,
one used a pod device, and the remainder did not report device
type.
Outcomes
Of the 56 included studies:
• 22 reported data on abstinence
• 39 reported data on adverse events
• 24 reported data on serious adverse events
• 36 reported data on carbon monoxide
• 9 reported data on heart rate
• 12 reported data on blood pressure
• 2 reported data on blood oxygen saturation
• 9 reported data on at least one known toxin/carcinogen
• 5 reported data on at least one measure of lung function
Study types and funding
Twenty-nine studies were RCTs, 13 of which contributed to
cessation analyses. Five studies used randomized cross-over
designs, and the remainder were uncontrolled cohort studies. Of
the 46 studies which reported funding information, 32 had no EC
industry funding or support.
Excluded studies
We list 92  studies excluded at full-text stage, along with reasons
for exclusion, in the Characteristics of excluded studies table. The
most common reason for exclusion was that studies were short-
term, following up participants for periods of less than one week.
Risk of bias in included studies
Overall, we judged five studies (Bullen 2013; Eisenberg 2020; Hajek
2019; Lee 2018; Lee 2019) to be at low risk of bias, ten to be at
unclear risk, and the remaining 41 at high risk of bias (note, this
includes the non-randomized studies, which we deemed to be at
high risk due to this lack of randomization).
Details of 'Risk of bias' judgments for each domain of each included
study can be found in the Characteristics of included studies table.
Figure 5 illustrates judgments for each included study.
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Adriaens 2014 + ? + + + ?
Baldassarri 2018 + ? + + - +
Bell 2017 - - + +
Bullen 2013 + + + + + +
Caponnetto 2013a + + + + + ?
Caponnetto 2013b - - + ?
Carpenter 2017 ? ? - - + ? +
Czoli 2019 ? - - ? + +
Dawkins 2020 - ? - + - +
Eisenberg 2020 + + + + + +
Ely 2013 - - + ? ?
Felicione 2019 ? ? ? ? + ?
George 2019 + + ? - ? +
Goniewicz 2017 - - + +
Guillaumier 2018 + + - - + +
Hajek 2015a - - ? ?
Hajek 2019 + + + + + +
Halpern 2018 ? ? - + - +
Hatsukami 2020 ? ? ? + + +
Hickling 2019 - - + +
Holliday 2019 + + - + + +
Humair 2014 - - ? ?
Ikonomidis 2018 ? ? - ? + ? ?
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Figure 5.   (Continued)
Humair 2014 - - ? ?
Ikonomidis 2018 ? ? - ? + ? ?
Ikonomidis 2020 + ? ? + + ?
Ioakeimidis 2018 ? ? + + ? ? -
Kumral 2016 ? ? - - ? +
Lee 2018 + + + + + +
Lee 2019 + + + + + +
Lucchiari 2020 + + + + + -
Martner 2019 - - ? ?
McRobbie 2015 - - + +
Meier 2017 ? ? + + ? +
NCT02648178 - - + ?
NCT02918630 ? ? ? ? ? - ?
Nides 2014 - - + +
Oncken 2015 ? ? + + + ?
Ozga-Hess 2019 ? ? - + - +
Pacifici 2015 - - + -
Polosa 2011 - - + ?
Polosa 2014b - - + ?
Polosa 2015 - - + ?
Pratt 2016 - - + +
Pulvers 2018 - - + +
Pulvers 2020 + + - + + +
Scheibein 2020 - - - - - ?
Smith 2020 ? ? + + + ?
Stein 2016 - - + +
Strasser 2016 ? ? ? + - +
Tseng 2016 + ? + + + +
Valentine 2018 - - ? ?
Van Staden 2013 - - + ?
Veldheer 2019 + + + + ? -
Wadia 2016 - - + +
Walele 2018 + + - - + +
Walker 2020 + + - + + ?
Yingst 2020 ? ? + + + ?
 
Allocation
We judged 23 studies to be at high risk of selection bias; for 22,
this is because the studies were not randomized. We also rated
a pilot cluster-randomized trial at high risk as randomization was
not carried out as intended for pragmatic reasons (Dawkins 2020).
We judged 14 studies to be at low risk of selection bias, and the
remainder to be at unclear risk as there was insuIicient information
with which to judge.
Blinding
Of the 35 studies assessed for these domains, we judged 16 to
be at low risk for both performance and detection bias. We rated
14 at high risk for performance or detection bias, or both. In these
studies, blinding was not used and diIerent levels of support were
provided; this alone or in conjunction with the outcome measures
being used (subjective rather than objective measures) meant we
thought there was a high risk of bias being introduced. We judged
the rest to be at unclear risk.
Incomplete outcome data
We judged most studies (40 out of 56) to be at low risk of attrition
bias. We rated six studies with substantial loss to follow-up at high
risk of attrition bias. The remainder did not provide suIicient data
on which to judge, and hence we judged them to be at unclear risk.
Selective reporting
Of the 56 studies, we considered that 29 were at low risk of reporting
bias, as all prespecified/expected outcomes were reported. We
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rated four at high risk, as data were not presented as specified in
the original protocols. We judged the rest to be at unclear risk, due
to insuIicient information with which to make a judgment.
Other potential sources of bias
We considered Ioakeimidis 2018 to be at high risk of other bias; data
were from a conference poster and the associated abstract, and quit
rates in the intervention arm diIered between the two sources.
E5ects of interventions
See: Summary of findings 1 Nicotine EC compared to NRT for
smoking cessation; Summary of findings 2 Nicotine EC compared
to non-nicotine EC for smoking cessation; Summary of findings 3
Nicotine EC compared to behavioral support only/no support for
smoking cessation
Data on our outcomes of interest are summarized below. Due to
the volume of data available, some relevant information is hosted
on a companion repository; these data are open-access and can
be found at https://doi.org/10.5287/bodleian:dX4Dgp7dJ. They are
referred to below as supplemental tables. Forest plots are available
through 'analysis' links; for some outcomes, benefit is plotted on
the right, for others on the leO. This is due to direction of eIect,
e.g. an increase in cessation is a benefit, whereas an increase in a
carcinogen is not.
Direct comparisons between nicotine EC and other
pharmacotherapies
Comparisons reported here include cartridge and refillable nicotine
ECs versus NRT, and cartridge nicotine ECs versus varenicline. Only
randomized controlled trials contribute data.
Cessation
Pooled data from three studies (2 cartridge, 1 refillable), all of which
we rated at low risk of bias, showed higher quit rates in people
randomized to nicotine EC than to NRT (RR 1.69, 95% CI 1.25 to 2.27;
I2 = 0%; 1498 participants; Analysis 1.1). One study (Ioakeimidis
2018), available as a conference presentation only and considered
at high risk of bias due to inconsistencies in the data reported and
an unclear definition of abstinence, found lower quit rates in people
allocated to nicotine EC (cartridge) compared to those allocated to
varenicline (RR 0.31, 95% CI 0.11 to 0.82; 54 participants; Analysis
2.1).
Adverse events
Pooled data from two studies (both considered at low risk of bias)
showed no evidence of a diIerence in the number of participants
reporting adverse events (AEs) between nicotine EC and NRT arms
(RR 0.98, 95% CI 0.80 to 1.19; I2 = 0%; 485 participants; Analysis
1.2). Hajek 2019 did not contribute data to this analysis due to the
way in which events were recorded; of their prespecified adverse
reactions of interest, nausea was more frequent in the NRT group,
throat/mouth irritation was more frequent in the nicotine EC group,
and there was little diIerence in other reactions (see Supplemental
Table 1 for more detail).
In Ioakeimidis 2018, reports of sleep disorders were evenly
distributed between groups, and nausea was more common in the
varenicline arm than in the nicotine EC arm (see Supplemental
Table 1 for more detail).
Serious adverse events
Two studies comparing nicotine ECs with NRT provided data on
SAEs; in one (Lee 2018) none occurred in either arm. In Hajek 2019
(n = 698), more events occurred in the nicotine EC arm than in the
NRT arm, but the confidence interval was wide and included no
diIerence as well as the possibility of more events in the NRT arm
(RR 1.37, 95% CI 0.77 to 2.41; Analysis 1.3). As noted above, Bullen
2013, which compared nicotine EC, non-nicotine EC, and NRT,
only reported that no serious adverse events (SAEs) occurred that
were considered related to study treatment. No events occurred in
Ioakeimidis 2018 (Analysis 2.2).
Carbon monoxide (CO)
Pooled data from two studies (Hatsukami 2020; Lee 2018; neither
considered at high risk of bias) comparing nicotine EC with NRT
found that CO levels decreased more in those randomized to
nicotine EC, but the point estimate was small, confidence intervals
were wide, and statistical heterogeneity was substantial (MD −0.66
ppm, 95% CI −1.94 to 0.62; I2 = 69%; 136 participants; Analysis 1.4).
Heart rate, blood pressure, and oxygen saturation
Only Hatsukami 2020 contributed data for these outcomes. A small
benefit in favor of EC was found for change in heart rate (Analysis
1.5). No diIerence was found for blood pressure or blood oxygen
saturation, although confidence intervals were wide (Analysis 1.6;
Analysis 1.7).
Toxicants
Again, only Hatsukami 2020 contributed data for these outcomes.
For 3-HPMA, 2-HPMA, HMPMA, PheT, and CEMA, point estimates
favored EC but confidence intervals included no diIerence
(Analysis 1.8; Analysis 1.10; Analysis 1.11; Analysis 1.12; Analysis
1.13). Both AAMA and NNAL decreased more in NRT than in EC
groups, with confidence intervals excluding no diIerence (Analysis
1.9; Analysis 1.14).
Lung function
Lee 2018 measured change in FEV1 and FEV1/FVC; for both
outcomes, point estimates favored EC over NRT; confidence
intervals excluded no diIerence for FEV1 (Analysis 1.15; Analysis
1.16).
Nicotine EC alone or versus control
Comparisons reported here include nicotine EC versus non-nicotine
EC, and nicotine EC compared to behavioral support only or to
no support. In this section, we also report results from studies
in which all participants received nicotine EC (cohort studies
and randomized studies which did not diIer across arms in EC
provision, device generation, or nicotine content).
Cessation
Randomized controlled trials
At six months or longer, quit rates were higher in nicotine EC groups
than in comparator groups. Compared to EC without nicotine
(placebo EC), pooled results showed nicotine EC produced higher
quit rates (RR 1.70, 95% CI 1.03 to 2.81; I2 = 0%; 3 studies of cartridge
devices, 1 refillable, 1057 participants; Analysis 3.1). The eIect size
increased when we removed the one study at high risk of bias
(Lucchiari 2020). The eIect was more pronounced when comparing
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nicotine EC to behavioral support only or to no support (RR 2.70,
95% CI 1.39 to 5.26; I2 = 0%; 5 studies (3 refillable, 2 cartridge), 2561
participants; Analysis 4.1). As this involved unblinded comparisons
with unequal levels of support, we judged all data contributing to
this outcome to be at high risk of bias.
Pulvers 2020 (pod device) measured cessation at six months in the
intervention group only, using self-report. As they did not measure
cessation at six months in the comparator group we could not
include these data in meta-analysis. At six months, 23 (24%) of
intervention participants were exclusively using EC and 10 (10.4%)
reported using neither EC nor combustible cigarettes (making a
combined quit rate of 34.4% in the intervention arm at six months).
Data from other studies
Eight studies provided all participants with nicotine EC and
assessed abstinence at six months or longer (Table 1; 1 refillable,
6 cartridge, 1 not specified). The highest proportion of quitters
was observed in Ely 2013 (cartridge), in which all participants (n
= 48) used EC and 18 used additional pharmacotherapy: 44% of
participants were abstinent at six months. The lowest quit rates
were seen in two studies where participants were not motivated
to quit at baseline: in Caponnetto 2013b, 14% of participants were
abstinent at 12 months, and in Polosa 2011 23% of participants
were abstinent at six months, but this fell to 13% at 24 months (both
studies used cartridge devices).
Adverse events
Randomized controlled trials
Pooled data from three studies (none at high risk of bias) showed no
evidence of a diIerence in the number of participants experiencing
adverse events when comparing nicotine EC to non-nicotine EC
(RR 1.01, 95% CI 0.91 to 1.11; I2 = 0%; 601 participants; Analysis
3.2). When comparing nicotine EC to behavioral support only or to
no support, more people in the groups randomized to nicotine EC
reported experiencing adverse events (RR 1.22, 95% CI 1.12 to 1.32;
I2 = 41%; 4 studies, 765 participants; Analysis 4.2). As this involved
unblinded comparisons with unequal levels of support, we judged
all data contributing to this outcome to be at high risk of bias.
A further seven randomized controlled trials provided adverse
event or related data for this comparison, but could not be
included in the meta-analysis due to the way in which data were
presented (see Supplemental Table 1). In the studies comparing
nicotine EC to non-nicotine EC, one found similar event rates across
arms (Caponnetto 2013a), and two reported more events in the
nicotine EC arms (Felicione 2019; Tseng 2016). In a further study
comparing nicotine to non-nicotine EC, events were reported by
type, with an increase in some seen in the nicotine group and an
increase in others seen in the non-nicotine group (Lucchiari 2020).
In the three studies comparing nicotine EC to behavioral support
only or traditional cigarettes, Kumral 2016 found an increase in
sinonasal symptoms in the group receiving nicotine EC compared
to behavioral support only, and Ozga-Hess 2019 found that throat
irritation, cough, and dry mouth increased in the e-cigarette group
relative to the traditional cigarette group. By contrast, Pulvers
2020 found a reduction in respiratory symptoms in the e-cigarettes
compared to the traditional cigarettes group.
Data from other studies
Seventeen studies provided all participants with nicotine EC and
assessed adverse events at one week or longer (see Supplemental
Table 1). In the seven studies which tracked event rates over
time, six showed adverse events reducing over time (Bell 2017;
Caponnetto 2013b; Goniewicz 2017; Polosa 2011; Polosa 2014b;
Pratt 2016). Hickling 2019 showed no change. The most commonly-




Four studies compared nicotine EC with non-nicotine EC and
reported data on SAEs; in three of these, no events occurred, so
results could not contribute to the meta-analysis, although they
are included in the forest plots for descriptive purposes. In the one
study (Eisenberg 2020, n = 255 for this comparison) where events
occurred, more were reported in the non-nicotine arm (RR 0.60,
95% CI 0.15 to 2.44; Analysis 3.3). We rated this study at low risk of
bias.
Six studies compared nicotine EC with behavioral support only or
no support and reported data on SAEs; in four of these, no events
occurred. Pooled results from the two studies in which events
occurred showed more events occurring in the nicotine EC arm,
but confidence intervals were wide and encompassed clinically
significant benefit and clinically significant harm (RR 1.17, 95% CI
0.33 to 4.09; I2 = 5%; 2 studies, 1011 participants; Analysis 4.3).
Bullen 2013, which compared nicotine EC, non-nicotine EC, and
NRT, only reported that no SAEs occurred that were considered to
be related to study treatment. In a study in people experiencing
homelessness (Dawkins 2020), SAEs were not reported, but authors
report that four to seven participants in the usual-care arm and
five to seven participants in the nicotine EC arm visited Accident
& Emergency services at a hospital. Further detail can be seen in
Supplemental Table 2.
Data from other studies
Seven studies provided all participants with nicotine EC and
reported SAEs at a week or longer (Supplemental Table 2).
In five of these (Bell 2017; Caponnetto 2013b; Humair 2014;
Polosa 2011; Valentine 2018), authors report that no SAEs
occurred. In NCT02648178 (19 participants), one death occurred (no
further detail provided). Hickling 2019 (50 participants) recruited
participants from mental health settings; five SAEs were recorded
during the study, all of which were psychiatric hospitalizations.
None were considered related to study treatment.
Carbon monoxide
Randomized controlled trials
Pooled data from two trials (neither considered at high risk of bias)
comparing nicotine EC with non-nicotine EC found lower exhaled
CO levels in people randomized to nicotine EC (MD −2.44 ppm,
95% CI −3.91 to −0.97; 171 participants; Analysis 3.4). Although
statistical heterogeneity was substantial (I2 = 71%), point estimates
in both studies favored nicotine EC. Three further randomized
studies measured CO levels in those assigned to nicotine EC and
those assigned to non-nicotine EC, but did not present data in a
way that could be pooled: George 2019 did not compare data by
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group; Tseng 2016 reports no between-group diIerences; and Meier
2017 found a slightly higher CO reading in those using nicotine EC,
but the clinical and statistical significance of this diIerence was
not clear (see Supplemental Table 3 for more detail). These data
are from all study participants based on group randomized, not on
subsequent EC or cigarette use.
Pooled data from six studies comparing nicotine EC to behavioral
support alone or no support resulted in a high I2 value (92%);
pooled results are not presented here (see Analysis 4.4 for
individual study data). Heterogeneity was primarily driven by
magnitude rather than direction of eIect, with results generally
favoring nicotine EC. Three further trials reported data which could
not be included in a meta-analysis. Walele 2018 compared nicotine
EC to cigarettes and found CO levels declined in the EC group
and remained similar to baseline in the cigarette group. Veldheer
2019 compared nicotine EC with a cigarette substitute (non-
pharmacological); change in CO was similar between groups. Czoli
2019 instructed baseline dual users to spend periods only using EC
or only using traditional cigarettes; CO measured during sole EC
use was lower than baseline and lower than during cigarette-only
periods. Further detail can be seen in Supplemental Table 3.
Data from other studies
Eighteen studies provided all participants with nicotine EC and
reported data on CO at one week or longer. In the 17 studies that
presented change over time, CO declined from baseline, although
in Ikonomidis 2018 CO levels were equivalent to baseline again at 24
weeks, and in Polosa 2014b a decline was observed in people who
quit smoking or reduced cigarette consumption by at least half, but
not in those who continued smoking at least half as many cigarettes
as they had from baseline.
Heart rate
Randomized controlled trials
One RCT (Caponnetto 2013a) provided data on heart rate and
compared nicotine EC with non-nicotine EC; there was a greater
decrease in heart rate in the nicotine EC arm (MD −2.80, 95% CI −3.85
to −1.74; 141 participants; Analysis 3.5). This was comparable with
findings from the one RCT (Hatsukami 2020) comparing nicotine
EC with no pharmacotherapy, which also found a greater reduction
in the EC arm (MD −2.70, 95% CI −4.25 to −1.15; 90 participants;
Analysis 4.5).
A further three RCTs provided data on heart rate which could not
be included in a meta-analysis. George 2019 compared nicotine
to non-nicotine EC and found no diIerence in heart rate between
arms; Walele 2018 compared a nicotine EC with a traditional
cigarette and reported "no clinically significant changes", and
Veldheer 2019 found decreases in both the nicotine EC and
QuitSmart cigarette substitute groups, with the decrease being
slightly greater in the latter group. See Supplemental Table 4 for
further information.
Data from other studies
Five studies in which all participants received a nicotine EC also
reported data on heart rate; changes were minimal and directions
of eIect were mixed (see Supplemental Table 4).
Blood pressure
Caponnetto 2013a found no diIerence in the change in systolic
blood pressure (BP) between nicotine EC and non-nicotine EC arms
(MD 0.60, 95% CI −0.99 to 2.19;1 41 participants; Analysis 3.6).
Similarly, Hatsukami 2020 and Ikonomidis 2018 found no diIerence
in the change in blood pressure when comparing nicotine EC to
cigarettes. However, Pulvers 2020 found a benefit in favor of the EC
arm; pooling data from these three studies resulted in high levels
of statistical heterogeneity (I2 = 82%), so pooled results are not
presented (Analysis 4.6). Three further RCTs measured change in
blood pressure but presented results in such a way that they could
not be pooled. George 2019 compared nicotine EC and non-nicotine
EC and combined data from both groups; BP declined over time.
Compared to a QuitSmart cigarette substitute, Veldheer 2019 found
EC led to a greater reduction in BP. Walele 2018 found "no clinically
significant changes" when comparing nicotine EC to a conventional
cigarette at two weeks. Further data can be found in Supplemental
Table 5.
Five studies which provided nicotine EC to all participants reported
change in blood pressure; results were mixed and small (Hickling
2019; Ikonomidis 2018; Oncken 2015; Van Staden 2013; Walele 2018;
see Supplemental Table 5).
Oxygen saturation
Hatsukami 2020 found a small increase in blood oxygen saturation
when comparing nicotine EC to cigarettes (MD 0.50%, 95% CI 0.31
to 0.69; 89 participants; Analysis 4.7). Van Staden 2013, a short-
term pre-post study which measured outcomes aOer two weeks of
EC use, found that people who smoked who switched to ECs had
significant improvement in blood oxygen saturation (96.2% (SD 1.8)
to 97.5% (SD 1.3); 1.3% increase, 95% CI 0.6 to 2.1; P = 0.002).
Toxicants
All randomized controlled trials measuring these outcomes
compared nicotine EC with no pharmacotherapy.
Two trials measured change in 3-HPMA (one at high risk of bias).
In both, the point estimate favored the EC arm, but statistical
heterogeneity was substantial (I2 = 97%), reflecting diIerences in
magnitude of eIect. We therefore do not present a pooled result,
but data from the studies can be seen in Analysis 4.8. Four further
studies in which all participants were given nicotine EC measured
3-HPMA; all found reductions over time (Supplemental Table 6).
Four  trials measured change in NNAL (three  at high risk of bias;
Analysis 4.9). Three of the four studies found results favoring
nicotine EC, but for the fourth the point estimate went in the
opposite direction; statistical heterogeneity was again high (I2 =
95%), so pooled results are not presented. Pulvers 2018, which
provided all participants with nicotine EC, found a reduction in
NNAL over time, and Czoli 2019, which was a cross-over trial,
found NNAL decreased when using nicotine EC compared to using
traditional cigarettes (Supplemental Table 6).
One trial found reductions in 2-HPMA and AAMA compared to
control (Analysis 4.10; Analysis 4.14), and a further two studies in
which all participants received nicotine EC found reductions in both
of these measures over time (Supplemental Table 6).
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One trial found reductions in S-PMA compared to control (Analysis
4.15); this was consistent with the one study (Goniewicz 2017) in
which all participants received nicotine EC that measured S-PMA,
where levels declined over time (Supplemental Table 6).
In single trials, changes favored EC for reductions in HMPMA
(Analysis 4.11), PheT (Analysis 4.12), and CEMA (Analysis 4.13). Of
the 19 remaining measurements in studies where all participants
received an EC, 14 reduced over time and five increased
(Supplemental Table 6).
Lung function
Caponnetto 2013a measured a number of lung function
parameters. FeNO increased more in the nicotine EC than the non-
nicotine EC group (MD 2.35, 95% CI 1.78 to 2.92; 90 participants;
Analysis 3.7). No diIerence was found between nicotine and non-
nicotine EC for FEV1, FVC, or FEV1/FVC (Analysis 3.8; Analysis 3.9;
Analysis 3.10).
Compared to behavioral support only/no support, Walele 2018
found improvements in FVC favoring nicotine EC (Analysis 4.16),
and no diIerence in FEV1 or PEF 25-75 (Analysis 4.17; Analysis
4.19). Pooled data from Walele 2018 and Pulvers 2020 showed
no diIerence in FEF 25-75, with substantial levels of statistical
heterogeneity (MD −0.06, 95% CI −0.18 to 0.06, I2 = 72%; 2 studies,
555 participants; Analysis 4.18).
Veldheer 2019, which randomized participants to nicotine EC or
the QuitSmart cigarette substitute, measured change in a number
of lung function parameters: direction of eIect was mixed across
these, with no statistically or clinically significant between-group
diIerences at 12 weeks (Supplemental Table 7).
Two studies which provided all participants with nicotine EC
measured change in lung function over time: Hickling 2019
found an increase in peak flow, and Oncken 2015 "no significant
diIerences" in airway function (Supplemental Table 7).
Combination therapy: nicotine EC and NRT
This section covers two comparisons: studies in which all arms
received NRT and participants were randomized to nicotine EC or
non-nicotine EC, and studies in which all participants received NRT
and one arm was randomized to nicotine EC in addition. All studies
contributing data are randomized controlled trials. No studies in
this group reported data on heart rate, blood pressure, oxygen, or
toxicants.
Cessation
Two trials (both at high risk of bias, both testing refillable devices)
in which all participants received NRT compared nicotine EC to
non-nicotine EC; pooled results favored nicotine EC (RR 1.77, 95%
CI 1.07 to 2.94; I2 = 0%; 1039 participants; Analysis 5.1). Walker
2020 also compared nicotine EC + NRT to NRT alone; the point
estimate favored nicotine EC but the confidence interval was wide
and included no diIerence (Analysis 6.1).
Adverse events
The two trials (both at high risk of bias) in which nicotine ECs
were compared to non-nicotine ECs in participants receiving NRT
found no evidence of a diIerence in the number of people
experiencing AEs between arms; data from Walker 2020 can be
seen in Analysis 5.2; Baldassarri 2018 reported results combined
across groups but noted "no significant diIerences by treatment
group" (Supplemental Table 1).
The two trials comparing nicotine EC + NRT to NRT alone that
contributed data to this outcome were both at high risk of bias.
Statistical heterogeneity was high when combining data (I2 = 79%)
and hence we do not present pooled results. In one study (Walker
2020), AEs were lower in the EC group and the confidence interval
excluded no diIerence, while in the other study (Guillaumier 2018)
AEs were higher in the EC group but the confidence interval was
wide (Analysis 6.2).
Serious adverse events
Walker 2020, comparing nicotine EC with non-nicotine EC as
adjuncts to NRT, had fewer SAEs in the nicotine EC group than in
the non-nicotine EC group, but the confidence interval includes no
diIerence (Analysis 5.3).
Three studies provided data on SAEs and compared nicotine EC
+ NRT to NRT alone. The pooled estimate favored the NRT-alone
group, but again the confidence interval was wide and included no
diIerence (RR 1.26, 95% CI 0.46 to 3.42: I2 = 0; 682 participants;
Analysis 6.3).
Carbon monoxide
Walker 2020 (which compared nicotine EC + NRT, non-nicotine
EC + NRT, and NRT alone) measured change in CO levels but did
not report data in a way that could be pooled. CO declined over
time, with the greatest reduction seen in the nicotine EC group
(see Supplemental Table 3). Baldassarri 2018, comparing nicotine
and non-nicotine EC as adjuncts to NRT, found a slightly greater
reduction in CO in the nicotine EC group, but the confidence interval
included no clear evidence of a diIerence (Analysis 5.4) between
groups.
Lung function
Baldassarri 2018, which compared nicotine EC to non-nicotine EC
and in which both groups received NRT, found no between-group
diIerences in FeNO, FEV1, or FVC (Analysis 5.5; Analysis 5.6; Analysis
5.7); confidence intervals were wide for all outcomes.
Comparisons based on nicotine dose
Two trials provided data comparing diIerent doses of nicotine
in EC (although other studies provided a range of doses, these
were not randomly assigned). In Caponnetto 2013a, where diIerent
concentrations were available via the same device, cessation and
adverse event data were not available. No serious adverse events
were reported in either arm (Analysis 7.1). There were no clinical
or statistically significant diIerences between arms for carbon
monoxide, heart rate, blood pressure, or lung function measures
(Analysis 7.2 to Analysis 7.8). In Yingst 2020 (cross-over, comparing
diIerent doses and diIerent devices) exhaled CO and reported
nausea were not diIerent between devices; self-reported dizziness
was low overall but slightly higher in the higher-dose arm. Further
detail can be found in Supplemental Table 1 and Supplemental
Table 3.
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Non-nicotine EC
Although non-nicotine ECs serve as a 'control group' in our primary
analysis, due to their behavioral properties they can also be
considered an intervention in and of themselves. Comparisons
included here are: non-nicotine EC versus NRT; non-nicotine EC
versus usual care; and non-nicotine EC as an adjunct to NRT. All
contributing data are from randomized controlled trials. None of
these studies reported data on change in CO, heart rate, blood
pressure, oxygen saturation, toxicants, or lung function.
Cessation
When comparing non-nicotine EC to behavioral support only,
pooled results from two studies (n = 388) found higher quit rates
in participants randomized to non-nicotine EC, but the confidence
interval included the possibility of no diIerence (RR 1.74, 95% CI
0.76 to 3.96; I2 = 0%; Analysis 8.1). When evaluating non-nicotine
EC as an adjunct to NRT, Walker 2020 also found higher quit rates
in participants randomized to non-nicotine EC, although again the
confidence interval included no diIerence (Analysis 9.1).
Lee 2019 compared non-nicotine EC with NRT; the point estimate
favored NRT but the confidence interval included no diIerence
(Analysis 10.1).
Adverse events
Eisenberg 2020 found a higher rate of adverse events in the EC
arm than in behavioral support only, with the confidence interval
excluding no diIerence (Analysis 8.2). By contrast, Walker 2020
found fewer adverse events in participants receiving non-nicotine
EC + NRT compared to NRT alone, with the confidence interval
excluding no diIerence (Analysis 9.2). Lee 2019 also found that
fewer participants receiving non-nicotine EC reported adverse
events than those receiving NRT, with the confidence interval
excluding no diIerence (Analysis 10.2).
Serious adverse events
Eisenberg 2020 found a higher rate of SAEs in the EC arm than
in the behavioral support-only arm, but confidence intervals were
wide and incorporated clinically significant benefit and clinically
significant harm (Analysis 8.3). In Walker 2020, more SAEs occurred
in the group randomized to non-nicotine EC + NRT than in the NRT-
alone group, but the confidence interval included no diIerence as
well as the potential for a clinically significant diIerence in favor of
the intervention (Analysis 9.3). No SAEs were reported in either arm
of Lee 2019 (non-nicotine EC versus NRT).
D I S C U S S I O N
Summary of main results
This update includes a further six studies compared with the
previously published version. Our three main comparisons,
nicotine EC compared to NRT, nicotine EC compared to non-
nicotine EC, and nicotine EC compared to behavioral support only/
no support still show increased quit rates in people assigned
to nicotine EC arms; this is moderate-certainty for the first two
comparisons, and very low certainty for the latter  (Summary of
findings 1; Summary of findings 2;   Summary of findings 3). In
absolute terms, pooled data suggest an additional four people for
every 100 would quit smoking with nicotine EC compared to non-
nicotine EC or to NRT, and that an additional seven people per
100 would quit if oIered a nicotine EC compared to being oIered
behavioral support alone or no support. Most data come from
studies of cartridge devices which deliver relatively little nicotine in
comparison to newer device models. However, within newer device
models with better nicotine delivery, this update includes the first
included study of a pod device (Pulvers 2020).
The certainty of the evidence for adverse events in nicotine EC
compared to non-nicotine EC has been upgraded from low- to
moderate-certainty evidence of no diIerence. Evidence on adverse
events (AEs) and serious adverse events (SAEs) was of low to very
low certainty across all other comparisons, due to a paucity of data.
SAEs were rare, in both intervention and comparator arms, with
many of the studies which measured SAEs reporting no such events
in either study arm. For nicotine EC compared to non-nicotine
EC, pooled data suggest no diIerence in the number of people
experiencing AEs and one fewer person per 100 experiencing SAEs
with nicotine EC compared to non-nicotine EC arms, but confidence
intervals include no diIerence. Conversely, data from comparisons
between nicotine EC and behavioral support alone or no support
suggest an additional 13 people per 100 assigned to nicotine EC
may experience AEs, with no diIerence in the number experiencing
SAEs. As with AEs from other smoking cessation treatments (e.g.
NRT,   Hartmann-Boyce 2018a), these events typically related to
irritation at site (e.g. dry mouth, cough) and resolved over time.
Compared to NRT, one fewer person per 100 might be expected
to experience an AE if assigned to nicotine EC, and two additional
people per 100 might be expected to experience an SAE. These
figures should be treated with caution, due to large confidence
intervals encompassing no clinically significant diIerence. The
small amount of contributing data, and the variation in 'control
group' risk across comparisons, reflect diIerent methods of
collecting data and diIerent lengths of follow-up. No studies in
any of the diIerent comparison conditions detected serious harms
considered to be related to EC use.
Beyond AEs and SAEs, we consider data on a range of safety- and
health-related outcomes, including carbon monoxide and other
toxins, lung function, blood pressure, pulse, and oxygen levels. Data
on all of these outcome measures are limited; for most outcomes
within most comparisons, only one study currently contributes
data. Pooled data from two studies in which all participants
received nicotine replacement therapy showed that nicotine EC
led to higher quit rates than non-nicotine EC, but we judged both
studies to be at high risk of bias, meaning the eIect remains
uncertain.
Overall completeness and applicability of evidence
This field of research and EC devices themselves continue to evolve
rapidly. This is the first update conducted as part of our 'living
systematic review' approach, with which we will proceed for at
least the next 12 months, meaning we can continue to rapidly
incorporate new evidence (see Appendix 1). This is important, as all
of our analyses currently suIer from imprecision.
This update captures data from the past year, up to February
2021. Subsequent monthly searches will keep this review current.
Although studies predominantly came from the USA and UK,
overall this review covers data from 14 countries; geographical
range in studies may be particularly important in this area, due
to the marked diIerences in EC regulation between countries;
for example, studies conducted in countries that limit nicotine
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dose in EC or allow only certain EC devices to be tested may
observe less pronounced eIects on quitting. This review includes
studies in some 'harder to reach' populations, including people
not motivated to quit smoking, people with substance misuse
disorders, and people experiencing homelessness. Quit rates in
these groups are traditionally lower, which may make it more
diIicult to detect eIects of interventions. However, it could be
that these groups may particularly stand to benefit from EC if they
are eIective, because in absolute terms conventional cessation
methods are oOen not as eIective for them.
As well as the rapid pace of research in this field, EC technology
itself continues to evolve, which poses a challenge when
considering the applicability of our evidence to the present. We had
downgraded the certainty of our data in the 2016 update, as the
devices tested in the trials were first-generation 'cig-a-like' devices
which did not deliver nicotine well, meaning the studies may have
yielded more conservative estimates than would be seen with
newer models, as newer devices and models have tended towards
improved nicotine delivery. Nicotine delivery is also relevant to the
comparator NRT arms tested; use of both a shorter- and a longer-
acting form of NRT shows the highest success, and it is important
that where possible this be the comparator chosen for such trials
(Lindson 2019).
Regarding EC device type, in the 2020 update and now in this
update, we have more data from newer devices, although there
will always be a time lag between current devices and the research
evidence available. None of the analyses of our primary outcomes
signified substantial levels of statistical heterogeneity, despite the
fact that diIerent devices were used in the included studies.
However, this could be because confidence intervals were wide
for individual studies, and does not rule out clinically significant
diIerences in eIects between EC types. As further data emerge,
we hope to be able to formally test for diIerences in subgroup
analyses, and ideally over time in head-to-head comparisons of
diIerent device types. Our review now includes one study of
a pod device (Pulvers 2020) and one study directly comparing
device types (Yingst 2020). However, neither contributes data to our
cessation outcomes.
The adverse eIects described in both the RCT and cohort studies
continue to look similar, regardless of the brand of EC used
or nicotine content, with placebo and nicotine-containing ECs
showing similar numbers and types of adverse events in direct
comparisons. They also reflect what is reported in survey data
(Dawkins 2013b; Etter 2011), so we believe that they are broadly
applicable to most EC brands.
There has been concern raised that the dual use of cigarettes and EC
may expose people to greater health risks, including higher nicotine
levels. However, given that people who smoke like to maintain
relatively stable blood nicotine levels (Russell 1990), receiving
nicotine from an alternative source (i.e. EC) is likely to reduce
nicotine intake from cigarettes, which should be accompanied
by a reduction in smoke and toxin intake (Fagerström 2004). In
a study assessing biochemical changes exclusively in dual-users,
there was a significant decrease in exhaled carbon monoxide levels
and urinary 3-HMPA (McRobbie 2015). In this update, we found one
new study conducted in dual-users. Similar to McRobbie 2015, Czoli
2019 found that levels of biomarkers of exposure to toxicants were
significantly lower when participants exclusively used EC compared
to dual use; by contrast, biomarkers of exposure  increased when
participants exclusively smoked as compared to dual use. These
results are supported by longer-term studies in people who smoke
and were provided with ECs, which found decreases in exhaled
carbon monoxide among dual-users (Adriaens 2014; Pacifici 2015;
Polosa 2011; Polosa 2014b).
The structure of our analyses follows standard practice of the
Cochrane Tobacco Addiction Group, i.e. evaluating outcomes on an
intention-to-treat basis, meaning our pooled results represent the
eIect of oering an EC intervention. This is diIerent from evaluating
the per protocol eIect, or the eIect only in those who use the EC
to quit smoking entirely, or continue to smoke whilst also using EC.
Some of our included studies have also assessed data using these
groupings and we have attempted to note this in the supplemental
tables. Although pragmatic and hopefully of use to those designing
and delivering interventions, we acknowledge that our intention-
to-treat approach limits the ability to use the data presented here
to draw conclusions about biomarkers in subgroups of participants
based on subsequent EC use/smoking profiles.
Certainty of the evidence
We consider the certainty of the evidence below as it relates
to primary outcomes for our three main comparisons: nicotine
EC versus NRT; nicotine EC versus non-nicotine EC; nicotine EC
versus behavioral support only/no support (Summary of findings
1; Summary of findings 2; Summary of findings 3). The certainty
of evidence for all other comparisons and outcomes should be
considered very low due to a paucity of data.
Our 'Summary of findings' tables and assessments of certainty are
based on the evidence from randomized controlled trials (RCTs).
The cohort studies that we include were all deemed to have high
risks of bias, which is inherent in the study design. Data presented
from these studies need to be interpreted with caution. However,
data from cohort studies were reassuringly consistent with data
from RCTs.
Risk of bias did not impact on the certainty of evidence for
comparisons between nicotine and non-nicotine EC, or between
nicotine EC and NRT. For the latter, we judged all three studies
to be at low risk of bias overall. For the former, removing the
one study at high risk of bias increased the eIect estimate for
our eIicacy outcome. Risk of bias decreased our certainty in the
eIect estimates for our nicotine EC versus behavioral support only/
no support comparison, as due to the nature of the comparison,
blinding was not possible and diIerential levels of support could
lead to bias. All but one of our main comparisons were downgraded
for imprecision, due to wide confidence intervals and few events.
Other than risk of bias and imprecision, we identified no other
issues which decreased the certainty of the primary outcomes for
our main comparisons. In the previous version of this review we
had downgraded cessation outcomes for indirectness, due to the
included studies testing devices that were no longer available due
to poor nicotine delivery (we therefore judged it plausible that our
analyses could be underestimating the eIect of devices available
at the time the review was published). In this version, we no longer
downgrade on this basis, as this update includes a wider range of
EC models, including more recent devices, and heterogeneity in
outcomes remains low.
Electronic cigarettes for smoking cessation (Review)









Cochrane Database of Systematic Reviews
Cessation
All three comparisons found eIect estimates favoring nicotine EC
for smoking cessation. For nicotine EC versus non-nicotine EC
and for nicotine EC versus NRT, we judged the evidence to be of
moderate certainty, meaning we think the true eIect is likely to be
close to the estimate of eIect. For nicotine EC versus behavioral
support only/no support, we judged the evidence to be of very
low certainty, meaning we have very little confidence in the eIect
estimate. Another way to look at this, however, is to consider
that nicotine EC versus non-nicotine EC comparisons isolate the
eIect of nicotine as provided by an EC, and nicotine EC versus
NRT comparisons isolate the eIect of the sensorimotor elements
provided by an EC. Given that both of these comparisons find
a benefit of nicotine EC for smoking cessation, it might logically
follow that the comparison between nicotine EC and behavioral
support only/no support would find a benefit in favor of nicotine
EC, since this comparison would capture both pharmacological and
sensorimotor mechanisms of eIect. This increases our confidence
in the eIect of nicotine EC when compared to behavioral support
alone or to no support.
Adverse and serious adverse events
In this update, we have upgraded the certainty of evidence
for adverse events in the nicotine EC versus non-nicotine EC
comparison; the addition of new data has led to narrower
confidence intervals, and as a result we have upgraded the
evidence from low to moderate certainty of no diIerence. For our
other comparisons and adverse eIect outcomes, eIect estimates
of adverse events and serious adverse events were judged to be of
low or very low certainty, with the main problem being imprecision.
This means the true eIect may be substantially diIerent from the
estimate of the eIect. None of the analyses signaled serious harm,
nor did complementary data from cohort studies, but unlike our
cessation analyses, many of the confidence intervals encompassed
the possibility of both clinically significant harm and clinically
significant benefit. This uncertainty should reduce as more studies
become available.
Potential biases in the review process
We consider the review process we used to be robust. For
outcome assessment, we followed the standard methods used for
Cochrane Tobacco Addiction Review Group cessation reviews. Our
search strategy included the Cochrane Tobacco Addiction Group
Specialized Register and we were able to capture a number of
ongoing studies. However, there may be unpublished data that our
searches did not uncover. We also considered participants lost to
follow-up as continuing to smoke, which is standard practice in this
field. There are concerns that frequently updating meta-analyses
can lead to issues with multiple testing; we followed Cochrane
guidance in conducting this living systematic review and hence do
not adjust for multiple testing (Brooker 2019).
Three of our review authors are authors of included studies. These
authors were not involved in the decisions about inclusion of their
studies, or in data extraction or 'Risk of bias' assessment for these
studies.
Agreements and disagreements with other studies or
reviews
This Cochrane Review aligns with but updates the conclusions of
the 2018 U.S. National Academies of Science, Engineering, and
Medicine‘s Consensus Study Report, Public Health Consequences
of E-cigarettes (NASEM 2018), which reviewed literature published
through August 2017 to address the question, “Do e-cigarettes help
smokers quit smoking combustible tobacco cigarettes?”. Focusing
on RCTs and existing systematic reviews, it used a prespecified
Level of Evidence framework to develop conclusions. The report’s
overall conclusion was that there was “limited evidence that e-
cigarettes may be eIective aids to promote smoking cessation.”
Based on the RCTs available, it concluded that there was “moderate
evidence” that e-cigarettes containing nicotine were more eIective
for cessation than e-cigarettes without nicotine, but “insuIicient
evidence” about the eIectiveness of e-cigarettes compared to no
treatment or to FDA-approved smoking cessation treatments. Our
review contradicts this latter point, as we now find moderate-
certainty evidence of benefit when comparing nicotine EC with NRT;
this is primarily due to a large RCT published aOer NASEM 2018.
A 2021 review from Public Health England, which cites the 2020
version of this Cochrane Review, concludes that, compared to their
2018 review, there is now stronger evidence that nicotine vaping
products are eIective for smoking cessation (McNeill 2021).
Findings are also broadly consistent with those from other reviews
published in the past year, with some exceptions. Amato 2020 did
not evaluate eIectiveness and focused only on safety; consistent
with our review, they found very low- to moderate-certainty
evidence on a range of possible adverse eIects, with the most
frequently reported being cough, dry mouth, shortness of breath,
irritation of the mouth and throat, and headache. Akiyama 2021
reviewed biomarker findings from clinical studies and concluded
that the use of EC could lead to a significant reduction in exposure
to harmful substances compared to traditional cigarettes; this is
again consistent with findings from our review. Martinez-Morata
2021 reviewed blood pressure findings and concluded that EC may
result in short-term elevations, but that more data are needed; our
review also lacks suIicient data to draw any conclusions about
blood pressure at one week or longer.
Zhang 2021 conducted a rapid review; while their pooled analysis
also suggested that EC increased quit rates compared to NRT or
non-nicotine EC, they judged the evidence to be of low certainty
according to GRADE. As with us, they downgraded by one level
due to inconsistency, but unlike us they also downgraded by
one level for statistical heterogeneity. Zhang 2021 combined
studies with NRT comparators and those with non-nicotine EC
comparators in the same analysis and found moderate statistical
heterogeneity; we evaluated these two comparisons separately and
did not find evidence of statistical heterogeneity. Patnode 2021
reviewed evidence on tobacco cessation interventions for the US
Preventive Services Task Force (USPFTS 2021). They state that none
of their included EC trials suggested higher rates of serious adverse
events; this is in line with our analyses. However, they report
that findings across EC trials were inconsistent for eIectiveness,
with some finding statistically significant evidence of benefit and
some finding no statistically significant diIerence. They did not
conduct statistical meta-analyses and include five trials, all of
which are included in our cessation meta-analyses. None of our
cessation meta-analyses, which include these trials, detected levels
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of heterogeneity beyond what would be expected from chance
alone. Wang 2021 reviewed data both from observational studies
and from randomized controlled trials; in the trials, e-cigarettes
were associated with increased smoking cessation (as with our
review). In observational studies, ECs were not associated with
increased smoking cessation. As discussed in Methods,   although
we included non-randomized studies in which an EC intervention
is provided in this review, we do not include observational studies
in which no EC intervention is provided, due to known issues with
confounding.
Reviews of ECs for policymaking are oOen broader in scope than
our review, which focuses exclusively on their role in supporting
smoking cessation in people who smoke. Outside of smoking
cessation, there remain unanswered questions about the impact of
EC availability and use on young people; we hope to evaluate this
in a separate review.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Evidence suggesting nicotine EC can aid in smoking cessation
is consistent across several comparisons. There was moderate-
certainty evidence, limited by imprecision, that EC with nicotine
increased quit rates at six months or longer compared to non-
nicotine EC and compared to NRT. There was very low-certainty
evidence (limited by risk of bias as well as imprecision) that EC with
nicotine increased quit rates compared to behavioral support alone
or to no support.
The eIect of nicotine EC when added to NRT was unclear.
None of the included studies (short- to mid-term, up to two years)
detected serious adverse events considered possibly related to EC
use. The most commonly-reported adverse eIects were throat/
mouth irritation, headache, cough, and nausea, which tended
to dissipate with continued use. In some studies, reduced toxin
concentrations and biomarkers of harm were observed in people
who smoked and switched to vaping, consistent with reductions
seen in smoking cessation.
Implications for research
Further randomized controlled trials of nicotine EC are needed,
following up participants at six months or longer. Studies with
active comparators (i.e. comparing nicotine EC to frontline smoking
cessation pharmacotherapies) are likely to be of particular use to
decision-makers. All studies (including uncontrolled intervention
cohort studies) should aim to assess the safety profile of electronic
cigarettes for as long as possible (the current review only includes
data up to two years), and ideally be powered to detect diIerences
in safety outcomes, including adverse events and serious adverse
events. Evidence from one well-conducted RCT suggests that
people who quit smoking using EC may continue to use EC longer
than they might use other stop-smoking pharmacotherapies,
making assessments of their long-term safety profile particularly
important. Safety results should be presented in both absolute
and relative risk terms (in comparison to the risks of continuing to
smoke tobacco).
Studies should oIer recent devices to participants, to be most
representative of what will be on the market at the time results
are released. Data on pod-type EC are particularly lacking, though
we now include one trial. Protocols and statistical analysis plans
should be registered in advance and openly available.
Further RCTs need to be adequately powered. Further trials of pod
devices would be of particular value, as would RCTs providing EC
in a way that would be used in real-world settings (e.g. taking into
account individual preferences for strengths and flavors of e-liquids
and even EC devices, and also allowing for changes in preferences
over time).
Further reviews, using best available methods, need to be
conducted to evaluate the possible relationships between EC
use and availability and youth uptake of EC and conventional
cigarettes.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Design: 3-armed RCT; with all participants then assigned to nicotine EC (treated as cohort in this re-
view)
Recruitment: Advertisement on university website, flyers on university campuses, emails to personnel
and advertisement in local newspaper
Setting: Community and laboratory, Belgium
Study start date/end date: Not stated
Participants Total N: 48 provided data
Randomized to: EC1 16; EC2 17; control 17
Inclusion criteria:
• Smoker for at least 3 years,





• Asthma or other respiratory diseases; psychiatric problems;





• Currently using any kind of smoking cessation therapy; prior use of EC
56% women, mean age 44, mean cpd 19, mean FTCD 5.79, all unwilling to quit with no baseline EC use
Interventions EC: Refillable
Adriaens 2014 
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Intervention: 2 intervention groups (EC1 and EC2) provided with EC and instructed to use EC or smoke
ad libitum (EC1 group provided with Joyetech eGO-C, EC2 group provided with Kanger T2-CC) and pro-
vided guidance on EC use. For both types, provided 30 mL bottles of tobacco-flavored e-liquid (Dekang
“Turkish Blend”), containing 18 mg/mL of nicotine. 4 bottles at baseline replenished at 4 weeks, keep
any remaining after 8 weeks
Control: 6 bottles for 2 months at week 8 (half offered EC1, half offered EC2); no guidance on use
Outcomes 3 lab sessions over 2 months (weeks 1, 4 and 8), plus online questionnaires, further follow-up at 3 and 6
m after last lab session
Cessation: measured but definition not provided, validated with eCO 5 ppm or less
Adverse events and biomarkers: eCO, salivary cotinine measured during lab sessions. Also collected
craving and withdrawal symptoms via lab sessions, “benefits and complaints”, mood, EC usage
Study funding "No external funding for this study was obtained. Electronic cigarettes and e-liquids were purchased at
E-cig4U (`t Rond 10, 4285 DE Woudrichem, The Netherlands; http://www.e-cig4u.nl/) with balances of
previous research funds obtained by Frank Baeyens."
Author declarations The authors declare no conflict of interest
Notes Randomization was for short-term outcomes only
Additional data provided from authors
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomization was performed by using a randomization tool available
on the website www.randomizer.org
Allocation concealment
(selection bias)





Low risk Unblinded but as this review only includes data on objective measurements
and not cessation judged unlikely to affect outcomes
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Unblinded but as this review only includes data on objective measurements




Low risk 36 out of 48 completed follow-up (11/16 in EC1 group, 12/17 in EC2 group,
13/17 in control group)
Selective reporting (re-
porting bias)
Unclear risk Outcome reporting somewhat non-traditional; for example, collecting com-
plaints but not explicitly adverse events, and incidence of AEs not reported.
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Methods Design: Randomized parallel-assignment double-blind trial
Recruitment: outpatient pulmonary and primary care clinics, Tobacco Treatment Service, referrals
from medical providers
Setting: Hospital outpatient and primary care clinics, USA
Study start date: October 2014; Study end date: June 2014
Participants Total N: 40
N per arm: Non-Nicotine: 20; Nicotine EC: 20
Inclusion criteria:
• Age 18 years or older
• Smoking 1 or more cpd
• Willing to quit smoking
Exclusion criteria:
• Unstable psychiatric or medical conditions requiring hospitalization within the past 4 months;
• Acute coronary syndromes or stroke within the past 30 days;
• History of allergic reactions to adhesives;
• Women who were pregnant, nursing, or not practicing effective contraception;
• Current use of an EC for the purpose of stopping tobacco cigarette smoking
Women: 52.5%; Mean age: 53 Mean cpd: 17 Mean FTND: 5.9; motivated to quit
E cigarette use at baseline: Not reported
Interventions EC: Refillable
Both groups received standard care (8 weeks nicotine patch and counseling) and were randomized to
nicotine EC or non-nicotine EC.
EC: eGO style EC (650 mAh battery, EVOD clearomizer, 3.7 V, 1.8 Ω single bottom coil), provided with e-
liquid purchased from an online vape shop (0 mg/ml or 24 mg/ml nicotine strength, 70/30 propylene
glycol/vegetable glycerin, tobacco flavor); Instructed to use it as needed as a substitute for tobacco to
try to satisfy cravings to smoke. If the patch alone proved adequate to prevent withdrawal and smoking
cravings, the participant was advised not to use the EC. Additional EC devices, replacement coils, and
liquid were provided as needed for the first 8 weeks of the study
Outcomes Questionnaires and CO measurements taken at baseline, treatment visits at week 2, 4, 6, 8 and fol-
low-up at week 24
Cessation: 7-day point prevalence abstinence, eCO ≤ 6 ppm
Adverse events and biomarkers: Side effects were measured although it is unclear whether a question-
naire with prespecified symptoms was used
Spirometry and FeNO at baseline and 6-month follow-up
Other outcomes: Change in reported number of cpd at weeks 8 and 24; Change in per cent predicted
FEV1 and FVC from baseline to week 24, and EC use patterns
Study funding "Funding for this study was provided by the Yale School of Medicine, Section of Pulmonary, Critical
Care, and Sleep Medicine and the National Heart, Lung, and Blood Institute grant T32HL007778. NHLBI
had no role in the study design, collection, analysis, or interpretation of the data, writing the manu-
script, or the decision to submit the paper for publication."
Baldassarri 2018  (Continued)
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Author declarations "Dr. Toll received a grant from Pfizer for medicine only for a research study, and he receives funding as
an expert witness in litigation filed against the tobacco industry. Dr. Chupp received grants from NIH,
Genetech, Glaxo Smith Kline, Astra Zeneca/Medimmune and Boston Scientific. He received consult-
ing/speaking fees from Genetech, Astra Zeneca/Medimmune, Mannkind, and Boston Scientific. There
are no other conflicts of interest for the remaining authors."
Notes New for 2020 update. Study listed as ongoing study NCT02498145 in 2016 review update
Additional data provided from authors
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “Participants were randomized using a random number generator with
1:1 blocked randomization (block size n= 8).”
Allocation concealment
(selection bias)
Unclear risk Both groups received standard care (nicotine patch and counseling) and were





Low risk Quote: “Treatment assignment was blinded to both the investigators and par-
ticipants”
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk Quote: “The study had a modest loss to follow-up (20%) at week 24.”
Number lost to follow-up in each group is not reported in the paper
Week 24 retention rate: Nicotine EC group: 19/20 (95%); Non-nicotine EC
group: 13/20 (65%); > 20% difference between groups
Selective reporting (re-
porting bias)
Low risk Outcomes reported align with those listed in the clinicaltrials.gov record. (reg-





Methods Design: Pragmatic, uncontrolled, mixed-methods trial
Recruitment: Targeted settings for people with HIV
Setting: Community, Brisbane, Australia
Study start date: 21 February 2017; Study end date: 26 October 2017
Participants Total N: 30
Inclusion criteria:
• Diagnosis of HIV
• Aged 18 years, or over
• Smoke ≥ 5 cpd at the time of enrolment into the trial
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• Have been smoking for at least 12 months
• Willing to attempt to quit tobacco smoking after study enrolment
Exclusion criteria:
• Participating in a smoking-cessation programmed
• Pregnant or breastfeeding or planning to be during trial period
• Experienced chest pain, or another cardiovascular event or procedure in the last month
• Being treated with oxygen therapy
Inclusion based on specific population characteristic: People living with HIV
29 participants identified as male, and 1 participant did not identify as male or female; Mean age: 42;
Mean cpd: 18
EC use at baseline: 46.7% (n = 14) Never tried; 50% (n = 15) Tried, never used for an extended period;
3.3% (n = 1) Used on a regularly (weekly) basis
Willing to attempt to quit
Interventions EC: Refillable
Single-arm study. Print materials to help quit smoking. Provided booklet with instructions on how to
use, store and handle EC; copies of device user manuals. Given Innokin Endura T18® vaporiser kit, In-
nokin Endura T22® vaporiser kit, 4 spare coils, 1 wall charger, 10 x 10-mL bottles of Nicophar® 12 mg
nicotine e-liquid. Supplies to last 12 weeks
Outcomes Weeks 1, 4, 8, 12, 24; Self-report and semistructured interviews
Cessation: 7 days point prevalence at weeks 4, 8, 12 and 24. Continuous abstinence at weeks 12 and 24.
No biochemical validation
Adverse events
Other outcomes: Acceptability and use of trial products; Number of quit attempts
Study funding "This work was supported by the HIV Foundation Queensland. The funder will play no role in the analy-
sis and interpretation of results. All trial products were purchased and the suppliers have no involve-
ment in the conduct of the trial or the interpretation or reporting of the results."
Author declarations "No other authors declare conflicts of interest. Mark Boyd has received research grant funding (paid to
the institution) from AbbVie, Gilead and Merck and received honoraria for participation in HIV Adviso-
ry Boards and for the preparation and delivery of educational materials from AbbVie, Boehringer-Ingel-
heim, Bristol Myers Squibb, Gilead, Janssen-Cilag, Merck and ViiV Healthcare."
Notes Additional data provided from authors. New for 2020 update
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Uncontrolled study
Allocation concealment
(selection bias)




Low risk Quote: “At Week 24, 26 of the 30 participants who enrolled in the study were
followed up.” (confirmed by authors)
Bell 2017  (Continued)
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Selective reporting (re-
porting bias)





Methods Design: 3 parallel groups RCT
Recruitment: People who smoke recruited from the community, via newspaper advertisements
Setting: Research Unit, New Zealand
Study start date: 6 September 2011; Study end date: 5 July 2013
Participants Total N: 657. 289 nicotine EC (NEC), 295 patch, 73 non-nicotine EC (PEC)
Inclusion criteria:
• 18 years of age or older;
• Smoked 10 or more cpd over past year;
• Wanted to stop smoking
Exclusion criteria:
• Pregnant and breastfeeding
• Using cessation medicines or using other support to quit
• Heart attack,
• Stroke,
• Severe angina in the last 2 weeks,
• Poorly-controlled medical disorder,
• Allergies,
• Other chemical dependence
62% women, mean age 42, ⅓ NZ Maori, smoking 18 cpd, mean FTND score 5.5
Motivated to quit
E cigarette use at baseline: Not specified
Interventions EC: Cig-a-like
Randomized to NEC, PATCH or PEC use for 13 weeks (from 1 week prior to TQD)
• NEC: Elusion brand 16 mg cartridges; sent product via courier
• PATCH: 21 mg/24-hour patch; sent voucher to exchange for NRT at pharmacy (dispensing costs cov-
ered)
• PEC: As per EC, but 0 mg cartridges
All participants referred to Quitline and received an invitation to access phone- or text-based support.
This was accessed by < 10%
Outcomes Sustained (≤ 5 cigarettes allowed) validated (exhaled breath CO < 10 ppm) abstinence at 6 months
≥ 50% self-reported reduction in baseline cigarettes at 6 months
Participants reporting any adverse events
Proportion of AEs that were serious
Bullen 2013 
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Proportion of unrelated AEs
Study funding Health Research Council of New Zealand
Author declarations "We declare that we have received no support from any companies for the submitted work and have
no non-financial interests that might be relevant to the submitted work. ML, via his company Health
New Zealand, previously did research funded by Ruyan (an e-cigarette manufacturer). CB and HM have
done research on Ruyan e-cigarettes funded by Health New Zealand, independently of Ruyan. HM has
received honoraria for speaking at research symposia, has received benefits in kind and travel support
from, and has provided consultancy to, the manufacturers of smoking cessation drugs. NW has provid-
ed consultancy to the manufacturers of smoking cessation drugs, received honoraria for speaking at a
research meeting and received benefits in kind and travel support from a manufacturer of smoking ces-
sation drugs. JW has provided consultancy to the manufacturers of smoking cessation medications."
Notes Accessed support: NEC: 115/289; PATCH: 106/295; PEC: 26/73
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computerized block randomization
Allocation concealment
(selection bias)





Low risk NEC and PEC were blind to treatment condition in relation to one another. No
blinding for NEC/PEC vs PATCH conditions, but as NEC and PATCH were both
active treatments performance bias judged unlikely
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk LTFU 22% (all considered to be smoking). Patch group had a higher LTFU and
withdrawal than EC (loss to follow-up 17% NEC, 27% patches, 22% PEC). How-
ever, minimal difference in per-protocol and ITT analyses
Selective reporting (re-
porting bias)





Methods Design: 3-arm double-blind randomized controlled trial: EC with 7.2 mg nicotine for 12 weeks; same for
6 weeks followed by 5.2 mg for 6 weeks: EC with no nicotine for 12 weeks
Recruitment: Newspaper advertisements
Setting: Outpatient clinic, Italy
Study start date: April 2010; Study end date:April 2012
Participants Total N: 300
Caponnetto 2013a 
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Inclusion criteria:
• Smoked at least 10 cpd for past 5 years;
• Age 18 - 70
• In good health
• Not currently or intending to quit smoking in the next 30 days
Exclusion criteria:
• Symptomatic cardiovascular or respiratory disease
• Regular psychotropic medicine use
• Current or past history of alcohol abuse
• Use of smokeless tobacco or NRT
• Pregnant or breastfeeding
36% women, mean age 44 (SD 12.5), mean cpd 20 (IQR: 15 - 25)
Not currently or intending to quit smoking in the next 30 days
E cigarette use at baseline: Not specified
Interventions EC: Cig-a-like
EC presented as a healthier alternative to tobacco smoke and could be freely used, ad libitum (up to 4
cartridges a day) for 12 weeks, as a tobacco substitute
EC used: 'Categoria' (model 401) with disposable cartridges
• Grp A: 12 weeks of 7.2 mg capsules ('Original')
• Grp B: 6 weeks 7.2 mg ('Original'), then 6 weeks 5.4 mg ('Categoria')
• Grp C: 12 weeks of 0 mg ('Original')
Baseline visit and up to 7 follow-up visits to receive more cartridges, hand-in diaries, measure CO and
vital signs
Outcomes Abstinence at 12 months (complete self-reported abstinence from tobacco smoking since previous visit
at 6 months, confirmed with CO < 7 ppm at 12 months)
≥ 50% reduction in baseline cigarettes at 12 months
Recorded AEs thought to be related to tobacco smoking and EC at baseline and at each study visit (7
follow-up visits over 12 weeks, plus at 24 and 52 weeks)
Study funding "This research was supported by a grant-in-aid from Lega Italiana AntiFumo. The study sponsor had no
involvement in the study design, collection, analysis, and interpretation of data, the writing of the man-
uscript or the decision to submit the manuscript for publication. RP and PC are currently funded by the
University of Catania, Italy. The e-cigarette supplier had no involvement in the study design, collection,
analysis, and interpretation of data, the writing of the manuscript or the decision to submit the manu-
script for publication."
Author declarations "RP has received lecture fees and research funding from Pfizer and GlaxoSmithKline, manufacturers of
stop smoking medications. He has served as a consultant for Pfizer and Arbi Group Srl, the distributor
of the CategoriaTM e-Cigarette. The other authors have no relevant conflict of interest to declare in re-
lation to this work."
Notes Additional data provided from authors
Risk of bias
Bias Authors' judgement Support for judgement
Caponnetto 2013a  (Continued)
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Random sequence genera-
tion (selection bias)
Low risk Computer-generated, block size 15 (5:5:5 ratio)
Allocation concealment
(selection bias)







Quote: “Blinding was ensured by the identical external appearance of the car-
tridges. The hospital pharmacy was in charge of randomization and packaging
of the cigarettes”
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk 211 (70.3%) and 183 (61%) attended 6- and 12-month follow-up (at 12 m, 35%
lost in 7.2 group; 37% lost in 5.4 group; 45% lost in no-nicotine group)
Selective reporting (re-
porting bias)
Unclear risk Unclear if original intention was to combine groups A+B or not. In sample size






Methods Design: Prospective cohort
Recruitment and setting: Inpatients at a psychiatric institution in Italy
Study start date/end date: Not specified
Participants Total N: 14
Inclusion criteria:
• Smoked ≥ 20 cpd for at least the past 10 years
• Diagnosis of schizophrenia
Exclusion criteria:
• Alcohol and illicit drug use
• Recent myocardial infarction
• Angina pectoris
• High blood pressure (BP > 140 mmHg systolic or 90 mmHg diastolic, or both)
• Diabetes mellitus
• Severe allergies
• Poorly-controlled asthma or other airway diseases
• Inclusion based on specific population characteristic: Diagnosis of schizophrenia
57% women, mean age 44.6 (SD 12.5), mean pack years smoked 28.8 (SD 12.9)
Motivated to quit: Not specified
E cigarette use at baseline: Not specified
Caponnetto 2013b 
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Interventions EC: Cig-a-like
Seen at baseline, given EC ('Categoria' brand) with an initial 4-week supply of 7.4 mg nicotine car-
tridges. Instructed to use ad libitum up to 4 cartridges a day. EC cartridges supplied at months 1, 2, and
3
No instruction on cessation or reduction was provided.
Outcomes Follow-up at 1, 2, 3, 6 and 12 months where cigarette consumption, CO, AEs and positive and negative
symptoms of schizophrenia were measured
Sustained reduction of ≥ 50% for at least 30 days at 12 months
30-day point prevalence CO-validated abstinence at 12 months
Adverse events
Study funding "We wish to thank Arbi Group Srl (Milano, Italy) for the free supplies of “Categoria” e-cigarette kits and
nicotine cartridges as well as their support. We would also like to thank LIAF (Lega Italiana AntiFumo)
for the collaboration."
Author declarations "Pasquale Caponnetto, Roberta Auditore, Cristina Russo and Giorgio Carlo Cappello declare no con-
flict of interest. Riccardo Polosa has received lecture fees and research funding from Pfizer and Glax-
oSmithKline, manufacturers of stop smoking medications. He has served as a consultant for Pfizer and
Arbi Group Srl (Milano, Italy), the distributor of the CategoriaTM e-cigarette."
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Prospective cohort; no randomization
Allocation concealment
(selection bias)




Low risk 0/14 lost to follow-up
Selective reporting (re-
porting bias)





Methods Design: Randomized parallel-assignment open-label trial
Recruitment: Recruitment from local urban community in southeastern USA, using various media out-
lets
Setting: Community, southeastern USA
Study start date: November 2014; Study end date: May 2016
Carpenter 2017 
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Participants Total N: 68
N per arm: Control group: 22; ENDS group: 46 (split into 2 non-randomized groups: BluCig 16 mg: 25;
BluCig 24 mg: 21)
Inclusion criteria:
• Age 18+
• Current smoker of ≥ 5 cpd for ≥ 1 year
• No recent history of cardiovascular distress, COPD, cancer (any non-dermatologic), or uncontrolled
diabetes mellitus
• Neither pregnant nor breastfeeding (verified)
• Absence of any major current psychiatric impairment, including current alcohol/drug abuse/depen-
dence
• Current, active use of email
• At least some concern for health effects of smoking (> none at all on a Likert scale)
• Not used any ENDS product in the past 6 months
• Never purchased an ENDS product
Exclusion criteria:
• Use of non-cigarette tobacco products (e.g. cigarillos) in the last 30 days
• Current use of any smoking cessation medications
• Current enrolment in a smoking cessation treatment study
Women: 59.7%; Mean age: 42.2; Mean cpd: 15.3; Heaviness of smoking (0 - 6): 2.9
EC use: Control: 9%; ENDS 16 mg group: 4%; ENDS 24mg group: 33%
Motivation to quit smoking in next month (0 – 10): Control: 4.0; ENDS 16 mg: 5.0; ENDS 24 mg: 4.4
Interventions EC: Cig-a-like
Intervention: At study start, choice of tobacco or menthol flavor Blu Starter Pack EC, with 16 mg/mL
nicotine. Midway through study, the manufacturer of Blu altered the product and discontinued avail-
ability of the device, replaced with BluPlusþ, with 24 mg/mL nicotine. 3-week sampling period, given
up to 7 cartridges at each of 3 weekly visits. Instructions on usage "kept minimal to preserve naturalis-
tic intent." The study team suggested that ENDS could be used "as you wish, to cut down or quit smok-
ing, help manage smoking restrictions, or both."
Control: own brand of cigarettes
Outcomes Weeks 2, 3, 4, 8, 12 and 16
Carbon monoxide, NNAL
Other outcomes: cessation (< 6 months), product evaluation, EMA
Study funding "Support was provided by NIH R21 DA037407 (to M.J. Carpenter), P01 CA200512 (to K.M. Cummings,
M.J. Carpenter, and M.L. Goniewicz), UL1 TR001450, and P30 CA138313. M.L. Goniewicz's laboratory is
supported via P30 CA016056. B.W. Heckman is supported via K12 DA031794 and K23 DA041616. T.L. Wa-
gener's effort is partially supported by the Oklahoma Tobacco Research Center, which is funded by the
Oklahoma Tobacco Settlement Endowment Trust."
Author declarations "M.L. Goniewicz is a consultant/advisory board member for Johnson & Johnson. K.M. Cummings re-
ports receiving a commercial research grant from and is a consultant/advisory board member for Pfiz-
er Inc., and has provided expert witness testimony for various plaintiffs in lawsuits involving cigarette
manufacturers. No potential conflicts of interest were disclosed by the other authors."
Carpenter 2017  (Continued)
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Notes New for 2020 update. Listed as ongoing study NCT02357173 in 2016 review update. Additional data pro-
vided from authors
In all, 25 participants (54%) received the Blu Starter Pack (16 mg), and 21 participants (46%) received
BluPlusþ (24 mg); no switches were made within participants. Note: this is not included in our analysis
of higher v lower as assignment to nicotine dose was not done at random; 24 mg and 16 mg merged in
our main analysis
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: “Randomization to group was stratified by motivation to quit in the
next 30 days (0–6 vs. 7–10 on a VAS scale) but proportioned 2:1 (ENDS:control)
to increase precision estimates for e-cigarette uptake and usage.”
Allocation concealment
(selection bias)





High risk Not blinded and includes non-active control
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk CO biochemically verified but abstinence not used as outcome in this review,





Low risk Retention rate:
Week 4: Control:19/22 (86%); ENDS 16 mg: 23/25 (92%); ENDS 24 mg: 20/21
(95%)




Unclear risk Not specified
Other bias Low risk Midway through the study, the manufacturer of Blu altered the product and
discontinued availability of the device, replaced with BluPlusþ, with 24 mg/
mL nicotine, again offered in both tobacco and menthol flavorings, and with
improved battery duration (4-watt battery for both devices). In all, 25 partici-
pants (54%) received the Blu Starter Pack (16 mg), and 21 participants (46%)
received BluPlusþ (24 mg); no switches were made within participants. The
change in product (IRB approved) allowed us the unexpected opportunity to
assess what impact, if any, the change in product design had on study out-
comes. Note that the manufacturer, style of device, and packaging did not
change, nor did our messaging to participants. The only difference was the
strength of product. Thus, trial outcomes are reported across 3 groups: control
versus 16 mg versus 24 mg ENDS. We have not rated this as high risk of bias as
our analyses do not compare on nicotine strength and both nicotine arms are
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Methods Design: Nonblinded within-participants cross-over
Recruitment: advertisements placed in newspapers, online, and in local vape shops, and received CAD
295 for participating in the study
Setting: Kitchener−Waterloo and Toronto, Ontario, Canada
Study start date: September 2015. Study end date: NR
Participants Total N: 48
29.2% female; mean age 35.9 (SD 11.7); mean cpd NR; dual EC users at baseline; not motivated to quit
Inclusion criteria:
• > 18
• Dual user s of tobacco cigarettes and e-cigarettes. Dual users were identified as current daily tobacco
cigarette smokers (had smoked ≥ 100 cigarettes in their lifetime, and smoked ≥ 5 cigarettes/day) and
current daily e-cigarette users (had used an e-cigarette at least once a day for each of the past 7 days)
Exclusion criteria:
• Serious intentions to quit smoking in the next 6 months
• use of other tobacco products in the past 7 days
• use of nicotine replacement therapy in the past 7 days
• use of any smoking cessation medications in the past 7 days
• participation in individual or group counseling programs for smoking cessation in the past 7 days
• experience of serious cardiac health issues
• experience of a heart attack or stroke within the last 3 months
• experience of cancer within the last year
• experience of asthma, chronic obstructive pulmonary disease, a seizure disorder, or any life-threat-
ening medical conditions with a prognosis of less than a year
• a history of psychosis, schizophrenia, bipolar disorder, or suicidal thoughts
Interventions EC: own choice (mainly tank)
3 consecutive 7-day periods in which the use of tobacco cigarettes and e-cigarettes was experimentally
manipulated
4 study conditions: Dual use (e-cigarette and tobacco cigarette); Tobacco cigarette; E-cigarette; No
product use
Virtually all dual users reported using tank systems (92%) and e-cigarettes with nicotine (94%)
To control for order effects, participants were randomly assigned to 1 of 2 condition orders, A or B
Following the baseline condition of dual use:
Group A participants switched to E-cigarette use, then to Tobacco cigarette use, and finally to No prod-
uct use
Group B participants switched to Tobacco cigarette use, then to E-cigarette use, and finally to No prod-
uct use
Outcomes Baseline (visit 1) and after each of the 7-day periods (visit 2 (week 1), visit 3 (week 2), visit 4 (week 3))
Carbon monoxide
Urinary concentration of cotinine
Czoli 2019  (Continued)
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Urinary concentrations of 1-hydroxypyrene (1-HOP) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol
(NNAL)
Study funding This research was supported by an Ontario Ministry of Health and LongTerm Care Health System Re-
search Fund grant (#06697 awarded to DH). Additional support was provided by the Canadian Institutes
of Health Research (CIHR), the Vanier Canada Graduate Scholarship (CDC), a CIHR and Public Health
Agency of Canada, Applied Public Health Chair (DH), and an Ontario Institute for Cancer Research In-
vestigator Award (GTF)
Author declarations MLG reports grants from and served as an advisory board member to pharmaceutical companies that
manufacture smoking cessation drugs. DH has provided paid expert testimony in tobacco litigation on
behalf of governments and class-action plaintiffs on issues related to tobacco product science and reg-
ulation. The other authors have no competing interests to declare
Notes New for 2021 update
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details of randomization method given
Allocation concealment
(selection bias)





High risk No blinding
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk All followed up
Selective reporting (re-
porting bias)





Methods Design: Prospective cohort 4-center pragmatic cluster feasibility trial
Recruitment: At homeless centers
Setting: 4 homeless centers in the UK
Study start date: 1 October 2018; Study end date: 31 March 2020
Participants Total N: 80
N per arm: EC 48; UC 32
Dawkins 2020 
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Inclusion criteria:
• Adults who smoke (18 and over) accessing homeless support services on a regular basis and also
known to staI
• Self-reported daily smokers only with smoking status also confirmed by support staI
• Smoking status was also biochemically verified by exhaled CO breath
Exclusion criteria:
• Non-smokers, or those reporting using another smoking cessation aid at the current time
• Anyone below the age 18 years, reporting pregnancy, or unable to consent, e.g. currently intoxicated
or unable to speak English
• All those not well known to centre staI were ineligible
Inclusion based on specific population characteristic: people accessing homeless centers
35% women; mean age 42.7; mean cpd 20; mean FTND: FTCD 5.51
Motivated to quit: “varied considerably; large majority expressed a desire to quit smoking in the near
future”
E-cigarette use at baseline: Not specified
Interventions EC: Refillable
Usual care: Written information on quitting smoking (adapted from NHS Choices); signposting to the
local stop-smoking service (SSS) by center staI
Intervention: as usual care, plus refillable EC provided once with e-liquid provided 1 x wk for 4 weeks,
Aspire PockeX (tank style), choice of 3 flavors (fruit, menthol, tobacco) and 2 nicotine strengths (12 mg/
mL or 18 mg/mL). Written info for EC use and support from center staI, who met once a week to pro-
vide e-liquid and troubleshoot EC use
Outcomes Weeks: 4, 12, 24; Clinic visits and self-report
Cessation: CO-validated sustained at 24 weeks
Adverse events and biomarkers: Self-reported negative effects in EC arm only – each participant asked
to rate on scale so cannot meta-analyse; exhaled CO; unintended consequences
Other outcomes measured:
Qualitative process evaluation; costs; self-reported positive and negative affects; recruitment rates; re-
tention; EC/other tobacco/nicotine product use at study end; HRQoL; healthcare service utilization;
other drug use/dependence; unintended consequences
Study funding This study is funded by the National Institute for Health Research Public Health (project reference:
17/44/29)
Author declarations SC, AF, JL, CB, AT, DR, IU, LB, SP have no competing interests. PH has received research grant from and
provided consultancy to Pfizer. LD has provided consultancy for the pharmaceutical industry relating
to the development of smoking cessation products
Notes New for 2021 update. Authors provided information prior to peer review
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Intention was to randomize but were unable to due to practical constraints
Dawkins 2020  (Continued)
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Quote: “Thus the actual allocation of centres to each arm was a pragmatic de-
cision based on centre readiness and staI/researcher availability though we
balance potential confounders and differences in environment by ensuring
each cluster (EC and UC) contained one day centre and one residential unit.”
Allocation concealment
(selection bias)
Unclear risk Quote: “Participants joined after cluster randomisation… Allocation was con-
cealed to participants until after the baseline assessment.”
Comment: But unclear if allocation was concealed for those recruiting, and al-





High risk Not blinded and different levels of support between arms, so performance bias
cannot be ruled out
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk 13/48 (27.1%) lost to follow-up in the intervention arm and 20/32 (62.5%) lost
to follow-up in the control arm at 24 weeks
Selective reporting (re-
porting bias)





Methods Design: 3-arm RCT
Recruitment: Community
Setting: Canada
Study start date: November 2016. Study end date: September 2019.
Participants Total N: 376; Nicotine e-cigarettes = 128; Non-nicotine e-cigarettes = 127; Counselling (control) = 121
47% female; mean age 52.66; mean cpd 21; mean FTND 6 (SD 2).
Motivated to quit - Yes
Inclusion criteria:
• Active smoker, 10 or more cigarettes per day, on average, for the past year
• Age of 18 years or older
• Motivated to quit according to the Motivation To Stop Scale (MTSS) (level 5 or higher)
• Able to understand and to provide informed consent in English or French
• Likely to be available for follow-up (1 year)
Exclusion criteria:
• Medical condition with a prognosis < 1 year
• Current or recent cancer (less than 1 year in remission)
• Pregnant or lactating women
Eisenberg 2020 
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• Current or recent use (in the past 30 days) of any pharmacotherapy or behavioral therapy for smoking
cessation (e.g. nicotine replacement
• Therapies, bupropion, varenicline, or counseling)
• Any e-cigarette use (nicotine or non-nicotine) in the past 60 days, or ever use of any e-cigarette for
more than 7 days consecutively
• History of psychosis, schizophrenia, or bipolar disorder
• Less than 1 month following a myocardial infarction, life-threatening arrhythmia, severe or worsening
angina pectoris, or cerebral vascular accident
• Use of any illegal drugs in the past year (excluding marijuana)
• Planned use of tobacco products other than conventional cigarettes (e.g. cigarillos, cigars, snuI,
shisha, etc.) or marijuana during the study period
Interventions EC: Cig-a-like
Nicotine e-cigarettes plus counseling:
12 weeks of e-cigarettes. Rechargeable base with prefilled, disposable, tobacco-flavored liquid car-
tridges (15 or 0 mg nicotine/mL), which were produced specifically for use in clinical studies (purchased
from NJOY Inc, Scottsdale, Arizona). 21 cartridges at baseline with additional cartridges supplied as
needed. Nicotine and nonnicotine e-cigarettes were identical in appearance. Instructed to be used as
desired. No schedule for e-cigarette tapering, but participants were aware that they would return their
e-cigarettes after 12 weeks
Participants received individual smoking cessation and relapse prevention counseling (minimum 30
minutes at baseline, 10 minutes during telephone follow-ups, and 15 - 20 minutes at clinic visits). Indi-
vidualized quit plans
Non-nicotine e-cigarettes plus counseling:
As above with 0 mg nicotine/mL in liquid cartridge
Counseling (control):
Participants received individual smoking cessation and relapse prevention counseling (minimum 30
minutes at baseline, 10 minutes during telephone follow-ups, and 15 - 20 minutes at clinic visits). Indi-
vidualized quit plans
Outcomes Follow-up was conducted by telephone at weeks 1, 2, 8, and 18, and at clinic visits at weeks 4, 12, 24,
and 52
Self-reported smoking (7-day recall), adherence, and adverse events (AEs) were assessed during fol-
low-up contacts
Biochemically-validated 7-day point prevalence smoking abstinence at 4, 12 and 24 weeks, defined as
self-reported abstinence in the past 7 days with exhaled carbon monoxide < 11 ppm
At baseline: cpd; FTND; Glover-Nilsson Smoking Behavioral Questionnaire (to assess behavioral depen-
dence on smoking); and Beck Depression Inventory II (BDI-II; to assess depressive symptoms)
Study funding This trial was funded by the Canadian Institutes of Health Research (CIHR; funding reference No.
133727 and 155969). Both nicotine e-cigarettes and nonnicotine e-cigarettes were purchased from
NJOY Inc (Scottsdale, Arizona)
Author declarations Dr Eisenberg reported receiving educational grants from Pfizer Inc for providing continuing medical ed-
ucation in cardiology. Dr Wilderman reported receiving financial compensation from Pfizer Inc for his
involvement in a smoking cessation study using varenicline. Dr Filion reported receiving salary support
from the Fonds de Recherche du Quebec, a William Dawson Scholar award from McGill University, and
personal fees from Institut National D’excellence en Santé et Services Sociaux. No other disclosures
were reported
Eisenberg 2020  (Continued)
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Notes New cessation and adverse event data for 2021 update. Previously listed as NCT02417467 (included
with SAE data only)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Eligible participants were randomized via an online central randomization sys-
tem. The system used a computer-generated randomization list containing
permuted blocks of 6 and 9, stratified by center
Allocation concealment
(selection bias)
Low risk Participants, investigators, and study personnel were blinded to nicotine con-





Low risk Participants, investigators, and study personnel were blinded to nicotine con-
tent in the e-cigarette groups
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Participants, investigators, and study personnel were blinded to nicotine con-




Low risk Low numbers lost to follow-up, treated as ITT
Selective reporting (re-
porting bias)
Low risk Due to a prolonged and unforeseen delay in e-cigarette manufacturing, en-
rolment was paused on 27 September 2019, and then terminated on 14 No-
vember 2019. Given reduced power, the timing of the primary endpoint was
changed from 52 weeks to 12 weeks on 04 December 2019. No 12-month fol-





Methods Design: Prospective cohort
Recruitment: Letter sent to family practice patients who currently smoked
Setting: Single family practice, Colorado USA
Study start date: 14 April 2013; Study end date: Not specified
Participants Letters sent to 640 patients, 48 chose to participate and 44 completed the program, 4 were lost to fol-
low-up
Inclusion criteria:
• Want to quit or switch from tobacco cigarettes to ECs
Exclusion criteria:
• None reported
Of the 44 participants, 66% women, all non-Hispanic/white, aged 20 - 75 (30% were age 51 - 60), 57%
had a high school education or less
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Motivated to quit: Want to quit or switch from tobacco cigarettes to ECs
E-cigarette use at baseline: Not specified
Interventions EC: Cig-a-like
The 6-month smoking cessation program was based on The '5 A's' model and transtheoretical model.
Options for treatment were discussed with each participant at the start of the program. All used an EC,
with 16 using bupropion and 2 using varenicline as well
Participants were provided with written information on “blu cig” and “smoke tip” ECs, about cost,
availability, nicotine dosage options
Outcomes Phone follow-ups at 2 weeks, 1 month, 3 months, and 6 months
At completion of program (using ITT)
Abstinence from smoking and EC use
Abstinence from smoking but not EC use
≥ 50% reduction of baseline cigarette consumption (still using ECs)
Study funding Not specified
Author declarations Not specified
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Prospective cohort
Allocation concealment
(selection bias)




Low risk 4/48 lost to follow-up
Selective reporting (re-
porting bias)
Unclear risk Unable to determine prespecified outcomes
Other bias Unclear risk No definition of abstinence provided





Methods Design: Double-blind RCT
Recruitment: People who smoke were recruited from an outpatient opioid-maintenance clinic in West
Virginia, USA
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Setting: Outpatient opioid-maintenance clinic in West Virginia, USA
Study start date/Study end date: Not reported
Participants Total N: 25; N per arm: Placebo (non-nicotine): 11; Active (18 mg/ml nicotine): 14
Inclusion criteria:
• ≥18 years of age
• Report smoking ≥10 cpd for ≥ one year
• Report a current interest in quitting smoking
Exclusion criteria:
• Reported regular use of any nicotine/tobacco product other than cigarettes, including EC, or were
already engaged in attempts to quit smoking
Inclusion based on specific population characteristic: People who smoke who were currently receiving
a buprenorphine/naloxone combination in sublingual form, and had maintained sobriety from opioids
and all other illicit substances for at least 90 consecutive days as verified via urinalysis
73.0% women; mean age 32.5; mean cpd 22; mean FTND 5.8
Motivated to quit: Quit ladder Score (range 1 - 10): 5.6 average
Interventions EC: Refillable
Compared nicotine (18 mg/ml) to non-nicotine EC.
Second-generation EC consisted of the eGo-T battery (900mAh, 3.3 V constant output) (Joyetech;
Irvine, CA) and the Kanger mini Protank-II, 1.5 ml Pyrex glass tank with a drip tip and atomizer head
coils (KangerTech; China), choice between tobacco (n = 15) and menthol (n = 10) flavored liquid (2-week
supply). Participants were then trained in EC device operation, including assembly, liquid filling, man-
ual battery operation, and cleaning/storage. Practised puffing on EC in the presence of a team mem-
ber, and asked questions if needed. Participants instructed to use their ECIG ad libitum every day for 2
weeks
Outcomes Baseline (day 1), 14 days, 28 days for clinic measures. Data also collected via text-messages over 2-
week intervention period
Withdrawal/side effects: Every evening during the 2-week intervention period, participants rated a va-
riety of effects possibly experienced as a result of nicotine/tobacco withdrawal and/or use of the ECIG:
nausea, dizziness, throat irritation/soreness, cough, dry mouth, headache, shortness of breath, irri-
tability/frustration/anger, craving/urge to smoke, and other. Each item was rated on a continuous scale
that ranged from 0 (not at all) to 100 (extremely)
Expired air CO
Other outcomes: Self-reported cigarette and EC use; readiness to quit at day 1, 14 and 28
Study funding Not reported
Author declarations Not reported
Notes New for 2020 update
Risk of bias
Bias Authors' judgement Support for judgement
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Random sequence genera-
tion (selection bias)
Unclear risk Quote: “Using a mixed factorial, simple randomization, double-blind study de-









Unclear risk Quote: “double-blind study design”, no further detail given
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Quote: “…80.6% completed the two-week intervention (n=14 active; n=11
placebo), and 70.9% also completed the follow-up session (n=13 active; n=9
placebo).”
Active follow-up completion rate: 13/14 = 93%; Placebo follow-up completion
rate: 9/11= 82%
N.B. 6 participants were disqualified post-randomization: 
Quote: “Of those individuals who were screened for the study, 93.9% were en-
rolled (n = 18 active; n = 13 placebo); two individuals who were ineligible pro-
vided an expired air CO level < 10 ppm. Six of the enrolled participants (n = 4
active and n = 2 placebo; n = 5 tobacco flavor and n = 1 menthol flavor) were
disqualified for responding to 7 or fewer days of text messages.”
Selective reporting (re-
porting bias)
Unclear risk All measures listed were reported: Self-reported cigarette use, text mes-
sage-based cigarette use, e-cig use, expired air CO, readiness to quit ladder,
withdrawal/side effect;
No study protocol or clinical trial record available to confirm all intended out-





Methods Design: Prospective, randomized controlled trial with a parallel, nonrandomized preference cohort
Recruitment: Participants were recruited from local advertisements, smoking cessation databases, and
visits to local businesses, as well as via the Scottish Primary Care Research Network
Setting: Single tertiary research centre, UK
Study start date: August 2016; Study end date: July 2018
Participants Total N: 114 in “final evaluable dataset” (145 recruited into the trial)
N per arm: Tobacco cigarettes (TC): 40; EC nicotine (16 mg): 37; EC-Nicotine-free: 37
Inclusion criteria:
• People who smoke ≥ 18 years of age who had smoked ≥ 15 cigarettes/day for at least 2 years
George 2019 
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• were free from established CV disease, diabetes, and chronic kidney disease; and were not on med-
ication for those conditions
• Willing to stop tobacco cigarettes for period of study if required
• Willing not to use electronic cigarettes if required
• Able to give informed consent
Exclusion criteria:
• Pregnant or lactating
• Women of childbearing potential who do not abstain from sex or use effective contraception
• On current prescribed medication for cardiovascular disease
• History of cardiovascular disease (excluding hypertension), diabetes, active malignance or chronic
renal disease
• Nut allergy
• Participation in another clinical trial (other than observational trials and registries) with an investiga-
tional product and/or intervention within 30 days before visit 1
65.4% women; mean age 46.9; mean cpd 18.7
Motivated to quit: TC group: No; EC nicotine (16 mg): Yes; EC-Nicotine-free: Yes.
Interventions EC: Cig-a-like
EC nicotine (16 mg) arm: EC containing 16 mg nicotine (Vapourlites Starter Kit with XR5 16 mg nicotine
cartomizer; Vapourlites, Peterlee, United Kingdom)
EC-Nicotine-free arm: Nicotine-free EC plus nicotine flavoring (Vapourlites Starter Kit with 0 mg nico-
tine cartomizer)
(non-randomized) TC arm: continued their usual daily smoking habits and did not use EC for the 4-
week period of the trial
Outcomes Week 4
Adverse events and biomarkers: BP, heart rate, adverse events
Other outcomes measured: Endothelial function, oxidized low-density lipoprotein, high-sensitivity C-
reactive protein, tissue plasminogen activator, and platelet activation inhibitor-1
Study funding "The VESUVIUS (Vascular Effects of Regular Cigarettes Versus Electronic Cigarette Use) trial was fund-
ed by the British Heart Foundation (grant PG/15/64/31681); and supported by Immunoassay Biomark-
er Core Laboratory, University of Dundee, the Tayside Medical Sciences Centre, and the NHS Tayside
Smoking Cessation Service. The funder had no role in the study design, data collection, data analysis,
data interpretation, writing of the report, or in the decision to submit for publication."
Author declarations "Dr. Donnan has received research grants from AbbVie, Shire, and Gilead Sciences. All other authors
have reported that they have no relationships relevant to the contents of this paper to disclose."
Notes New for 2020 update
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Consented participants who were willing to quit smoking were randomized
to one of the EC arms in a 1:1 fashion using a centrally controlled web-based
good clinical practices– compliant randomization system to either: 1) EC con-
taining 16 mg nicotine; or 2) nicotine-free EC plus nicotine flavoring because
it was considered by the institutional ethics committee as ethically unaccept-
able to randomize those who were willing to quit smoking into a smoking arm.
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Unclear risk Not specified
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Not blinded and AE/SAE data are self-report only. For other outcomes, low risk
as objectively measured:
Quote: “Patients fasted overnight and measurements were conducted at base-
line and 1 month according to the International Brachial Artery Reactivity Task
Force guidelines (19) by a single operator (M.H.) blinded to study allocation at
a single site.”
“Pulse wave velocity and augmentation index were measured at baseline and




Unclear risk Number randomized not provided per group.
Quote: “A total of 145 patients were recruited into the trial (Figure 1). A final




Low risk Clinical trial record lists: Change in FMD; Change in oxidized LDL; Change in
PAI-1; Change in hs-CRP; Change in Pulse Wave Velocity; Change in tPA; Change
in Augmentation Index@75bpm





Methods Design: Longitudinal within-subjects observational
Recruitment: Advertisements in the media, the internet, posted advertisements in clinics and offices,
and by word of mouth
Setting: University, Poland
Study start date: March 2011; Study end date: June 2011
Participants Total N: 22 started out and 2 dropped out in the first week due to an adverse event (nausea) and inabili-
ty to commit to clinic visits. This resulted in analytic sample of 20
Inclusion criteria:
• 18 or older, current daily cigarette smokers (> 5 cpd within the last 12 months)
• May have had interest in quitting smoking, in good health (at the clinic screening visit)
• Able to communicate in Polish
• Able to use an e-cigarette safely
Exclusion criteria:
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• Diagnosed as having asthma, COPD, hypertension, inhaled allergies, chronic heart disease, or cancer
• were taking a cardiac medication
• were pregnant
60% women; mean age 31; mean cpd 16; mean FTND 3.9
Motivated to quit: At the time of screening, 95% of participants (n = 19) reported planning to quit smok-
ing, with 80% (n = 16) reporting that they have made at least 1 quit attempt prior to involvement in the
study
E cigarette use at baseline: Not reported
Interventions EC: Cig-a-like
Pen-style M201 e-cigarettes for 2 weeks, with an automatically-operated battery with an output power
of 4.6 Volts (280 mAh) and the heating element resistance of 3.6 – 3.8 Ohms. At baseline, provided with
EC (M201 Mild, Poland) with 20 tobacco-flavored cartridges a week containing 11.0 ± 1.5 mg of nicotine
in a mixture of propylene glycol and vegetable glycerin (50:50). Encouraged to substitute their regular
cigarettes with the e-cigarette for 2 weeks and refrain from smoking
Outcomes Day 7, Day 14
Adverse events and biomarkers:
• Biomarkers were metabolites of 13 major carcinogens and toxicants in cigarette smoke: 1 tobac-
co-specific nitrosamine (NNK), eight volatile organic compounds (1.3-butadiene, crotonaldehyde,
acrolein, benzene, acrylamide, acrylonitrile, ethylene oxide, and propylene oxide), and 4 polycyclic
aromatic hydrocarbons (naphthalene, fluorene, phenanthrene, and pyrene)
• Questionnaire on ‘health’: At each visit, participants were asked, “In the last week, have you experi-
enced any of the following symptoms?”, while providing a response of “never,” “rarely,” or “often” to
the following list of health effects: daytime cough, difficulty concentrating, difficulty breathing dur-
ing sleep, difficulty sleeping, dizziness, headache, irritability, nausea, nighttime cough, chest pain,
phlegm, shortness of breath, tightness in chest, visual disturbances, and wheezing. Responses of
“rarely” or “often” were combined to indicate presence of an adverse health effect
• Expired CO
Other outcomes measured:
• 7 nicotine metabolites (3-Hydroxycotinine, Cotinine, Cotinine N-Oxide, Nicotine N-Oxide, Norcotinine,
Nornicotine, Nicotine)
• Revised Minnesota Nicotine Withdrawal Scale (MNWS-R) administered to measure ‘withdrawal symp-
toms’ (0 - 5 rating scale)
Study funding “This work was supported by the Ministry of Science and Higher Education of Poland (grant number N
N404 025638). Instrumentation and analytical chemistry at UCSF was supported by the National Insti-
tutes of Health, P30 DA012393 and S10 RR026437. The study sponsor had no involvement in the study
design, collection, analysis, and interpretation of data, the writing of the manuscript or the decision to
submit the manuscript for publication.”
Author declarations "MLG was a faculty member of the Medical University of Silesia, Poland during the study. He received a
research grant from Pfizer, a pharmaceutical company that markets smoking cessation medications.
MLG and NLB have been consultants to pharmaceutical companies that market smoking cessation
medications. NLB has been an expert witness in litigation against tobacco companies. The other au-
thors declare no potential conflicts of interest."
Notes New for 2020 update
Risk of bias
Bias Authors' judgement Support for judgement
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Random sequence genera-
tion (selection bias)
High risk Not randomized
Allocation concealment
(selection bias)













Methods Design: Pragmatic, open-label, single-centre, 2-arm randomized controlled trial
Recruitment: Withdrawal service in Melbourne, Australia
Setting: Substance use disorder treatment setting, and following discharge, community setting, Mel-
bourne, Australia
Study start date: 1 August 2017; Study end date: April 2019.
Participants Total N: 100
N per arm: EC intervention = 50; NRT Control = 50
Inclusion criteria:
• Aged 18 years or over
• Tobacco smoker on entering the residential service
• Have the capacity to consent and able to understand the participant materials and follow the study
instructions and procedures (e.g. sufficient English language ability)
Exclusion criteria:
• Have used an END containing nicotine in the past month;
• Currently pregnant or breast-feeding (measured by self-report);
• Currently enrolled in another study;
• Scheduled to be transferred to a long-term rehabilitation unit following discharge from the residential
withdrawal unit.
Inclusion based on specific population characteristic: Participants were discharged from a smoke-free
alcohol or other drugs (AOD) residential withdrawal service
32% women; mean age 40.9; mean cpd 21
Motivated to quit: Median (SD) = 7.3 (2.4) of 1 to 10 scale with 10 "highly motivated"
Interventions EC: Refillable.
Up to an hours training session, information pack. Innokin Endura T22 starter kit and refill liquid
(Nicophar). 4-week supply of liquid nicotine, with further supplies of liquid nicotine mailed twice at 4-
week intervals. Dosing schedule of e-liquid dependent nicotine dependence score: high-nicotine-de-
pendence category assigned initial 4-week e-liquid supply (total 8 × 10 ml bottles) consisting of: 2 × 10
ml bottles of 18 mg e-liquid and 6 × 10 ml bottles of 12 mg e-liquid. The second and third batches = 8 ×
Guillaumier 2018 
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10 ml bottles of 12 mg e-liquid only. Participants scoring in the moderate- and low-dependence cate-
gories: three 4-week supplies of 8 × 10 ml bottles of 12 mg e-liquid. Participants given 1-week supply of
nicotine patches for use while getting used to the EC.
NRT control: Information pack, 12 weeks NRT on the same schedule as for ENDs. 4-week supply of
patches plus a nicotine spray and inhaler, followed by refills including patches plus inhaler, gum and
lozenges.
Both groups received proactive referral to quitline counseling (call-back service), which provides calls
at pre-discharge and on days 1, 3, 7, 14 and 28 post-discharge, with an emphasis on relapse prevention.
Counsellors trained on the use of ENDs.
Outcomes Week 6, 12; self-report.
Adverse events collected
Other outcomes measured:
• Acceptability and feasibility of interventions
• Treatment adherence
• Cigarettes smoked per day - Heaviness of Smoking Index
• Frequency of cravings
• Minnesota Nicotine Withdrawal Scale (MNWS)
• 10-item Kessler Psychological Distress Scale (Kessler-10)
• Quitting self-efficacy, motivation to quit and the Heaviness of Smoking Index were assessed at base-
line
Study funding "The study is supported by a VicHealth Innovation Research Grant (2016–0096). AG is supported by a
post-doctoral fellowship from the Heart Foundation. ALB is supported by an Australian National Health
and Medical Research Council (NHMRC) senior research fellowship and a Faculty of Health and Medi-
cine, University of Newcastle Gladys M Brawn senior research fellowship. BB is supported by an Aus-
tralian NHMRC career development fellowship (GNT1063206) and a Faculty of Health and Medicine,
University of Newcastle Gladys M Brawn career development fellowship."
"This study was supported by a VicHealth Innovation Research Grant (2016-0096)."
Author declarations "The authors declare that they have no competing interests."
"None to declare."
Notes New for 2020 update; additional data originally provided by authors and subsequently published
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “Upon completing the baseline survey, participants were randomised
1:1 to an intervention via a computer-sequenced 4–6 block randomisation em-
bedded in the tablet device software.”
Allocation concealment
(selection bias)
Low risk Quote: “At the end of the baseline survey, participants will be randomised 1:1
to an intervention via a computer-sequenced 4–6 block randomisation em-





High risk Quote: “Participants were informed of their intervention group by the RA and
provided with a training session of up to one hour.”
“Due to the nature of the intervention, neither participants nor staI can be
blinded to allocation. However, the data safety monitoring committee and the
statistician responsible for the data analysis will be blinded.”
Guillaumier 2018  (Continued)
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Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Quote: “At 6 and 12-weeks, 63 participants (63%) and 50 participants (50%)
were followed up, respectively. While slightly higher retention rates were evi-
dence in the VNP group at 6-weeks (68% vs 58% in NRT group; p=0.300); there










Methods Design: Prospective cohort, intervention provided
Recruitment: People who smoke attending stop-smoking service
Study start date: March 2014; Study end date: March 2015
Setting: Stop-smoking service, London, UK
Participants Total N: 100 (69 of whom accepted offer of EC)
Inclusion criteria:
• All people who smoked joining stop-smoking service
38% women (those who accepted) 55% women (those who declined), mean age 41, mean cpd 14, all
motivated to quit. EC use at baseline not specified but some who declined EC offer had used EC in the
past
Motivated to quit: Yes
E-cigarette use at baseline: Not specified
Interventions EC: Cig-a-like and refillable
EC: offered to all people who smoke joining service; offered choice of ‘cig-a-like’ (Gamucci, 1.6% or
2.2% nicotine per ml) product or tank model (EVOD, 1.8%; later replaced with Aspire product due to
leakage issues). 69% of those offered received an EC on TQD
Medication: Offered stop-smoking medications including NRT and varenicline as in standard protocol.
Of EC users 33% opted to also use NRT, 29% varenicline, 38% nothing
Support: weekly, as in standard protocol
Outcomes Adverse events collected throughout, method for collection unclear
Also collected: 4-week biochemically-validated abstinence, participant feedback, cost
Study funding "The pilot study was sponsored by City of London Corporation."
Author declarations "Peter Hajek received research funds from and provided consultancy to manufacturers of smoking ces-
sation medications. The remaining authors have no conflicts of interest to declare."
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Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Not randomized
Allocation concealment
(selection bias)













Methods Design: Multicentre pragmatic randomized controlled trial to examine the efficacy of e-cigarettes com-
pared with nicotine replacement therapy
Recruitment: participants attending UK stop-smoking service and via social media
Setting: U.K. National Health Service stop-smoking services
Study start date: 1 April 2015; Study end date: 31 March 2018
Participants Total N: 886
N per arm: EC: 439; NRT: 447
Inclusion criteria:
• Adults who smoke (aged 18 or over) with no strong preference to use or not to use nicotine replace-
ment or e-cigarettes, and were currently not using either type of product
• Able to read/write/understand English
Exclusion criteria:
• Pregnant or breastfeeding
• Strong preference to use or not use NRT or EC, currently not using either type of product
48% women; median age 41; median cpd 15 ; mean FTND 4.6; 41.5% reported past use of ECs
Motivated to quit: Not reported
Interventions EC: Refillable
NRT: Informed of range of NRT products and selected preferred product, encouraged to use combina-
tion. Participants free to switch products. Supplies provided for up to 3 months
EC: Starter pack (1 Kit, Aspire UK) provided along with 30 ml bottle of Tobacco Royale flavor e-liquid,
concentration 18 mg/ml. Participants showed how to use and asked to purchase future e-liquid on-
line or from local vape shops and to buy different EC device if the 1 provided did not meet their needs.
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Enouraged to experiment with e-liquids of different strengths and flavors. If unable to obtain own sup-
ply, provided with further 10-ml bottle (not proactively offered). Oral and written info on how to oper-
ate EC
Both arms received multi-session behavioral support as per UK stop-smoking service practice (one-to-
one sessions weekly with local clinicians, exhaled CO monitored for at least 4 weeks post-TQD); signed
behavioral contract not to use other therapy for at least 4 weeks
Outcomes Weeks 4, 26 and 52
Cessation: Sustained and biochemically-validated CO < 8 ppm
Adverse events and biomarkers: “adverse reactions”: presence or absence of nausea, sleep distur-
bance and throat and mouth irritation, and respiratory symptoms (presence or absence of shortness of
breath, wheezing, coughing and phlegm), death
Other outcomes measured:
• Use and ratings of trial products
• Rating of withdrawal symptoms (weeks 1 - 6)
• Reduction of cigarette consumption
• Cost effectiveness
Study funding “Supported by the National Institute for Health Research (NIHR) Health Technology Assessment Pro-
gramme (project number, 12/167/135) and by a grant (A16893) from the Cancer Research UK Preven-
tion Trials Unit.”
Author declarations From ICJME disclosure forms: “Miss Natalie Bisal has nothing to disclose. Dr. Dawkins reports person-
al fees from Johnson & Johnson, outside the submitted work; Dr. Goniewicz reports personal fees from
Johnson and Johnson, outside the submitted work; Dr. Hajek reports grants and personal fees from
Pfizer, outside the submitted work; Ms. Li reports grants from NCCHTA, during the conduct of the study;
Dr. McRobbie reports grants from NIHR HTA program, during the conduct of the study; personal fees
from Pfizer, personal fees from Johnson & Johnson, outside the submitted work; Dr. Myers Smith has
nothing to disclose. Dr. Parrott has nothing to disclose. Dr. Pesola has nothing to disclose. Mrs Anna
Phillips-Waller has nothing to disclose. Dr. Przulj reports grants from Pfizer, outside the submitted
work; Dr. Ross has nothing to disclose. Dr. Sasieni has nothing to disclose. Ms. Wu has nothing to dis-
close."
Notes New for 2020 update, listed as ongoing study ISRCTN60477608 in 2016 review update
Note higher use of allocated product at 12 m in intervention group compared to control group: “Among
participants with 1-year abstinence, 80% (63 of 79) were using e-cigarettes at 52 weeks in the e-ciga-
rette group and 9% (4 of 44) were using nicotine replacement in the nicotine-replacement group.”
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “Randomization took place on the quit date to limit differential
dropout. Randomization sequences (1:1 ratio in permuted blocks of 20, strat-
ified according to trial site) were generated with the use of a pseudorandom
number generator in Stata software and were embedded into an application
that only revealed the next treatment assignment once a participant had been
entered into the database.”
Allocation concealment
(selection bias)
Low risk Refer to 'Random sequence generation'.
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Low risk Not blinded, but as both arms contained active interventions performance
bias judged unlikely
Blinding of outcome as-
sessment (detection bias)
All outcomes














Methods Design: Randomized clinical trial
Recruitment: Eligible participants were employees and their spouses at 54 companies that used Vitality
wellness programs
Setting: Online resources via workplace setting (54 companies), USA
Study start date: First phase of recruitment October 2014, second phase November 2015 (to meet re-
cruitment target); Study end date: 20 April 2017
Participants Total N: 6006
N per arm: Usual care: 813; Free e-cigarettes: 1199; Free cessation aids: 1588; Reward incentives plus
free cessation aids: 1198; Redeemable deposit plus free cessation aids: 1208.
Inclusion criteria:
• At least 18 years old
• Reported current smoking on a health risk assessment within the previous year
• Employees and their spouses that used Vitality wellness programs
Exclusion criteria:
• Participants who express wanting to opt out of this program will be un-enroled and excluded
51.1% women; median age 44; median cpd 10
Ecig use at baseline: 10.7% current use; 23.1% past but not current use; 39.7% never used ECs
Motivated to quit: Unselected sample (total sample): 9.2% no plan to quit; 61.6% want to quit later;
27.7% want to quit/need help
Interventions EC: Cig-a-like
a) Usual care:
Standardized Vitality program aimed at promoting tobacco cessation. This program includes existing
employee benefits for quitting and the use of text/email messages to encourage tobacco cessation
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b) as (a), plus free EC:
Free NJOY e-cigarettes (including battery sticks, a USB charger, and up to 20 chambers with 1.0 to 1.5%
nicotine per week in participants’ chosen flavors). Use of all products was free until 6 months after the
quit date
c) as (b) plus access to free NRT, bupropion or varenicline
d) as (c) plus incentives across 6 m for testing negative for tobacco use
e) as (c) plus provide money at start and lose money from this fund if they do not test negative across 6
m
Outcomes Months 1, 3, 6 and 12
Cessation: Sustained smoking abstinence for 6 months, biochemical validation (urine cotinine, anaba-
sine and blood carboxyhemoglobin)
Other outcomes measured: Costs
Study funding "Supported by a grant from the Vitality Institute to the University of Pennsylvania Center for Health In-
centives and Behavioral Economics."
Author declarations "Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
Check these and: Dr. Troxel reports other from VAL Health, outside the submitted work. Dr. Volpp re-
ports grants and personal fees from CVS Health, personal fees from VAL Health, grants from Humana,
grants from Merck, grants from Weight Watchers, grants from Hawaii Medical Services Association,
grants from Oscar Health Insurance, outside the submitted work. All of the other authors state that they
have nothing to disclose."
Notes New for 2020 update. Study listed as ongoing study NCT02328794 in 2016 review update
Only arms (a) and (b) included in our analyses.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not specified
Allocation concealment
(selection bias)





High risk Not blinded and different amounts of support given to each group
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk At 12 months very low numbers completed biochemical validation. Submitted
a sample n = CG:1, free e-cigs;4, free cessation:5, rewards: 14, deposits:16
Selective reporting (re-
porting bias)
Low risk Expected outcomes reported and checked with trial registration
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Methods Design: randomized trial
Recruitment: Media advertisements
Setting: Clinic visits in community, USA
Study start date: 25 November 2014; Study end date: 2 December 2018
Participants Total N: 264
N per arm: Usual brand: 36; AD-E: 76; CS-E: 76; CS-NRT: 76.
Inclusion criteria:
• At least 18 years of age
• Smoking at least 5 cpd for the past year with a breath CO at least 10 ppm or NicAlert test = level 6 if
CO less than 10 ppm
• In stable physical and mental health
Exclusion criteria:
• A serious quit attempt in the past 3 months
• Recent (< 3 months) alcohol or drug abuse problems
• Regular use of other nicotine or tobacco products (e.g. > 9 days per month to minimize confounding
effects of these products on biomarker outcomes)
• Planning to quit smoking in the next 3 months
• Chronic conditions affecting results of biomarker analyses (e.g., liver disease)
• Currently using NRT or other cessation medications
• Pregnant, planning to become pregnant, or breastfeeding
49% women; mean age 45.2; mean cpd 15.2; mean FTND 3.4
E cigarette use at baseline: Not reported
Motivated to quit: Initially uninterested
Interventions EC: Cig-a-like, but the only cig-a-like product with high nicotine content
Usual brand arm: Purchased their own usual brand of cigarettes; at end of clinical trial phase (week 8),
offered ECs or NRT for up to 8 weeks, with a choice of product and no specific instructions for use
EC AD-E arm: Use EC whenever you like instead of a cigarette; can smoke as many or as few cigarettes
as you want
EC CS-E arm: Complete substitution with e-cigarettes (i.e. “you will stop smoking cigarettes and use
only e-cigarettes”)
The primary e-cigarette product was Vuse Solo (4.8% nicotine, manufactured by RJ Reynolds, Inc). Ini-
tially a choice of Blu cigarettes (cartridge-based system, marketed previously by Lorillard) and Fin (pre-
filled tanks system, manufactured by Fin Branding Group) was offered; but because Vuse attained the
highest market share during the early phase of the study, switched exclusively to Vuse. Participants
could choose 1 of 4 flavors: tobacco, mint, menthol, and berry. Participants were provided 7 cartridges
a week with the option of returning to the clinic before their next visit to obtain additional cartridges
if needed. All products provided free to the participants. All unused products and used EC cartridges
were collected at each visit
CS-NRT arm: Complete substitution with 4 mg nicotine gum or lozenge, with the participant choosing
what product they would like to use (i.e. “you will stop smoking cigarettes and use only nicotine gum
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or lozenge”). The 4 mg was down-titrated to 2 mg if adverse side effects were experienced. Nicotine
gum came in mint, cinnamon, and fruit flavors, while the nicotine lozenge was mint or cherry flavors.
All these products were provided free to the participants and unused products were collected at each
visit
Behavioural support: CS-E arm and CS-NRT arm: received brief counseling on how to avoid smoking
cigarettes
Outcomes 2-week baseline period (weeks −1 and 0);
Week 1, 2, 3, 4, 6 and 8
Adverse events and biomarkers:
• Urinary total nicotine equivalents (total nicotine + total cotinine + total 3′-hydroxycotinine; TNE)
• Exhaled CO
• Urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its glucuronides (total NNAL, biomarker
for NNK)
• Urinary phenanthrene tetraol (PheT, an indicator of carcinogenic polycyclic aromatic hydrocarbons)
• Urinary metabolites of VOCs (mercapturic acids)—2-cyanoethylmercapturic acid (CEMA, biomark-
er for acrylonitrile), 3-hydroxypropylmercapturic acid (3-HPMA, biomarker for acrolein), 3-hy-
droxy-1-methylpropylmercapturic acid (HMPMA, biomarker for crotonaldehyde/methylvinyl ketone),
2-hydroxypropylmercapturic acid (2-HPMA, biomarker for propylene oxide), and N-acetyl-S-(car-
bamoylethyl)-L-cysteine(AAMA, biomarker for acrylamide)
• A safety check for adverse events was conducted at a week-20 follow-up
• Blood pressure, heart rate and oxygen saturation
Other outcomes measured:
• Cessation (< 6 months)
Study funding "supported by grants U19CA157345 from the National Cancer Institute (DKH/PS), UL1 TR000062 and
UL1 TR002494 from the National Center for Advancing Translational Science of the National Institutes
of Health, and T32 DA007097 from the National Institute of Drug Abuse (EM). The content is solely the
responsibility of the authors and does not necessarily represent the official views of the funding agen-
cies"
Author declarations "RJC is a member of the FDA Tobacco Products Scientific Advisory Committee. PGS serves or has
served as an expert witness in tobacco company litigation on behalf of plaintiffs"
Notes New for 2020 update. AD-E arm not included in this review
Additional data provided from authors.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not specified
Allocation concealment
(selection bias)





Unclear risk Not blinded and some interventions contained different levels of support
Hatsukami 2020  (Continued)
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Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Quote: “There was a significant difference in dropout rates across groups fol-
lowing study entry (p = .041), with the highest dropout rates observed in the
complete substitution groups, particularly in the NRT group…”
AD-E: Week 1 = 73/76; Week 2 = 73/76; Week 4 = 69/76; Week 6 = 66/76; Week 8 =
65/76 = 85%
CS-E: Week 1 =69/76; Week 2 = 67/76; Week 4 = 66/76; Week 6 = 61/76; Week 8 =
58/76 = 69.7%
CS-NRT: Week 1 =72/76; Week 2 = 65/76; Week 4 = 60/76; Week 6 = 57/76; Week
8 = 53/76 = 69.7%




Low risk Table in supplementary section describes that heart rate, blood pressure and
oxygen levels were measured, but findings not reported in paper; however,





Methods Design: Single-group assignment – pre-test post-test pilot study
Recruitment: Participants were referred from community mental health teams within the South Lon-
don and Maudsley NHS Foundation Trust.
Setting: Healthcare setting, UK.
Study start date: 24 September 2014; Study end date: 2 May 2017
Participants Total N: 50
Inclusion criteria:
• Aged 18–70 years;
• Daily smoker (unwilling to quit soon);
• Exhaled CO level of more than five parts per million;
• An established clinical diagnosis of schizophreniform, schizophrenia, schizoaffective disorder or bipo-
lar disorder, or attending an early detection service in a high-risk state
Exclusion criteria:
• The use of e-cigarettes on more than two occasions in the past 30 days;
• Intention to quit smoking in the next 30 days;
• Medication use that may reduce smoking (including, bupropion, nicotine replacement therapies,
acamprosate, varenicline, baclofen, clonidine, naltrexone, buprenorphine, nortriptyline, disulfiram
and anti-seizure medications)
• Hospitalisation/change in dose of psychotropic medication(s) in the last 30 days;
• Unstable physical health in the past 3 months;
• A previous serious stomach ulcer and/or phaeochromocytoma
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• Severe heartburn, stroke, unstable kidney/liver disease, an uncontrolled overactive thyroid gland in
the past 3 months;
• Individuals who meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-
IV) criteria for illicit/alcohol drug dependency;
• Medical contraindications to nicotine;
• Asthma
• Suicidal ideation/suicide attempt in the past month
• Pregnancy
Inclusion based on specific population characteristic: People who smoke tobacco with a psychotic dis-
order (established clinical diagnosis of schizophreniform, schizophrenia, schizoaffective disorder or
bipolar disorder, or attending an early detection service in a high-risk state)
24% women; mean age 38.96; mean cpd 17.94; mean FTND not reported
Motivated to quit: “unwilling to quit soon”
E-cigarette use at baseline: Must not have used e-cigarettes on more than 2 occasions in the past 30
days
Interventions EC: Cig-a-like
Participants provided with free tobacco-flavored NJOY traditional bold disposable e-cigarette (4.5%
nicotine) in an "amount equivalent to 150% of their daily tobacco use (as recommended by the manu-
facturer)" for 6 weeks. Participants were instructed in the use EC; not required to stop smoking tobac-
co, but were encouraged to replace it with EC as much as possible. Followed up at 4 weeks and encour-
aged to continue EC use, informed about EC types and where these could be purchased
Outcomes Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 24
Self-reported and biochemical validation
Cessation: Tobacco use, as measured by the Time Line Follow Back. Tobacco cigarette use was also
indexed weekly by measuring exhaled CO levels with a Smokerlyzer ED50 CO meter (Bedfont Instru-
ments, UK)
Adverse events and biomarkers:
• Side effects associated with e-cigarette use – reported weekly
• Respiratory symptoms: lung capacity (measured by Wright’s Mini Peak-flow Meter (Clement Clarke In-
ternational Ltd., UK) at baseline, weeks 6, 10 and 24; Peak flow was obtained 3 times at each assess-
ment
• Heart rate and blood pressure
• Occurrence of (serious) adverse events was assessed on a weekly basis
In a subsample of participants (N = 8), 3-hydroxypropylmercapturic acid (3-HPMA, a measure of the tox-
icant acrolein) and formic acid were measured at baseline and week 6. These participants were chosen
as their tobacco intake had decreased by more than 50% in this period. The measurement of 3-HPMA




• Motivation to Stop Scale (MTSS)
• Smoking Consequences Questionnaire-Adult (SCQ-A)
• Positive and Negative Syndrome Scale (PANSS)
• Calgary Depression Scale for Schizophrenia (CDSS)
Hickling 2019  (Continued)
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Study funding "This work was funded by the Maudsley Charity (grant number 715); and supported by the National In-
stitute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS
Foundation Trust and King’s College London."
Author declarations "R.P-I. has received honoraria and speaker support from Lundbeck. L.D. has provided consultancy for
the pharmaceutical industry (Johnson & Johnson 2015, 2017) and acted as an expert witness for an
e-cigarette patent infringement case (Porzio, Bromberg & Newman Attorneys at Law, 2015). Between
2011 and 2013, she conducted research for several independent electronic cigarette companies (Total-
ly Wicked, SKYCIGS and E-Lites) for which the University of East London received funds. The e-cigarette
companies involved had no input into the design, conduct or write up of these projects and she has not
received any funds from e-cigarette companies in the last 4 years. She has no links with, and has not
received any funds from, the tobacco industry, although two e-cigarette companies that she worked
with in 2013 were subsequently acquired by the tobacco industry (SKYCIGs and E-Lites). L.H., T.R., K-
V.S., J.M., A.M. and P.M. have no conflicts of interest."
Notes Study listed as ongoing study NCT02212041 in the 2016 review update
Additional data provided from authors
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Uncontrolled study
Allocation concealment
(selection bias)




Low risk Follow-up: Week 6: 46/50; Week 10: 42/50; Week 24: 40/50
Selective reporting (re-
porting bias)
Low risk Report all outcomes listed on http://clinical trials.gov except NNAL. Authors






Methods Design: Pilot RCT
Recruitment: Recruited via the Newcastle Dental Hospital and by primary care practitioners working in
the north-east England region
Setting: Dental clinical research facility (DCRF), located in the Newcastle Dental Hospital, Newcastle
upon Tyne, UK.
Study start date: 20 September 2016; Study end date: 31 July 2018
Participants Total N: 80
N per arm: Intervention group: 40; Control group: 40
Inclusion criteria:
• Aged over 18 years old; smoker (≥10 cigarettes/day)
Holliday 2019 
Electronic cigarettes for smoking cessation (Review)









Cochrane Database of Systematic Reviews
• Willing and able to come to the DCRF for the required study visits
• Having a minimum of 16 natural teeth (excluding third molars)
• Being diagnosed with periodontitis
Exclusion criteria:
• Having used an e-cigarette for more than 2 days in the last 30 days
• Infectious or systemic diseases that may be unduly affected by participation in this study
• Haemodynamically unstable
• Patients taking the medication adenosine (due to drug interaction risk)
• Lack of capacity to be able to consent to the research project or inability to follow study instructions,
or both
• Participation in a dental research study within the previous 20 days
• Pregnant by medical history, or nursing
• Received any non-surgical periodontal therapy other than a routine scale and polish in the last 6
months
• Currently undergoing or requiring extensive dental, orthodontic or implant treatment, or treatment
for peri-implantitis
Inclusion based on specific population characteristic: Periodontitis
52.5% women; mean age 44.36; mean cpd 17.4; mean FTND 5
Motivated to quit: Not selected on motivation and not reported
E-cigarette use at baseline: Not currently using an e-cigarette, or not having used 1 for more than 2
days in the last 30 days
Interventions EC: Refillable
All participants given standard stop-smoking advice (10 - 15 minutes in duration) and offer of referral to
stop-smoking services
Intervention: given EC starter kit (Vype eTank clearomizer) and brief training on its use by a dentist.
Provided with an approximately 2-week supply of e-liquid (20 ml) with a choice of flavor (Blended To-
bacco, Crisp Mint, Dark Cherry and Vpure (flavorless)) and nicotine strength (0 mg/ml, 6 mg/ml, 12 mg/
ml, 18 mg/ml) and information on where to buy more. EC intervention delivered directly following the
standard stop-smoking advice and was expected to be 10 - 15 minutes in duration
Control group: no further intervention
Outcomes Months 1 and 6; Self-report and biochemical validation of smoking status
Cessation: Rates of continuous eCO-verified smoking abstinence at 6 months were calculated following
the Russell Standard (RS6)
Adverse events and biomarkers: expired air CO, adverse events monitored at each study visit
Other outcomes measured:
• Feasibility outcomes
• Oral health outcomes
• Smoking behavior outcomes comprised: self-reported tobacco and e-cigarette use, eCO, e-salivary
cotinine (SC), salivary anabasine (SA), FTND and Mood and Physical Symptoms Scale (MPS)
Study funding "Richard Holliday is funded by a National Institute for Health Research Doctoral Research Fellowship
(DRF-2015-08-077). This paper presents independent research funded by the National Institute for
Health Research (NIHR). The views expressed are those of the authors and not necessarily those of the
NHS, the NIHR or the Department of Health and Social Care."
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Author declarations "The authors declare that they have no competing interests."
Notes New for 2020 update.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Low risk Quote: "The randomisation allocation schedule will be generated by a statisti-






High risk Nature of study precluded blinding; different levels of support across interven-
tion arms
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Attrition < 50%
Selective reporting (re-
porting bias)





Methods Design: Prospective cohort
Recruitment: People attending an outpatient clinic
Setting: University hospital outpatient clinic, Switzerland
Study start date/end date: Not specified
Participants Total N: 17
Inclusion criteria:
• Wish to reduce tobacco use or had failed to stop smoking using varenicline, bupropion or NRT in past
Inclusion based on specific population characteristic: No
Mean 23 cpd, 82% had a psychiatric illness
Motivated to quit: Yes
E-cigarette use at baseline: Not specified
Interventions EC: Cig-a-like
Humair 2014 
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Offered an EC with nicotine
59% also reported using NRT or varenicline in addition to EC
Outcomes Smoking cessation and reduction by at least 30% at 12 months (self-report)
Adverse events
No significant side effects
Study funding Not specified
Author declarations Not specified
Notes Abstract only, hence little detail available
Not clear if EC was provided by clinic or if participants had to buy their own
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Prospective cohort
Allocation concealment
(selection bias)




Unclear risk Numbers lost to follow-up not reported
Selective reporting (re-
porting bias)





Methods Design: (acute phase) Randomized cross-over assignment (outcomes measured within hours of the in-
tervention and hence do not meet the criteria of 1 week or more); chronic phase: non-randomized, sin-
gle-group assignment
Recruitment: Hospital smoking cessation unit
Setting: Hospital smoking-cessation unit, Greece
Study start date: 31 January 2017; Study end date: Estimated completion date: December 2021
Participants Total N: 90
Inclusion criteria:
• Active conventional cigarette smoker
• Adults 18 to 60 years
Exclusion criteria:
• Health condition adversely affected by smoking, history or presence of cardiovascular disease
Ikonomidis 2018 
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Inclusion based on specific population characteristic: No
54% women; mean age 50.2; mean cpd 23.4; mean FTND: Not reported
Motivated to quit: Yes – recruited from smoking cessation unit
E-cigarette use at baseline: Not reported
Interventions EC: not clear
E cigarette details: In the chronic phase, all 70 participants were instructed to replace their convention-
al cigarettes (con-cig) with an e-cig containing nicotine (12 mg/dL (e-cig fluid with nicotine concentra-
tion of 12 mg/mL (propylene glycol 74.3%, glycerin 20%, flavoring 4.5%, nicotine 1.2%))) for 1 month
Outcomes 1 month; Self-report and objective measures
Cessation: Self-report cessation at 1 month. CO measured at 1 month. Cessation data not used as < 6
months
Adverse events and biomarkers:
• Exhaled CO concentration
• Heart rate; blood pressure
Other outcomes measured:
• Oxidative stress as assessed by malondialdehyde (MDA) plasma concentrations
• Aortic stiffness as assessed by pulse wave velocity (PWV) and augmentation index (AIX75)
Study funding This study was supported by a grant from the Hellenic Cardiology Society and Hellenic Society of Lipidi-
ology and Atherosclerosis.
Author declarations None
Notes New for 2020 update. Acute phase of trial not relevant for the review as very short-term outcomes
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not specified
Allocation concealment
(selection bias)





High risk Not blinded and differential levels of support given
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk 70 participants and 20 controls recruited – no dropout
Selective reporting (re-
porting bias)
Unclear risk NCT record states that chronic endothelial integrity, platelet aggregation and
high-shear stress-dependent platelet function would be assessed but is not re-
Ikonomidis 2018  (Continued)
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ported in this research letter – however study estimated completion date is
December 2021, so perhaps data not ready for publication or limited capacity
in the research letter – not the primary publication







Recruitment: Smoking cessation clinic of second cardiology department of National and Kapodistrian
University of Athens, Attikon General Hospital
Setting: Hospital smoking-cessation unit, Greece
Study start date: NS
Participants N = 40; Arm 1 E-cigarette n = 20; Arm 2 conventional tobacco cigarette n = 20
80% female; mean age 44.8 (SD 11.3); mean cpd: 25.8 (C-cig 25.5 SD 9.3. E-cig: 26.2 SD 9.1)
Inclusion criteria:
• smokers without cardiovascular disease, who used to smoke 25.8 ± 9.2 conventional cigarettes per
day of their choice
Exclusion criteria:
• abnormal renal function
• hepatic failure (bilirubin > 2 mg/dl)
• active malignancy
• people treated with drugs that affect platelet function
• history of coronary artery disease or peripheral artery disease
• history of cardiomyopathy
• age < 21 years old
• people with thrombocytopenia (PLTs < 100 × 109 /L)
• anemia (HCT < 28%)
• alcohol or drug abuse
• pregnancy
• risk factors for cardiovascular disease
Interventions EC: Refillable
E-cig: second-generation e-cig device and popular in Greek Market e-liquid (NOBACCO eGo Epsilon BDC
1100, eGo battery, 1100 mAh, operating at 3.9 V - propylene glycol 74.3%, glycerin 20%, flavoring 4.5%,
nicotine 1.2%/12 mg/ml)
Outcomes Baseline, 4 months: Exhaled CO concentration; blood pressure
Also, cpd; Ppatelet function by Platelet Function Analyzer PFA-100 and Light Transmission Aggregome-
try; Pulse wave velocity; Plasma malondialdehyde levels as oxidative stress index
Study funding "There was no funding for this study"
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Author declarations "The authors declare that they have no known competing financial interests or personal relationships
that could have appeared to influence the work reported in this paper."
Notes New for 2021 update
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Unclear risk Not possible
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk All followed up (confirmed via contact with authors)
Selective reporting (re-
porting bias)
Unclear risk No protocol or clinical trial record available to confirm whether all prespeci-





Methods Design: Randomized controlled trial
Recruitment: Not specified
Setting: Hospital, Greece.
Study start date/Study end date: Not specified
Participants Total N: 54
N per arm: Arm 1: 27; Arm 2: 27
Inclusion criteria:
• ≥10 cpd
• Motivation to quit
• Hospitalized with acute coronary syndrome (ACS)
• 18 or older
Exclusion criteria:
• Prior EC use
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• History of neuropsychiatric disorders
• Prior varenicline use or use of SC pharmacotherapy at time of ACS
• Cardiogencic shock or renal impairment
• Hepatic impairment prior to ACS
• Excessive alcohol use or current use of marijuana or non-cigarette tobacco products
Inclusion based on specific population characteristic: People who have experienced acute coronary
syndrome
65% women; mean age 52; mean cpd 21; mean FTND 5.6
Motivated to quit: Yes
E-cigarette use at baseline: No prior EC use
Interventions EC: information on whether cig-a-like or refillable not provided
Both arms given "low intensity counselling"
Intervention 1: 12-week use of EC 12 mg/ml nicotine
Intervention 2: 12-week varenicline
Outcomes Weeks: 4, 12, 24
Cessation: 7-day PP at 24 weeks, self-report
Adverse events and biomarkers: Unclear how these were reported. Abstract says no SAEs, poster im-
plies this may have just been CV or neuropsychiatric SAEs. Abstract says nothing about AEs but nausea
and sleeping disorders given in table in poster. Implies (S)AEs collected during treatment period only
Other outcomes measured: Not specified
Study funding Not reported
Author declarations Not reported
Notes New for 2020 update. Abstract and poster only; limited data available
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not specified
Allocation concealment
(selection bias)





Low risk Not specified but equal amounts of contact and support between arms so per-
formance bias judged unlikely
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Not specified
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Unclear risk Abstract/poster only so not able to judge
Other bias High risk Abstract and poster only. Two different figures presented for quit rate in EC
arm (no difference in those presented in varenicline arm) between abstract
and poster. Poster percentage aligns with figure, so using that (16.5%) as op-
posed to abstract figure (32.5%). Contacted authors but no reply. Calculated n
quit based on percentages but unclear what denominators were; EC calculates





Methods Design: Prospective randomized clinical trial
Recruitment: All patients admitted to a smoking cessation clinic at the Department of Otorhinolaryn-
gology-Head and Neck Surgery, Okmeydanı Training and Research hospital
Setting: Smoking cessation clinic, Turkey
Study start date: March 2013; Study end date: November 2013
Participants Total N: 98 but analysis excludes 16 from intervention and 10 from control who did not stop smoking;
thus 72 analyzed
N per arm: EC: 58 (42 ana lysed); Non-EC 40 (30 ana lysed)
Inclusion criteria:
• Smoked at least one pack of cigarettes a day for at least 5 years.
Exclusion criteria:
• History of allergic rhinitis, chronic sinusitis, vasomotor rhinitis, asthma, malignancy, or surgery in up-
per respiratory tract;
• Age under 18;
• Use of psychoactive drugs
Inclusion based on specific population characteristic: No
44% women; mean age 36; mean cpd and mean FTND not specified
Motivated to quit: “All patients were willing to quit smoking”
E-cigarette use at baseline: Not specified
Interventions EC: Unclear
EC arm: “used EC to quit smoking” – allowed to select brand and flavor, used “medium density” liquid
(11 - 12 mg/ml) (no further detail given)
Non-EC arm: Received cognitive behavioral therapy (no further detail given)
Outcomes 3 Months
Kumral 2016 
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Sino-nasal outcome test (SNOT-22) via self-administered questionnaire, to evaluate changes in subjec-
tive symptoms. Saccharin transit test to evaluate nasal mucociliary clearance (MCC) function which au-
thors state is “an important defence mechanism”
Study funding Not specified
Author declarations Not specified
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: “Patients participating in the study were randomly divided into two
groups; EC smokers (group 1) and non-EC smokers (group 2).”
No further detail provided
Allocation concealment
(selection bias)





High risk Participants were not blinded. The trial is described as single-blinded and out-
come assessors were blinded. No placebo used
Blinding of outcome as-
sessment (detection bias)
All outcomes





Unclear risk Dropout rate not clear. Only ana lysed people who quit
Selective reporting (re-
porting bias)





Methods Randomized parallel-assignment double-blind pilot trial
Setting: San Francisco Veterans Affairs Medical Center (SFVAMC), USA
Recruitment: veterans awaiting surgery
Recruitment: In VA hospital presenting for surgery
Study start date: August 2015; Study end date: May 2016
Participants Total N: 50
N per arm: NRT: 30; END: 20
Inclusion criteria:
Lee 2018 
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• Presented to the anesthesia preoperative clinic for elective surgery 3 or more days before surgery
• Currently smoked more than 2 cigarettes per day, having smoked at least once in the last 7 days
Exclusion criteria:
• Exclusively used other forms of tobacco or marijuana only
• Pregnant or breastfeeding
• Unstable cardiac condition
• Currently using smoking cessation pharmacotherapy
• Were already enrolled in a smoking cessation trial
• Currently used e-cigarettes on a daily basis
Inclusion based on specific population characteristic: Patients awaiting elective surgery
10% women; mean age 54; mean cpd 14; mean FTND 3.3
Motivated to quit: Not specified
E-cigarette use at baseline: Not specified but excluded daily users
Interventions EC: Cig-a-like
Both groups receive: i) referral to the California Smokers' Helpline, ii) brief advice lasting less than 2
minutes, iii) a brochure from the ASA about quitting smoking before surgery
EC arm: 6-week supply of NJOY e-cigarettes (disposable, first generation). Instructed to use Bold (4.5%)
ad lib for 3 weeks, then Gold (2.4%) ad lib for 2 weeks and then study (0%) ad lib for final week. Number
of ECs issued corresponded to baseline cpd, assuming 1 EC = 10 cigarettes. Asked to refrain from the
use of all study products at the end of 6 weeks
NRT arm: 5-week Nicoderm CQ patches, 1 week placebo patches. Dose based on cpd at baseline: ≥ 10
cpd, 21 mg/day for 3 weeks, 14 mg/day for 1 week, 7 mg/day for 1 week, 0 mg/day for 1 week. < 10 cpd
at baseline: 14 mg/day for 3 weeks, 7 mg/day for 2 weeks, 0 mg/day for 1 week
Outcomes 30 Days (phone), 8 Weeks (in person), 6 Months (phone)
Cessation: 7-day PP at 30 days (not validated), 8 weeks (CO-validated), 6 months (not validated). Smok-
ing cessation for at least 48 hours on day of surgery (CO-validated)
Adverse events and biomarkers:
• Adverse events, side effects, and surgical complications by self-report at 30 days, 8 weeks
• At 8 weeks exhaled CO, FEV1 and FVC
Other outcomes measured:
• Attitudes and usage
• Salivary cotinine
• Smoking reduction
Study funding “This work was funded by internal UCSF Department of Anesthesia and Perioperative Care funds (San
Francisco, California, United States of America) and the UCSF Resource Allocation Program grant, ad-
ministered by the Helen Diller Family Comprehensive Cancer Center developmental funds from the Na-
tional Cancer Institute Cancer Center Support Grant (P30 CA 82103-16). E-cigarettes were purchased
from NJOY using these funds. NJOY had no involvement in the design, execution, or analysis of the
study. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.”
Author declarations “The authors declare there are no competing interests”
Notes 3 NRT participants used EC, 2 EC participants used nicotine patch
Lee 2018  (Continued)
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Study listed as ongoing study NCT02482233 in the 2016 review update
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “Randomization was computer-generated, with randomly permuted
block sizes of 3 or 6, in a 2:1 ratio using the ralloc program”
Allocation concealment
(selection bias)






Low risk Not blinded but both interventions active with equal amounts of support so
performance bias judged unlikely
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Self-report only at 6 months and participants not blinded to condition, but





Low risk 1 NRT and 1 ENDs loss to follow-up at 6 months
Selective reporting (re-
porting bias)





Methods Design: Randomized controlled trial
Recruitment: Recruited from motor company.
Setting: Motor company, medical office in Korea
Study start date: 5 January 2012; Study end date: 31 August 2012
Participants Total N: 150
N per arm: EC: 75; NRT: 75
Inclusion criteria:
• Male
• At least 10 cpd in previous year
• Smoked for at least 3 years
• Motivate to stop smoking entirely or reduce consumption
Exclusion criteria:
• Past history of serious clinical disease
• Attempted to stop smoking in past 12 months by using NRTs
Inclusion based on specific population characteristic: No
Lee 2019 
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0% women; mean age 42.3; mean cpd: Not reported, 1.01 packs per day; mean FTND 4.05
Motivated to quit: Yes, or to reduce
E-cigarette use at baseline: Not specified
Interventions EC: Refillable
Both arms received 50 mins education session on smoking cessation and use of smoking cessation
aids in medical office (no further detail given). Asked to return to medical office every 4 weeks (to 24
weeks?) for “evaluation and counseling by an independent health practitioner”
Arm 1: 50-min education sessions on smoking cessation and the use of smoking-cessation aids, in-
structed to visit the medical office each month for evaluation and counseling by a health practition-
er who was unaffiliated with the study. Participants supplied with eGo-CTM EC (nicotine 0.01 mg/mL)
from Ovale in 12-wk supply
Arm 2: As (1) but instead of EC given 2 mg nicotine gum in 12-wk supply
Outcomes 12, 24 weeks (in person)
Cessation: continuous abstinence from 9 - 24 weeks, exhaled CO < 10 ppm, negative urine cotinine
Adverse events and biomarkers: Yes but just note ‘adverse events’
Other outcomes measured: 7-day PPA, cigarette reduction
Study funding “none”
Author declarations “none declared”
Notes Study listed as ongoing study KCT0001277 in the 2016 review update
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “computer-generated randomization sequence with a block size of 2”
Allocation concealment
(selection bias)
Low risk Quote: “The enrolment and assignment of all subjects were performed by a





Low risk Not blinded but both interventions active with equal amounts of support, so
performance bias judged unlikely
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk 61/75 NRT and 71/75 EC FU at 24 weeks
Selective reporting (re-
porting bias)
Low risk All prespecified outcomes reported
Lee 2019  (Continued)
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Study characteristics
Methods Design: Randomized parallel-assignment double-blind trial
Recruitment: Participants enrolled in lung cancer-screening program
Setting: Early lung cancer detection program (Cosmos II) at European Institute of Oncology, Italy
Study start date: September 2014; Study end date: January 2016
Participants Total N: 210
N per arm: 70 participants per arm
Inclusion criteria:
• Participants are involved in the COSMOS II study
• Participants are 55 years or more and have smoked at least 10 cigarettes a day for the past 10 years
• Participants wish to reduce tobacco smoking (motivational score higher than 10) who are not treated
at a smoking centre
• Signed informed consent
Exclusion criteria:
• Symptomatic cardiovascular disease
• Symptomatic severe respiratory disease
• Regular psychotropic medication use
• Current or past history of alcohol abuse
• Use of smokeless tobacco or NRT
• Participation in another antismoking program in the current year
Inclusion based on specific population characteristic: 55 years of age or older
37% women; mean age 62.8; mean cpd 19.38; mean FTND 4.37
Motivated to quit: yes
E-cigarette use at baseline: Excluded people who smoke who had ever regularly used e-cigarettes for
more than 1 week alone or in combination with tobacco cigarettes
Interventions EC: Cig-a-like
Both arms received “low intensity counseling” – phone at week 1, 4, 8 and 12, approx. 10 mins each
Nicotine EC arm: e-cigarette kit and 12 10-mL liquid cartridges (8 mg/mL nicotine concentration). Dur-
ing the first week, participants could use the e-cigarette ad libitum. At the end of the first week, asked
to use only EC for the next 11 weeks
Nicotine-free EC (placebo) arm: Nicotine-free EC – same as above but with nicotine-free EC
Outcomes Months 3, 6 and 12 (but only 3- and 6-month data available)
Cessation: Continuous abstinence for previous month, CO ≤ 7 ppm
Adverse events and biomarkers: FOR EC ARMS ONLY:
• Exhaled CO
• Leicester Cough Questionnaire (LCQ)
• Respiratory symptoms (self-report)
• Side effects using checklist
Lucchiari 2020 
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Study funding This study was supported by a grant from Fondazione Umberto Veronesi (FUV)
Author declarations The authors declare no conflicts of interest
Notes Listed as ongoing study Lucchiari 2016 (NCT02422914) in 2016 review; new for 2020 update
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “A randomization list using a permuted block design (40 blocks of 6
subjects randomly assigned to 1 of the 3 treatment arms) had been previously
prepared by independent personnel.”
Allocation concealment
(selection bias)
Low risk Double-blind, active and placebo e-cigarettes labeled by independent person-





Low risk “double blind” for nicotine vs no nicotine EC but limited info given; however,
as similar levels of support across arms performance bias judged unlikely
Blinding of outcome as-
sessment (detection bias)
All outcomes








High risk Paper states data also collected at 12 m but this is not presented and unclear





Methods Design: A nonconcurrent multiple baseline across participants design. Three phases were included:
Baseline, EC, and EC + CM. Half the participants received the EC phase following baseline; the other half
received EC + CM following baseline
Recruitment: Community
Setting: Set-up meetings occurred at the University of Florida Behavioral Health and Technology Re-
search Clinic, USA
Study start date/Study end date: Not specified.
Participants Total N: 12
Inclusion criteria:
Martner 2019 
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• 18 - 65 years old
• Smoked ≥ 2 years
• Smoked ≥ 8 cpd on average
• Smoked in the past 24 hours
• Expressed a desire to quit smoking (yes/no)
• Had reliable access to the internet and a computer or smartphone
• Breath CO ≥ 10 ppm at set-up
Exclusion criteria:
• Current or previous medical condition that would pose an increased risk to participation
• Use of benzodiazepines, cocaine, or opiates in the previous 6 months
• Smoke marijuana more than twice a month
• Exposed to elevated CO levels (e.g. spouse smokes in house)
• Pregnant or expected to become pregnant in the next 6 months
58.3% women; mean age 37.5; mean cpd 16.25; mean FTND 5
Motivated to quit: Expressed a desire to quit smoking.
E-cigarette use at baseline: 3 participants never tried an EC prior to the study; 2 owned an EC but quit
using it more than a month prior to the study; remaining 7 had tried an EC more than a year prior to the
study but never owned one
Interventions EC: Refillable
All participants provided with smokio electronic cigarettes (second-generation ECs) and V2 e-liquid
with a concentration of 24 mg/ml (2.4%) of nicotine. Researchers provided participants with a copy of
the National Cancer Institute’s brochure Clearing the Air (http://smokefree. gov). Then researchers and
participants read through a manual that described the study procedures, and showed participants how
to use the software to measure CO and how to use the EC
Participants initially received EC without contingency for a period of 14 days following the quit at-
tempt. If participants failed to reduce CO levels during this phase, they received contingency manage-
ment in addition to EC
Outcomes 4 weeks
Adverse events and biomarkers: Adverse events collected in 4-day smoking behavior questionnaires;
eCO
Other outcomes measured: acceptability and use of EC; overall experience of study
Study funding "The study was supported in part by crowd-sourced funding enabled by Experiment.com. Preparation
of this paper was supported in part by Grant P30DA029926."
Author declarations "The authors declare no conflicts of interest."
Notes N of 1 (within-participants randomized design, not between groups). New for 2020 update.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Not randomized
Allocation concealment
(selection bias)
High risk Not randomized
Martner 2019  (Continued)
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Unclear risk No details provided.
Selective reporting (re-
porting bias)





Methods Design: Prospective cohort
Recruitment: advertisements in free London newspapers
Setting: Smokers' clinic, East London, UK
Study start date: February 2013; Study end date: September 2013
Participants Total N: 40
Inclusion criteria:
• People who smoke daily who want to quit
• Aged 18 and older
Exclusion criteria:
• Pregnant and breastfeeding women
• Current serious medical illness
• EC use for more than 1 week in the past
45% women, mean age 47 (SD 12), mean cpd 19 (SD 10), mean FTND 5.2 (SD 2.8), 65% in full-time em-
ployment
Motivated to quit: Yes
E-cigarette use at baseline: Excluded those who had used EC for more than 1 week in the past
Interventions EC: Cig-a-like
Participants attended baseline session 1 week prior to their TQD. On the TQD, participants were provid-
ed with an EC (Green Smoke, 1st generation device, 2.4% nicotine cartridges). 2 cartridges a day were
supplied initially, with the supply adjusted to actual use later. Attended 4 weekly follow-up sessions
and received standard behavioral support
Outcomes Cigarette consumption and CO readings collected at each session. Urine sample for cotinine and 3-HP-
MA analysis collected at baseline and 4 weeks post-TQD
Change in urinary 3-HPMA (ng/mg creatinine) at 4 weeks
Change in urinary cotinine (ng/mg creatinine) at 4 weeks
Change in CO at 4 weeks
Study funding "This study was funded by a grant given to P. Hajek, H. McRobbie, and M.L.Goniewicz from the UK Med-
icines and Healthcare Products Regulatory Agency (MHRA). The costs of publication of this article were
defrayed in part by the payment of page charges. This article must therefore be hereby marked adver-
tisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact."
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Author declarations "H. McRobbie is Clincal Director at The Dragon Institute; reports receiving commercial research grant
from Pfizer; and has received speakers bureau honoraria from Johnson&Johnson and Pfizer. M.L. Go-
niewicz reports receiving commercial research grant from Pfizer. P. Hajek has received speakers bu-
reau honoraria from and is a consultant/advisory board member for the manufacturers of stop-smok-
ing medications. No potential conflicts of interest were disclosed by the other authors."
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Prospective cohort
Allocation concealment
(selection bias)




Low risk 7/40 participants were lost to follow-up
Selective reporting (re-
porting bias)





Methods Design: Randomized cross-over trial (e-cig vs placebo)
Recruitment: via local media outlets
Setting: Community, USA
Study start date/Study end date: Not specified.
Participants Total N: 24
Inclusion criteria:
• ≥ 18,
• People who smoke daily (≥ 10 cpd)
• Not interested in quitting in next 30 days
• English-speaking
• Interested in using EC
Exclusion criteria:
• Using cessation meds
• Use of ECs in last 6 m
• Exhaled CO < 6 ppm,
• History of CV trauma or uncontrolled hypertension
• Pregnant
Inclusion based on specific population characteristic: No
Meier 2017 
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25% women; mean age 48.5; mean cpd 16.3; FTND not reported
Motivated to quit: No (eligibility criteria was to not want to quit in next 30 days)
E-cigarette use at baseline: 8/24 (33%) had previously tried an EC, avg 9.4 months since last use, avg
length of use 3.6 days
Interventions EC: Cig-a-like
Smoked “as usual” for 1 week followed by 2 weeks of either placebo or active 1st generation EC BluCig
starter kit with up to 7 cartridges (prefilled, with either active 16 mg or 0 mg nicotine solution)
Participants were instructed “this e-cig may or may not contain nicotine; we ask that you try it at least
once, but use it however you like; smoke regular cigarettes as you wish.” Shown how to charge the de-
vice and sampled the product during the visit. Provided a handout on how to use the product (e.g.,
switching cartridges) and general information about ECs
Outcomes 1 week in each condition, in person
Adverse events and biomarkers:





• Perceived reward from ECs
• Intentions/confidence to quit
• Cotinine
• Withdrawal symptoms
Study funding “..supported by grants P01 CA138389, P30 CA138313 (Hollings Cancer Center Support Grant) from the
National Cancer Institute of the National Institutes of Health and UL1 TR000062 from the National Cen-
ter for Advancing Translational Science of the National Institutes of Health. BWH was supported by
K12DA031794”
Author declarations “KMC has received grant funding from the Pfizer, Inc., to study the impact of a hospital-based tobacco
cessation intervention. He also receives funding as an expert witness in litigation filed against the to-
bacco industry. We have no other declarations of interests to declare”
Notes New for 2020 update.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: “Participants were randomized to receive either an active or placebo
EC first”, no further information provided.
Allocation concealment
(selection bias)





Low risk Quote: “Participants and research staI conducting sessions were blinded to
dose. All cartridges were pre-loaded by the manufacturer. Labeling was re-
moved by a research team member not involved in participant contact to
mask placebo versus active ECs. We restricted flavor options to regular tobac-
co flavor or menthol to most closely match usual cigarette brand flavor profile
and reduce unwanted variance in product”
Meier 2017  (Continued)
Electronic cigarettes for smoking cessation (Review)









Cochrane Database of Systematic Reviews
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quote: “Participants and research staI conducting sessions were blinded to
dose. All cartridges were pre-loaded by the manufacturer. Labeling was re-
moved by a research team member not involved in participant contact to
mask placebo versus active ECs. We restricted flavor options to regular tobac-
co flavor or menthol to most closely match usual cigarette brand flavor profile




Unclear risk Not specified
Selective reporting (re-
porting bias)





Methods Setting: Medical centre, USA
Recruitment: People with cancer
Design: Non-randomized single-group assignment trial
Recruitment: Clinical settings, including outpatient clinics and the infusion suite
Study start date: June 2016; Study end date: May 2018
Participants Total N: 19
Inclusion criteria:
• Histological or cytological diagnosis of aerodigestive tract cancers or bladder cancer within the past
5 years (more than 1 tobacco-related malignancy is allowed)
• AJCC stages I - IV
• Daily smoking (at least 10 cigarettes per day for 10 years) and breath CO2 ≥ 8 ppm
• Does not wish to quit smoking now (anyone wishing to quit smoking will be referred for smoking ces-
sation counseling through the WRJ VAMC or DHMC program)
• May be receiving anti-cancer agents
• Age 18 or older
• Fluent in English
• Patient must be capable and willing to provide informed written consent for study participation
• Able to participate in study visits
Exclusion criteria:
• Cancer surgery planned in the next 9 weeks
• Treatment with radiation planned for the next 9 weeks
• Actively trying to quit smoking, or planning to in the next 30 days. (If a patient reports that they plan to
quit smoking in the next 30 days, we will call them after the 30 days to see if they are still trying to quit)
• Any use of e-cigarettes in the past 30 days
• Pregnant or trying to get pregnant
Inclusion based on specific population characteristic: Patients with stage I - IV aerodigestive tract can-
cers or bladder cancer who smoke daily
NCT02648178 
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42.1% women; mean age: not reported -categories 18 - 65 years: N = 9, > 65 years: N = 10; cpd and FTND:
not reported.
Motivated to quit: No (inclusion criterion)
E-cigarette use at baseline: Not specified but EC use within 30 days is an exclusion criterion
Interventions EC: Cig-a-like and refillable
Instructed on use of EC, and given a supply that is "approximately equivalent to their current nicotine
intake". Given Halo Triton EC (leak-proof refillable tank system) or Halo G6 leak proof prefilled car-
tomizers. Began participants with 18 mg/ml and moved nicotine content up or down based on partici-
pant preference. Choice of flavors, provided for 9 weeks
Outcomes Weeks 3, 6, 9, 12. Self-report at clinic visits
Adverse events and biomarkers:
• Averse events assessed with a checklist for commonly-occurring side effects from e-cigarettes and
nicotine products
• Exhaled carbon dioxide
• Expired carbon monoxide
• Urine propylene glycol
• Urine 4- (methylnitrosamino)-1-(-3pyridyl)-1butanol (NNAL) 40 and 1- hydroxy naphthalene (1-HOP)
Other outcomes measured:
• Timeline Follow-Back Questionnaire (TLFB)
• EC appeal assessed with attitudinal ratings, on a 5-point Likert-type scale
• e-cigarette ease of use, satisfaction, and enjoyment, and willingness to continue to purchase e-ciga-
rettes in the future
• Change in daily cigarette smoking given 10 or more E-cig sessions
• Average number of E-cigs used per day
• The co-ordinators will conduct and audiorecord a 10 - 15-minute qualitative interview at 9 weeks so-
liciting perceptions about e-cigarettes to be transcribed and analyzed for common themes that could
be useful in developing the larger intervention
• urine nicotine and cotinine
Study funding Not reported – data extracted from clinical trial registry record
Author declarations Not reported – data extracted from clinical trial registry record
Notes Study listed as ongoing study in the 2016 review update
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Not randomized, single-group assignment
Allocation concealment
(selection bias)




Low risk 19 enrolled; 10 participants followed up at 12 weeks
NCT02648178  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk The following measures were not reported: exhaled carbon dioxide; urine
propylene glycol; urine nicotine, cotinine, NNAL and 1- hydroxy naphthalene








Setting: SMI clinics, USA
Study start date: October 2016; Study end date: August 2017
Participants Total N: 7
N per arm: NRT: 4; EC+NRT 3
Inclusion criteria:
• Be diagnosed with schizophrenia (or other SMI, not clear)
• Be in stable medical condition (DSM-V)
• Report smoking ≥ 10 tobacco cigarettes/day
• Present a breath CO ≥ 10 ppm
• Report wanting to reduce their cigarette smoking
• Be fluent in English
• Have a stable living situation
Exclusion criteria:
• Be currently pregnant or breastfeeding
• Report wanting to quit smoking in the immediate future
• Test positive for illicit drugs except THC
• Have any illness, medical condition, or use of medications, which in the opinion of the study physicians
would preclude safe or successful completion of the study, or both
Inclusion based on specific population characteristic: Yes - SMI (schizophrenia and schizoaffective dis-
order, bipolar disorder, or PTSD)
43% women; mean age 48.3; mean cpd: NR; mean FTND: NR
Motivated to quit: Wanted to quit or reduce their cigarette smoking but did not want to quit in the im-
mediate future (this was an exclusion criterion) NB – trial registry states wanted to reduce and protocol
states wanted to quit or reduce as inclusion criteria
E-cigarette use at baseline: Not specified
Interventions EC: Refillable
Both arms received a nicotine patch 21 mg for 4 weeks
EC + NRT: 4 weeks: 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech;
Shenzhen, China). Nicotine concentrations 36 mg/ml. Verbal and written instructions on how to use
and maintain the e-cigarettes at Week 1 visit
NCT02918630 
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NRT arm: NRT only
Outcomes 5 weeks
Cessation: n/a but “change in smoking”
Adverse events and biomarkers:
Breath CO, COPD-related symptoms, EC side effects (e-cig side effects questionnaire), AEs, SAEs
Other outcomes measured:
Urinary cotinine, cpd, tobacco dependence, craving, withdrawal symptoms, desire to quit, confidence
to quit, EC dependence, EC use, satisfaction with EC, nicotine dependence, schizophrenia symptoms
(brief psychiatric rating scale), cognitive domains associated with schizophrenia (MATRICS consensus
cognitive battery), changes in positive symptoms of schizophrenia (scale for the assessment of positive
symptoms), changes in negative schizophrenia symptoms (scale for the assessment of negative symp-
toms), suicide ideation (Columbia Suicide Severity Rating Scale)
Study funding Not reported
Author declarations Not reported
Notes New for 2020 update. Information from http://clinical trials gov registry and unpublished protocol; dis-
crepancies between the two in terms of trial methods. Feasibility for future NIH grant application. In-
tended to recruit 20 participants but only 7 started and completed
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not reported
Allocation concealment
(selection bias)





Unclear risk “double-blind” but “open-label” elsewhere, no further info given
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Not reported
Selective reporting (re-
porting bias)
High risk Schizophrenia and COPD outcomes not reported.
Other bias Unclear risk Some discrepancies between clinicaltrials record and protocol linked to from
record, including when NRT started and inclusion criteria (just schizophrenia
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Study characteristics
Methods Design: Open-label non-comparative study
Recruitment: Study site database and community advertisements
Setting: Clinical Trials Unit, USA
Study start date: April 2013; Study end date: 10 July 2013
Participants Total N: 29
Inclusion criteria:
• Age 18 - 65 years
• Good health
• BMI 18 - 35
• Smoking 10+ cpd
• CO > 10 ppm
Exclusion criteria:
• Pregnancy or breastfeeding
• Other drug dependency
• Use of any psychiatric or opioid medications
• EC within the previous 14 days
• Use of NRT in last 30 days
• Want to reduce or quit smoking within the next 30 days
Exclusion criterion: EC within the previous 14 days; use of NRT in last 30 days
44% women; mean age 43; mean cpd 20.1; mean FTND 4.5
Motivated to quit: no
E-cigarette use at baseline
Interventions EC: Cig-a-like
Participants attended 3 clinic visits at 1-week intervals
Visit 1: Baseline
Visit 2: Provided with 1st generation type - 'NJOY® King Bold' (NJOY, Inc. Scottsdale, AZ), with 26 mg
nicotine. Used ad libitum for 20 minutes in the clinic, then ad libitum use over the next week. Recorded
use of regular cigarettes and puIs on EC
Visit 3: Participants abstained from all sources of nicotine for 12 hours prior to visit
Outcomes Adverse events
Study funding Funding for this study was provided by NJOY, Inc., Scottsdale, AZ
Author declarations Dr Nides has received compensation from NJOY, Inc. and GlaxoSmithKline. Dr Leischow has received
compensation from GlaxoSmithKline, Pfizer, and Cypress Bioscience. Mr Simmons and Ms Bhatter have
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Prospective cohort
Allocation concealment
(selection bias)




Low risk 2 participants dropped out between visits 1 and 2
Selective reporting (re-
porting bias)





Methods Design: Randomized cross-over study
Recruitment: Newspaper advertisements, radio announcements, and from local general medicine
practices
Setting: Lab-based study, Connecticut, USA
Study start date: October 2012; Study end date: June 2015
Participants Total N: 27
Inclusion criteria:
• non-treatment-seeking people who smoke who were willing to try EC for 2 weeks and abstain from
conventional cigarette smoking
• 18 – 55 years of age who smoked at least 10 cpd
Exclusion criteria:
• Pregnant
• Previous myocardial infarction or stroke
• Uncontrolled hypertension (blood pressure (BP) > 160/100)
• Insulin-dependent diabetes
• COPD or current asthma
• Known allergy to propylene glycol
45% women; mean age 42; 70% white; 15% Hispanic, 15% black; mean cpd 16; 45% had tried EC at
baseline, 50% smoked menthol cigarettes
Motivated to quit: No
E-cigarette use at baseline: Not specified
Interventions EC: Cig-a-like
Prescribed Joye eGo-C (www.joyetech.com) and e-Juice (18 mg/mL nicotine) procured from Ameri-
can eLiquid (www.americanliquid.com) Cross-over study between menthol-flavored and non-menthol
Oncken 2015 
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tobacco-flavored EC. Requested not to smoke their regular cigarettes during study period, but most
(60%) reported intermittently smoking cigarettes during study
Outcomes Follow-up at 1 wk and 2 weeks
BP, heart rate, body plethysmography, static lung volumes and airways resistance (Raw) and specific
conductance (sGaw) – taken at lab visits after abstaining from EC for at least 2 hrs, then taken again af-
ter inhaling EC and repeated 5 mins later
Adverse events also reported but method for measuring not stated
Also measured nicotine concentrations, rates of cigarette and EC use
Study funding This project was supported by Academic Enhancement funds from the Department of Medicine at the
University of Connecticut Health Center (to CO) and the Clinical Research Center at the University of
Connecticut Health Center
Author declarations CO is currently receiving study medication (nicotine inhaler and placebo) from Pfizer pharmaceuticals
for an NIH funded of nicotine inhaler for smoking cessation during pregnancy
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not stated;
Quote: "Subjects were then randomly assigned to use the menthol or plain e-









Low risk No detail given on blinding but equal levels of support between arms, so per-
formance bias judged unlikely
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Some subjective outcomes but equal levels of support between arms so differ-




Low risk 20/27 followed up
Selective reporting (re-
porting bias)
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Recruitment: Cigarette smokers were recruited from the community via fliers, online postings, and
word of mouth
Setting: Morgantown, West Virginia, USA
Study start date: Not reported. Study end date: Not reported
Participants Total N: 60; E-cigarette plus own brand = 30. Own brand cigarette (control) = 30
38.3% female; mean age completers 35.1 (SD 11) (N = 34) non-completers 36.8 (SD 12.9) (N = 26); mean
cpd completers 16.7 (SD 4.9), non-completers 19.6 (SD 6.1); mean FTND completers 5.3 (SD 1.8), non-
completers 5.9 (SD 1.9)
Inclusion criteria:
• 18 to 60 years of age; smoking ≥ 10 cigarettes per day for ≥ 1 year
• exhaled air carbon monoxide (CO) level of ≥ 10 ppm (Micro+™ basic monitor; CoVita; Haddonfield, NJ)
• Contemplation or Preparation Stage of Change (indicating interest in a quit attempt within the next
1 - 6 months)
Exclusion criteria:
• reported chronic health or psychiatric conditions
• past month use of marijuana ≥ 5 days
• past month use of any other illicit drugs, or regular use of ECIGs or other tobacco products (i.e. ≥ 1
day per week)
• individuals in the Precontemplation (no interest in quitting) or Action (actively trying to quit) Stage
of Change
• currently breast- feeding or tested positive for pregnancy via urinalysis
Interventions EC: Refillable
E-cigarette (18 mg/ml ) plus own brand cigarette. Kanger mini Protank-II, which is a 1.5 ml Pyrex glass
tank with a drip tip and atomizer head coils (KangerTech; China), and a 3.3 V constant output, 900 mAh,
eGo-T battery (Joyetech; Irvine, CA). The liquid (The Vapor Room, Sky Vapors LLC, Frostburg, MD) was
labeled as 70% propylene glycol and 30% vegetable glycerin, with a nicotine concentration request-
ed of 18 mg/ml. Participants could choose tobacco, menthol or wild berry flavor and could switch be-
tween sessions. Ad libitum use for 4 weeks
Own brand cigarette ad libitum use for 4 weeks
Outcomes Daily for salivary cotinine samples. Daily self-monitoring device to log e-cigarette and cigarette use.
Collected used cigarette filters
Weekly CO breath test
Attended the laboratory weekly for assessments (Days 8, 15, 22, and 29). Then completed a follow-up
visit 1-month post-intervention
self-reported withdrawal symptoms
Reported experience of specific symptoms rated using a visual analog scale with a range from 0 (not at
all) to 100 (extremely). e.g. craving, irritability, dry mouth, throat irritation, and cough
Study funding Financial support provided to MDB and GAD by WVU Senate Grant for Research, and to GAD, MDB, and
NAT by Cooperative Agreement Number 1-U48-DP-005004 from the Centers for Disease Control and
Prevention (CDC) to the West Virginia Prevention Research Center. Support provided to NJF and JEOH
by the National Institute of General Medical Sciences (NIGMS T32 GM081741). Additional support pro-
vided by WV Tobacco Cessation QuitLine
Ozga-Hess 2019  (Continued)
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Author declarations Author SGF has consulted for various pharmaceutical companies on matters relating to smoking cessa-
tion. All other authors declare that they have no conflicts of interest
Notes New for 2021 update
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Using a simple randomized design"
Comment: not adequately explained
Allocation concealment
(selection bias)





High risk Participants and investigators were not blind
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk 40% retention, but no difference between groups
Selective reporting (re-
porting bias)





Methods Design: Uncontrolled pre-post pilot study
Recruitment: Word of mouth
Setting: Hospital-based smoking cessation clinic, Italy
Study start date/end date: Not specified
Participants Total N: 34
Inclusion criteria:
• Adults who smoke, unwilling to quit smoking tobacco cigarettes and who have never tried a quit-
smoking protocol or have refused any smoking cessation treatment, or both
Exclusion criteria:
• None stated
Inclusion based on specific population characteristic: No
47.1% women, mean age 40.6, mean cpd 21.5
Pacifici 2015 
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no EC use at baseline, not motivated to quit
Interventions EC: Refillable
Participants were given commercially-available EC (AVATAR device, Battery 550 mAh/3.9 V, W: 7.8, car-
tomizer with 2, 2 ohm resistance, tank capacity 1.5 mL, temperature of the aerosol: 55/65 degrees), 2
different chargers for each EC and PUFFIT e-liquids with nicotine content matching the individual nico-
tine daily intake and tobacco and/or other flavors freely chosen by each participant
W1: nicotine-free e-liquid
W2&3: Own EC with personal nicotine dosage, encouraged to use as substitute for traditional cigarettes
W4: Encouraged to forego all traditional cigarettes
Throughout: assistance at any time of day from centre staI with any EC-related problem, plus fol-
low-up group sessions and smartphone messaging application
Behavioural support:
Multi-component medically-assisted training program with monitoring of nicotine intake as a biomark-
er of correct EC use, including Information about general working principles, safety and risks of EC, to-
gether with medically-assisted face-to-face training on how to correctly use the device to absorb nico-
tine vapor
Outcomes Follow-up at 1, 4 and 8 m
Cessation (measure not defined)
Adverse events
Exhaled CO, COT, 3-HCOT concentration
cpd
Study funding The authors thank Renata Solimini, Adele Minutillo, Emilia Marchei and Maria Concetta Rotolo for their
technical assistance. This work was supported by the Department of Therapeutic Research and Medi-
cines Evaluation Istituto Superiore di Sanità, Roma, Italy
Author declarations The authors declare no conflict of interest
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Not controlled
Allocation concealment
(selection bias)




Low risk All participants followed up
Selective reporting (re-
porting bias)
High risk AEs measured but not reported
Pacifici 2015  (Continued)
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Study characteristics
Methods Design: Prospective cohort
Recruitment: Advertisments in local hospital in Catania, Italy
Setting: not specified
Study start date: February 2010; Study end date: June 2010
Participants Total N: 40, hospital staI
Inclusion criteria:
• Healthy people who smoke
• 18 - 60 years old
• smoking ≥ 15 cpd for at least the past 10 years, and not wanting to quit smoking at any time in the
next 30 days
Exclusion criteria:
• History of alcohol and illicit drug use
• Psychiatric illness
• Recent myocardial infarction
• Angina pectoris
• High blood pressure (BP > 140 mmHg systolic or 90 mmHg diastolic, or both)
• Diabetes mellitus
• Severe allergies
• Poorly-controlled asthma or other airways diseases
35% women, mean age 42.9 (SD 8.8), median cpd 25 (IQR 20 - 30), median FTND 6.0 (IQR 6 - 8)
Motivated to quit: No
E-cigarette use at baseline: Not specified
Interventions EC: Cig-a-like
Seen at baseline, given EC ('Categoria' brand) with an initial 4-week supply of 7.4 mg nicotine car-
tridges. Instructed to use ad libitum up to 4 cartridges per day. EC cartridges supplied at months 1, 2,
and 3
No instruction on cessation or reduction was provided
Outcomes Follow-up at 1, 2, 3, 6, 18 and 24 months where cigarette consumption, CO, and AEs were measured, in-
cl. 30-day PP CO-validated abstinence at 6 months and CO-validated abstinence at 18 and 24 months
(not otherwise defined)
Adverse events
Study funding "We wish to thank Arbi Group Srl (Milano, Italy) for the free supplies of ‘Categoria’ e-Cigarette kits and
nicotine cartridges as well as their support. We would also like to thank the study participants for all
their time and effort and LIAF (Lega Italiana AntiFumo) for the collaboration"
Author declarations "None of the authors have any competing interests to declare, but RP has received lecture fees from
Pfizer and, from Feb 2011, he has been serving as a consultant for Arbi Group Srl.Arbi Group Srl (Milano,
Italy), the manufacturer of the e-Cigarette supplied the product, and unrestricted technical and cus-
tomer support. They were not involved in the study design, running of the study or analysis and presen-
tation of the data"
Polosa 2011 
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Notes Smoking cessation services provided to those who spontaneously asked for assistance with quitting.
These participants were excluded from the study protocol
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Prospective cohort
Allocation concealment
(selection bias)




Low risk 13/40 were lost to follow-up, but used ITT analysis
Selective reporting (re-
porting bias)





Methods Design: Prospective cohort study
Recruitment: Volunteers, leaflets, cessation service kiosk in hospital
Setting: Smoking cessation clinic, Italy
Study start date: January 2013; Study end date: November 2013
Participants Total N: 50
Inclusion criteria:
• Healthy people who smoke
• 18 – 60 years old
• Smoking ≥ 15 conventional cpd for at least 10 years
• Unwilling to quit
Exclusion criteria:
• none stated
40% women, mean age 41, mean cpd 25, mean FTND 6.0
No EC use at baseline, not motivated to quit
Interventions EC: Refillable
2nd generation devices (personal vaporisers - PVs): EGO/CE4 model, filled with tobacco aroma e-Liquid
containing 9 mg/ml nicotine; instructed to use the study products ad libitum (up to a maximum of 5 ml/
day; i.e. half vial)
Behavioural support:
Polosa 2014b 
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Participants were instructed how to charge, fill, activate and use the EC. Key troubleshooting was ad-
dressed and phone numbers were supplied for assistance. “No emphasis on encouragement, motiva-
tion and reward for the smoking cessation-related efforts were provided during the study.”
Outcomes 4, 8, 12 and 24 weeks
30-day PP verified by CO ≤ 10 ppm
Adverse events
Cpd, exhaled CO, reduction rates, product usage, and opinions of the EC products
Study funding "The authors wish to thank FlavourArt (Oleggio, NO, Italy; www.flavourart.it). Authors wish to thank
LIAF, Lega Italiana Anti Fumo (Italian acronym for Italian Anti Smoking League) for supporting this re-
search"
Author declarations "RP has received lecture fees and research funding from Pfizer and GlaxoSmithKline, manufacturers
of stop smoking medications. He has also served as a consultant for Pfizer and Arbi Group Srl, an Ital-
ian distributor of e-Cigarettes. RP is currently scientific advisor for LIAF, Lega Italiana Anti Fumo (Italian
acronym for Italian Anti Smoking League). PC, MM, JBM, and CR have no relevant competing interest to




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Not controlled
Allocation concealment
(selection bias)




Low risk 76% followed up, ITT analysis used, no significant differences in baseline char-
acteristics between completers and those lost to follow-up
Selective reporting (re-
porting bias)





Methods Design: Prospective cohort
Recruitment: Professional retail staI in participating vape shops
Setting: 7 vape shops in Catania province, Italy
Study start date/end date: Not specified
Participants Total N: 71
Inclusion criteria:
Polosa 2015 
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• Adults who smoke (≥ 18)
• making first purchase at participating vape shop (definition of smoker not stated)
Exclusion criteria:
• none stated
38% women, mean age 41.7, mean cpd 24.9, mean FTND 5
No EC use at baseline
Interventions EC: Refillable
Instructed how to charge, fill, activate and use EC; key troubleshooting advice provided; phone number
available for technical support “Encouraged to use these products in anticipation of reducing the num-
ber of cig/day smoked”
Outcomes 6 and 12 m follow-up
30-day PPA via self-report
Details of product purchase
Sustained 50% and 80% reduction in cpd from baseline
Study funding Authors wish to thank the local participating Vape Shops and LIAF, Lega Italiana Anti Fumo (Italian
acronym for the Italian Anti-Smoking League) for supporting this research
Author declarations Riccardo Polosa has received lecture fees and research funding from Pfizer and GlaxoSmithKline, man-
ufacturers of stop smoking medications. He has also served as a consultant for Pfizer and Arbi Group
Srl, an Italian distributor of e-Cigarettes. Riccardo Polosa is currently scientific advisor for LIAF, Lega
Italiana Anti Fumo (Italian acronym for Italian Anti-Smoking League). Jacques Le-Houezec is a consul-
tant for Johnson & Johnson France, a manufacturer of nicotine replacement therapy, and was reim-
bursed for travel and accommodation to present at a conference in Shenzhen (China) organized by the
e-cig manufacturer association (CECMOL). Pasquale Caponnetto and Fabio Cibella have no relevant
conflict of interest to declare in relation to this work
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Not controlled
Allocation concealment
(selection bias)
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Study characteristics
Methods Design: Observational study – uncontrolled experimental study
Recruitment: community mental health centre through self-referral and clinician referrals
Setting: community mental health centre (USA)
Study start date: October 2013; Study end date: June 2014
Participants Total N: 19 (21 originally recruited, however 2 participants did not return for any weekly visits so 19 an-
alyzed)
Inclusion criteria:
• Age ≥ 18
• Primary DSM-IV axis I diagnosis, based on chart review and confirmation by the community mental
health centre team psychiatrist, of schizophrenia, schizoaffective disorder, or bipolar disorder
• SMI defined by at least moderate impairment in multiple domains of life functioning due to mental
illness
• Smoking at least 10 cigarettes per day
• History of failed treatment-facilitated quit attempts
• Voluntary informed consent for participation
Exclusion criteria:
• Current use of e-cigarettes
• Medical instability
• Primary diagnosis of dementia or significant cognitive impairment defined as a Mini Mental Status
Examination (MMSE) score < 24
Inclusion based on specific population characteristic: Psychiatrically stable, in-treatment, people who
smoke with a schizophrenia spectrum disorder or bipolar disorder
68% women; mean age 42; mean cpd: Only cigarettes per week reported: 192 (SD = 159.3). This would
be an average of 27 cpd; mean FTND 5.5
Motivated to quit: “None of the participants was actively engaged in a quit attempt during the study”
E-cigarette use at baseline: E-cig use was an exclusion criterion
Interventions EC: Cig-a-like
E-cigarette details: (NJOY brand) based on each participant's level of use of combustible tobacco. Each
e-cigarette cartridge was approximately equivalent to 2 packs of combustible cigarettes. Trained re-
search interviewers instructed participants on the proper use of e-cigarettes
Outcomes Week 1, 2, 3, 4
Adverse events and biomarkers:
• Breath CO level
• Possible side effects
Other outcomes measured:
• Use of tobacco products
• Fagerström nicotine dependence scores
• Appeal of EC
• Level of enjoyment of EC
• Satisfaction with EC compared with usual combustible tobacco
Pratt 2016 
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• Willingness to purchase EC
Study funding “Financial support to purchase the e-cigarettes and pay small stipends to the participants in this un-
funded pilot study came from Dr. Mary Brunette's discretionary reserve account.”
Author declarations “All authors declare that they have no conflicts of interest”
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Not randomized
Allocation concealment
(selection bias)




Low risk 2 dropouts (9.5%) failed to return to clinic. Analysis based on 19 participants
Selective reporting (re-
porting bias)





Methods Design: Observational uncontrolled experimental study
Recruitment: Community
Setting: Visits took place in University labs, USA
Study start date: January 2015; Study end date: April 2015
Participants Total N: 40
Inclusion criteria:
• Being 18 years of age or older
• Cigarette smoking on at least 4 days of the past 30 days for at least 1 year
• Never using EC regularly (less than 25 lifetime uses)
• Not having used EC on more than 3 of the past 30 days
• Being willing to switch from smoking regular cigarettes to ECs
• Fluency in English
• Having regular access to a telephone and transportation to attend appointments
• Being willing to abstain from using marijuana during the study
Exclusion criteria:
• Any use of other tobacco products (OTPs) including smokeless tobacco, cigarillos, pipes, cigars, hand-
rolled cigarettes, and hookah in the past 30 days
• Being currently in a smoking cessation program or another clinical trial
Pulvers 2018 
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• Past 30 day use of nicotine replacement therapy or medication which aids smoking cessation includ-
ing bupropion, clonidine, nortriptyline, or varenicline
• Having uncontrolled asthma, severe allergies, or diabetes mellitus
• Currently taking prescription medication for emotional distress, depression, or other psychological
problems
• Current dependence on a substance other than nicotine
• Presence of any cardiovascular or pulmonary illnesses in the past 6 months
• For women, pregnancy or plans to become pregnant in the next 6 months
Inclusion based on specific population characteristic: No
27% women; mean age 30.08; mean cpd 8.76; FTND not reported
Motivated to quit: over half either did not intend to quit at all or did not intend to quit in the next 6
months 22/40 (55%)
E-cigarette use at baseline: Inclusion criteria included the following:
• Never using EC regularly (less than 25 lifetime uses)
• Not having used EC on more than 3 of the past 30 days
Interventions EC: Refillable
2nd generation EC starter kit with 2 e-Go C batteries (3.7 volts/650 MaH), a USB connection cord, an
AC adapter, and a carrying case, and a supply of Saturn V4i atomizers (2.4 ohms) filled with liquid in
their preferred flavor (28 atomizers total; 2/day). Provided 24 mg/mL dosage vegetable glycerin liquid
in a tester sample to all participants. Those who reported the 24 mg was too strong were provided 12
mg/mL dosage liquid. The first session included brief education, training, action planning for making a
complete switch to EC. A referral to the California Smokers’ Helpline was made at the final visit (week
4).
Outcomes 3 lab visits (baseline, week 2, and week 4) and 2 phone visits (week 1 and week 3). Biological samples
were taken at all 3 in-person visits (baseline, week 2, and week 4). However, due to budgetary restric-
tions, only the baseline and week 4 biological data were analyzed
Adverse events and biomarkers:
• Biochemical measures only: Breath samples were taken with a Micro + (Bedfont, Haddonfield, NJ) to
measure CO
• Urine samples taken to test for change in tobacco toxicant exposure by following measures:
* concentrations of NNAL measured by liquid chromatography–tandem mass spectrometry (LC–MS/
MS)
* metabolites of a panel of potentially toxic VOCs, including benzene (PMA), ethylene oxide (HEMA),
N-nitrosodimethylamine (MMA), acrylonitrile (CNEMA), acrolein(3-HPMA), propylene oxide (2-HP-
MA), acrylamide (AAMA), and crotonaldehyde (HPMMA) measured by LC–MS/MS,2
Other outcomes measured:
Cotinine, change in tobacco consumption (cpd using TLFB interview), change in frequency of EC use,
change in nicotine dependence and attitudes/behavior, change in 30-day nicotine exposure
Study funding “This study was funded by the University of Minnesota (JSA), P30 DA012393 (NLB), P50 CA180890 (NLB),
and California State University San Marcos (KP).”
Author declarations “Benowitz is a consultant to pharmaceutical companies that market smoking cessation medications
and has been an expert witness in litigation against tobacco companies. The other authors have no
conflicts of interest.”
Notes New for 2020 update
Pulvers 2018  (Continued)
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Not randomized
Allocation concealment
(selection bias)




Low risk 37/40 provided follow-up data
Selective reporting (re-
porting bias)





Methods Design: RCT. Unblinded. 2:1 ratio
Recruitment: Participants were recruited from the San Diego, California, and Kansas City, Missouri and
Kansas, metropolitan areas
Setting: USA
Study start date: May 2018. Study end date: May 2019
Participants Total N = 186; Electronic-cigarettes = 125. Own brand cigarette = 61
40.3% female; mean age 43.3 (SD 12.5); mean cpd 12.1 (SD 7.2). E-cigarettes use at baseline: 0.05 (0.3%)
Inclusion criteria:
• > 21 years of age
• Smoked cigarettes on > 25 of past 30 days
• Smoked > 5 cigarettes per day on days smoked
• Smoked cigarettes > 6 months
• Carbon monoxide > 5 PPM at baseline
• Systolic BP of < 160 mmHg and diastolic BP of < 105 mmHg at baseline
• · Hispanic/Latino or African American/Black
• · Fluent in English or Spanish
• · Willing to switch from smoking cigarettes to ECs for 6 weeks
• · Regular access to telephone
• · Transportation to attend appointments (KC Only)
Exclusion criteria:
• Primary use of other tobacco products or equal use of cigarettes and other tobacco products
• Electronic cigarette use on > 4 of the past 30 days
• Currently in a smoking cessation program or another clinical trial
• Use of nicotine replacement therapy or medication which aids smoking cessation in the past 30 days
• Hospitalization for a psychiatric issue in the past 30 days
Pulvers 2020 
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• Heart-related event in the past 30 days. Examples include heart attack, stroke, severe angina (i.e. chest
pain), ischemic heart disease, and vascular disease
• Uncontrolled blood pressure at baseline
• Planning to move out of study centers (San Diego or Kansas City) in the next 6 weeks
• Another person in the household enrolled in the study
• Women: pregnant, breast-feeding, or planning to become pregnant in the next 6 months
• Unstable mental status or health status
Interventions EC: pod
Electronic-cigarettes: JUUL (5% nicotine); Choice of flavors (Menthol, Mango, Cool Mint, Virginia To-
bacco); Given 1 pod per pack of cigarettes; Given a 2-week supply at baseline and then a further 4-week
supply at week-2 visit. At each follow-up appointment (week 1, telephone call; week 2, in-person visit;
and week 4, telephone call), barriers and benefits of switching to e-cigarette were discussed and action
planning for exclusive switching was revisited. Compensated on a schedule of USD 20 at baseline, USD
40 at week 2 and USD 60 at week 6
Own brand cigarettes: Compensated on a schedule of USD 20 at baseline, USD 40 at week 2 and USD
60 at week 6
Outcomes Baseline, week 2 and week 6. Telephone survey at 6 months
Change in past 7-day combustible cigarette use measured by 7-day timeline follow-back interview
30-day point prevalence at 6 months (EC group only)
• reduction in toxicant exposure, as measured by NNAL excretion.
• Cotinine
• CO
Lung function; Pulmonary function test of small airway disease that is most sensitive to effects of cig-
arette smoking; mean midexpiratory phase of forced expiratory (FEF25%-75%); respiratory symptoms
as measured with the American Thoracic Society Questionnaire (scores range from 0 - 32, with higher
scores indicating greater respiratory symptoms)
Blood pressure
Adverse events: respiratory symptoms
Study funding Drs Pulvers and Nollen and Ms Rice were supported by grant No. 5SC3GM122628 from the National In-
stitutes of Health (NIH). Drs Schmid and Ahluwalia were supported in part by grant No. P20GM130414,
from the NIH-funded Center of Biomedical Research Excellence (COBRE). Dr Schmid was partially sup-
ported by Institutional Development Award No. U54GM115677 from the National Institute of General
Medical Sciences of the NIH, which funds Advance Clinical and Translational Research (Advance-CTR)
Author declarations Dr Schmid reported serving as a consultant for legal firms representing Eli Lilly, Boehringer-Ingelheim,
and Gilead outside the submitted work. Dr Benowitz reported receiving personal fees from Pfizer and
Achieve Life Sciences and serving as a consultant to pharmaceutical companies that market smoking
cessation medications and as an expert witness in litigation against tobacco companies outside the
submitted work. Dr Ahluwalia reported receiving personal fees from Lucy Goods outside the submitted
work. No other disclosures were reported.
Notes New for 2021 update. Additional data provided by authors
Risk of bias
Bias Authors' judgement Support for judgement
Pulvers 2020  (Continued)
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Random sequence genera-
tion (selection bias)
Low risk Randomization sequence was generated with an Excel (Microsoft) random
number formula applied to each site (2:1 ratio)
Allocation concealment
(selection bias)
Low risk Allocation was placed into sealed individual envelopes labeled with partic-
ipant identification numbers for each site, retrieved from a locked cabinet






High risk Could not be blinded
Blinding of outcome as-
sessment (detection bias)
All outcomes













Methods Design: Non-randomized single-arm
Recruitment: From supported temporary accommodation (STA) service STA project workers and sup-
port staI identified potential study participants who smoked and wished to quit
Setting: Dublin Simon Community, Ireland
Study start date: Recruitment February 2019 (overall trial start date March 2018). Study end date: June
2019
Participants Total N: 23 but only report baseline for the 9 that completed the study. % female 8.7% (2/23) at base-
line, (22.2% 2/9) completed and reported; mean age 43.89 (SD 7.36); mean cpd 25.22 (SD 7.77); mean
FTND 7.89 (SD 1.2); mean CO 21.89 (SD 14.4 corresp)
E-cigarettes use at baseline: no
Motivated to quit: yes
Inclusion criteria:
• > 5 CO ppm (carbon monoxide)
• Active smoking status
• Expressed intention to quit using ENDS-device
Exclusion criteria:
• Self-reported pregnancy
• Exhibition of florid psychotic or substance use-related symptoms which could have affected ability
to consent
Scheibein 2020 
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Interventions EC: Refillable
Electronic-cigarette: Endura T22e Electronic Nicotine Delivery System and 2 10 ml bottles of fluid
strengths (0, 6, 11, 18 and 20 mg/ml) and flavors ('Purple Berry', 'Ice Menthol', 'Regular Blend' and
'American Tobacco')
Outcomes Baseline (‘week 1’), week 4, week 8, week 12: CO, adverse events
Also number of cigarettes smoked; Fagerström Test Scores
Study funding This study was completed as part of a Tobacco Harm Reduction Scholarship funded by Knowledge Ac-
tion Change
Author declarations FS was a recipient of a Tobacco Harm Reduction Scholarship provided by Knowledge Action Change.
He is currently the recipient of an Enhanced Scholarship from the same organization. AM and KM acted
as mentors for both the Tobacco Harm Reduction Scholarship and Enhanced Scholarship.
AM is an associate of New Nicotine Alliance.
KM is a recipient of a grant from the Foundation for a Smoke Free World.
JW declares no interests.
WR declares no interests
Notes New for 2021 update
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Only 1 arm
Allocation concealment
(selection bias)





High risk Not randomized
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk 9/23 completed. Reason was many people moved away so not linked to unac-
ceptability of the study. Incomplete paperwork to enable to be followed
Selective reporting (re-
porting bias)
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Methods Design: Double-blind randomized controlled trial
Recruitment: Recruited from the local area via advertising on craigslist social media
Setting: Laboratory and electronic diaries, USA
Study start date/Study end date: Not specified.
Participants Total N: 30
N per arm: PG/VG ratio 70/30 = NR; PG/VG ratio 50/50 = NR; PG/VG ratio 0/100 = NR
Inclusion criteria:
• adults age ≥ 18 who have been smoking at least 5 cigarettes daily for the past year (expired CO > 8)
• usual brand is non-menthol
• use of ENDS on 5 or fewer lifetime occasions
• regular use of e-mail or smartphone ownership with capacity to receive SMS text and internet access
(necessary for electronic diaries)
Exclusion criteria:
• unwilling to use ENDS as part of the trial
• use of smokeless, hookah, or tobacco products other than cigarettes ≥ 10 days in the past 30 days
• pregnant, trying to become pregnant, or breastfeeding
• recent history of cardiovascular distress in the last 3 months (arrhythmia, heart attack, stroke, uncon-
trolled hypertension)
• current use of cessation medications
• another household member currently enrolled in the study (to prevent contamination of e-liquid as-
signment during sampling)
30% women; mean age 43.7; mean cpd 18.5; mean FTND 5.4
Motivated to quit: Not specified
E-cigarette use at baseline: Participants had used an e-cigarette an average of 1.6 times in their life,
and no one reported use in the last 30 days
Interventions EC: Cig-a-like
EC provided for 1 week. All aspects of the ENDS device and e-liquid were held constant between groups
with the exception of PG/VG ratio:
PG/VG ratio 70/30; PG/VG ratio 50/50; PG/VG ratio 0/100. Ego-T 1100 mAh battery and disposable
cartomizers (510 Smoketech, 1.5-Ω dual coil). E-liquid was tobacco-flavored (Classic Tobacco, Ameri-
can E-liquid) and contained 18 mg nicotine/ml
Outcomes 1 week; 2 lab visits pre and post and participant diaries
Adverse events and biomarkers: Participants provided a CO sample at each visit
Other outcomes measured: cpd, ENDS puIs
Study funding Funding for this project was provided by pilot funding from the National Cancer Institute (P01CA200512
to K.M.C.). Salary support provided by the National Institute on Drug Abuse (K12DA031794 to T.T.S.,
K23DA041616 to B.W.H.)
Author declarations M.J.C. has received consulting honoraria from Pfizer. K.M.C. has received payment as a consultant to
Pfizer, Inc., for service on an external advisory panel to assess ways to improve smoking cessation de-
livery in health care settings. He also has served as paid expert witness in litigation filed against the to-
bacco industry
Smith 2020  (Continued)
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Notes Additional data provided from authors. New for 2020 update.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: “At the conclusion of the lab visit, participants were randomized and
assigned to take home one of the three e-liquids to use at home for a 1-week
sampling period (10 participants/ratio).”
Quote: “Participants were randomly assigned to receive one e-liquid to take
home for 1 week.” (no further detail given)
Allocation concealment
(selection bias)





Low risk Quote: “PG/VG ratio was blinded from participant and staI members who con-
ducted experimental sessions.”
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk Number of participants at follow-up not reported, but this may be due to the
1-week follow-up and it seems that all participants (excluding 1 participant
who was not randomized) were followed up
Selective reporting (re-
porting bias)
Unclear risk No protocol. Few details for CO measurements, just percentage change for





Methods Design: Non-controlled open-label experimental study
Recruitment: A flyer posted at a large methadone maintenance treatment program
Setting: Methadone maintenance treatment program, USA
Study start date: April 2015; Study end date: Not specified
Participants Total N: 12
Inclusion criteria:
• current moderate or heavy cigarette use (10+ cpd for at least 12 months prior to enrolment)
• current MMT for at least 3 months
• ready to make a smoking quit attempt in the next 14 days
• plan to remain on MMT for at least 12 weeks
Exclusion criteria:
• used e-cigarettes on more than 2 of the past 30 days
• currently used medications that may reduce smoking (bupropion, varenicline, NRT)
Stein 2016 
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• had unstable medical or psychiatric conditions (past-month suicidal ideation or past-year suicide at-
tempt, hospitalization for myocardial infarction or stroke in the prior 3 months)
• had regular use of marijuana (self-report or positive urine drug test)
Inclusion based on specific population characteristic: People receiving MMT for opoid use disorder
50% women; mean age 45.9; mean cpd 17.8; mean FTND: Not reported
Motivated to quit: yes
E-cigarette use at baseline: Had not used e-cigarettes for more than 2 of the past 30 days
Interventions EC: Cig-a-like
2 week supply of NJOY e-cigarettes at week 1 (quit day), consisting of 5 packs of NJOY e-cigarettes (15
in total). Participants could request an additional 5 pack (20 in total) for the following 2-week study
period, if they ran out before a study visit. Participants instructed to use EC exclusively for a total of 6
weeks (end of treatment). They were referred to the state telephone QuitLine for supportive counseling
at the quit-day visit (week 1)
Outcomes Participants quit and received e-cigs at week 1. Assessments were carried out at week 3, 5, 7 and 9
Adverse events and biomarkers:
• “Side effects” of e-cigarettes were recorded. Side effects were rated none, slight, mild, moderate and
severe at every assessment visit. An adverse effect possibly related to e-cigarette use was defined as
positive if the value at baseline was either none or slight AND the value at any of 3, 5, or 7 weeks was
mild or more severe
Other outcomes measured:
• Reduction in the average cpd
• E-cig adherence
• Nicotine withdrawal
Study funding “MDS is a recipient of National Institute on Drug Abuse Award K24 DA000512. This award funded the
project described here.”
Author declarations “None declared.”
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk No randomization
Allocation concealment
(selection bias)




Low risk Quote: “One individual dropped out after week 3 and did not return; another
completed all follow-up assessments except week 7.”
Selective reporting (re-
porting bias)
Low risk All expected outcomes reported
Stein 2016  (Continued)
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Study characteristics
Methods Design: Randomized, factorial trial (Participants were randomized to one of the 5 brands of e-cigarettes
– although only 4 brands analyzed)
Recruitment: Media ads
Setting: Recruitment from the community, study took place at University, USA.
Study start date/Study end date: Not specified.
Participants Total N: Analysis based on 24 (28 originally recruited, but the first 4 participants enrolled experienced
malfunctioning NJOY e-cigs and withdrew – the project was removed from the market before the 5th
participant was randomized)
N per arm: blu: 6; Green Smoke: 6; V2: 6; White Cloud: 6
Inclusion criteria:
• Age 18 to 65 and self-reported smoking at least 10 cigarettes per day.
Exclusion criteria:
• Use of other tobacco or nicotine-containing products, including e-cigarettes (no more than 3 previous
episodes of use and not currently using)
• Current diagnosis or evidence of substance abuse or dependence or major depression
• Current or history of psychotic or bipolar disorder
• History of suicide attempt
• History of cancer or cardiovascular disease
• Uncontrolled hypertension
• Use of smoking cessation medications
• Any current plans to try to quit smoking
• Current pregnancy or lactation
Inclusion based on specific population characteristic: Not applicable
29% women; mean age 43.3; mean cpd 17; mean FTND 3.7
Motivated to quit: Participants had no current plans to try to quit smoking (eligibility criterion)
E-cigarette use at baseline: No more than 3 previous episodes of use and not currently using (eligibility
criterion)
Interventions EC: Cig-a-like
All participants received nicotine EC and were instructed to use them exclusively for 9 days
The 5 brands selected, including brand reported nicotine levels, were: (1) NJOY (18mg nicotine) – this
brand was discontinued and not analyzed as the e-cigs provided malfunctioned; (2) V2, 18 mg nico-
tine; (3) Green Smoke, 18.9 - 20.7 mg nicotine; (4) blu, 20 - 24mg nicotine; and (5) White Cloud, 23 - 24
mg nicotine. Each brand advertised the delivery of the same level of nicotine (appropriate for about a
pack/day smoker), provided the standard tobacco flavor (no other flavors made available), and used a
disposable cigarette-like device
Outcomes Day 10 is the only testing point of interest for us but participants were also tested at days 1 and 5
Adverse events and biomarkers:
• breath CO
Strasser 2016 
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• direct effects of nicotine (e.g. dizzy, nauseas, headache) - visual analogue scale with a single word




• direct effects of the e-cigarette (e.g. satisfying, calming, pleasant, smoke another right now) - visu-
al analogue scale with a single word scored from 0 (not at all) to 100 (extremely). Total scores were
summed such that higher scores indicated positive responses
• cotinine
• withdrawal and craving
Study funding “National Cancer Institute (NCI) of the National Institutes of Health (NIH) and FDA Center for Tobacco
Products (CTP) under Award Number P50CA179546, as well as grants from the National Cancer Institute
(P50 CA143187, P30 CA16520, and P30 DA12393)”
Author declarations “Dr Benowitz has served on scientific advisory boards for Pfizer and GlaxoSmithKline related to smok-
ing cessation medications and has been an expert witness in litigation against tobacco companies.
Dr Schnoll receives medication and placebo free of charge from Pfizer and has provided consultation
to Pfizer and GlaxoSmithKline. These companies had no involvement in this study. Dr Strasser has re-
ceived funding through the Pfizer GRAND program, an independent peer-reviewed grant program fund-




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Although participants were randomized to different brands of EC, no descrip-
tion on how randomization was carried out
Allocation concealment
(selection bias)





Unclear risk No description of whether groups were blind to other conditions, but given
similar levels of support between arms, so performance bias judged unlikely
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Unclear whether any blinding took place, some outcomes were measured us-




High risk For blu, Green Smoke, and V2 groups, 83% of participants completed the 10-
day study; only 33% of participants randomized to White Cloud completed the
10-day study; meaning loss to follow-up was considerably higher in this group
Selective reporting (re-
porting bias)
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Methods Design: 2-arm; double-blind placebo-controlled RCT
Recruitment: Advertisements placed in Craigslist as well as flyers distributed on the street and placed in
New York City venues with details for how to contact study staI.
Setting: Community, USA
Study start date: July 2014 – 2015 (month unclear); Study end date: Not specified
Participants Total N: 99 (100 were randomized but 1 participant randomized to the control arm was found to be in-
eligible between randomization and baseline)
N per arm: Nicotine EC: 50; Placebo EC: 49
Inclusion criteria:
• age 21 – 35 (confirmed with some form of identification document)
• daily smoker
• smoked ≧ 10 cigarettes a day (verified by a CO level of ≥ 8 ppm)
• interested in reducing cigarette consumption
• able to provide consent
• had a cell phone and was willing/able to receive text messages and counseling on their cell phone
• willing to use an EC for 3 weeks
Exclusion criteria:
• Pregnant and/or breastfeeding
• had a history of asthma, other airways diseases, or heart disease
• were currently using smoking cessation medications (including other forms of NRT, bupropion, or
varenicline), or enrolled in a smoking cessation program or another cessation trial.
• Use of EC in the past 14 days or any other tobacco products (pipe, cigar, cigarillos, snuI, chewing
tobacco, rolling tobacco, or hookah/shisha) in the past 30 days
• having a moderate to severe drug use disorder defined as a score of at least 5 on the Drug Abuse
Screening Test-10 and/or a hazardous or active alcohol use disorder defined as at least 7 for men and
at least 5 for women on the Alcohol Use Disorders Identification
Inclusion based on specific population characteristic: Young adults
32.3% women; mean age 28.43; mean cpd 14.33; FTND not measured but time to first cigarette was
measured categorically. The mode category was 6 - 30 mins (39/99; 41.5%) Smoking behavioral depen-
dence scale (11 items): mode category ‘Moderate’ (51/99; 51.5%)
Motivated to quit: Readiness to quit (1 – 10 scale, 1 – 8 apply to current people who smoke): 5.57 ± 1.49
E-cigarette use at baseline: No use of e-cigs in past 14 days (eligibility criterion)
Interventions EC: Cig-a-like
E-cigarette details:
3 weeks of disposable 4.5% nicotine NJOY, King Bold (NJOY, Inc, Scottsdale, AZ) which resemble con-
ventional cigarettes. NJOY also manufactured the non-nicotine placebo EC. Both nicotine and placebo
ECs were tobacco-flavored. The products were purchased by the investigators and provided to the par-
ticipants free of charge
Other stop-smoking pharmacotherapies: None
Behavioural support:
Prior to receiving the ECs, participants were required to complete a 20- to 30-minute telephone coun-
seling session with a trained tobacco cessation Counsellor. The purpose of the telephone counseling
was to review current smoking patterns and offer behavioral and environmental change strategies.
Tseng 2016  (Continued)
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These included specific smoking reduction options, such as eliminating cigarettes at work and in the
home, carrying only those cigarettes needed for that day, dropping cigarettes associated with less in-
tense triggers first, avoiding smoking triggers, and other strategies to manage urges.18 participants
were asked to reduce the number of cigarettes smoked daily by at least 50% of the total number of cig-
arettes smoked per day at baseline. To mimic real-life EC use, minimum EC use instruction was provid-
ed. Participants were encouraged to replace cigarettes with as much or as little use of an EC as needed
in order to reduce nicotine withdrawal symptoms
Outcomes Week 1, 3
Cessation: Not applicable
Adverse events and biomarkers: adverse events and symptoms related to EC use
Other outcomes measured:
• self-reported reduction of at least 50% in the number of cpd
• percentage reduction in number of cpd
• Use of ECs
• satisfaction with ECs
Study funding “This work was supported by the National Center for Advancing Translational Sciences at the National
Institutes of Health (grant number UL1TR000038).”
Author declarations “None declared”
Notes Study listed as ongoing study NCT02628964 in the 2016 review update
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “computer generated”
Allocation concealment
(selection bias)
Unclear risk Quote: “…was concealed from research assistants. Blinding of the allocation
of nicotine or placebo EC was ensured by the identical appearance of the ECs”.
However, not enough information given on how allocation was concealed at





Low risk Quote: “Blinding of the allocation of nicotine or placebo EC was ensured by the
identical appearance of the ECs”
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quote: "Blinding of the allocation of nicotine or placebo EC was ensured by the




Low risk Nicotine EC ltfu: 10/50; Placebo EC ltfu: 10/49
Selective reporting (re-
porting bias)
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Study characteristics
Methods Design: Open-label prospective cohort study
Recruitment: Recruited from within the Department of Veterans Affairs (VA) Connecticut Healthcare
System by word of mouth
Setting: Receiving psychiatric services from Department of Veterans Affairs healthcare system, USA
Study start date/Study end date: Not specified.
Participants Total N: 50 (sample analyzed for primary outcomes on week 1 completers – N = 43)
Inclusion criteria:
• Without an immediate intention to stop smoking
• Smoking history of at least 5 cigarettes a day for the past year
Exclusion criteria:
• Current untreated medical or psychiatric or substance use disorders, or both, as determined by a re-
view of the veteran’s electronic medical record
• current use of nicotine replacement or other cessation pharmacotherapies
• use of e-cigarettes or smokeless tobacco products for more than 2 of the past 30 days
Inclusion based on specific population characteristic: Military veteran people who smoke who had no
immediate intention to stop smoking and were currently receiving psychiatric services from the De-
partment of Veterans Affairs healthcare system.
7% women; mean age 56.9; mean cpd 16.6; mean FTND 4.9
Motivated to quit: Had no immediate intention to stop smoking
E-cigarette use at baseline: E-cigarettes or smokeless tobacco products may have been used for less
than 2 of the past 30 days
Interventions EC: Refillable
All given eVic Supreme (Joyetech), "a commercial, variable-power, tank-type device". 6.5 mL tank
(Delta 23, Joyetech) and a C3 triple coil atomizer head (Joyetech) with a total resistance of 1.8 ohms.
Participants could choose flavor (menthol or tobacco) and nicotine concentration (12 or 24 mg/mL).
Participants taught how to use EC, with additional materials dispensed as needed. Participants were
informed that they could use the study e-cigarette or regular tobacco cigarettes, or both, ad libitum
during study participation
Outcomes Week 1, 2, 3, 4, 8 (Weekly lab visits and 1 month follow-up)
Adverse events and biomarkers: Alveolar (breath) CO levels (ppm)
Other outcomes measured:
• Number of cpd
• The frequency of e-cigarette use (mean days/week)
• The amount of money spent on combustible cigarettes (US dollars/week)
• Fagerström Test of Nicotine Dependence
• Contemplation Ladder
• E-cigarette questionnaire (assessed changes in perceptions about e-cigarettes (e.g. harmfulness, ben-
efits, cost), motivations to use (or not use) them, and the reasons for e-cigarette or combustible ciga-
rette preferences) (measured at baseline and follow-up)
• Cotinine
Valentine 2018 
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Study funding "This research was supported by the New England Mental Illness Research, Education and Clinical Cen-
ter and the U.S. Department of Veterans Affairs. Statistical analyses, biochemical assays, and analyses
of e-cigarette solutions were supported by the Administrative and Laboratory cores of P50DA036151
(Yale TCORS) from the National Institutes of Health and the U.S. Food and Drug Administration Center
for Tobacco Products. The content is solely the responsibility of the authors and does not necessarily
represent the official views of the National Institutes of Health or of the U.S. Food and Drug Administra-
tion."
Author declarations "Ralitza Gueorguivea, PhD, discloses consulting fees for Palo Alto Health Sciences and Mathematica
Policy Research and a provisional patent submission by Yale University: Chekroud, A. M., Gueorguieva,
R., & Krystal, K. H. “Treatment Selection for Major Depressive Disorder” (filing date June 3, 2016, USPTO
docket number Y0087.70116US00). The authors report no other financial relationships with commer-
cial interests."
Notes New for 2020 update.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Uncontrolled cohort study
Allocation concealment
(selection bias)




Unclear risk Follow-up: 31/50 at week 8
Selective reporting (re-
porting bias)





Methods Design: Single-group within-subject design
Recruitment: Participants from a military hospital in South Africa
Setting: South Africa
Study start date/ end date: Not specified
Participants Total N: 15, mean age 38 years, smoked 20 cpd (range 10 - 30), for an average of 17 years (range 5 - 27)
Total N: 13 completed the study (5 women)
Inclusion criteria:
• Adults who smoke daily, of at least 10 cpd
Exclusion criteria:
• History of lung disease
Inclusion based on specific population characteristic: No
Van Staden 2013 
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Motivated to quit: Not specified
E-cigarette use at baseline: Not specified
Interventions EC: Cig-a-like
Participants were asked to use an EC only for 2 weeks (i.e. no cigarettes)
EC: 'Twisp eGo' cartridge 0.8 ml containing 0.0144 mg of nicotine
Outcomes The following measurements were taken at baseline and 2-week follow-up:
• Blood pressure and pulse
• Arterial and venous COHb and blood oxygen saturation
Study funding "We are grateful for the sponsorship of the eGo e-cigarette packs by Twisp and also for the valuable
advice and laboratory assistance given by Col. (Dr) J Lubbe, Chemical Pathologist, 1 Military Hospital,
Pretoria with regard to the measurement of the cotinine levels. We also wish to acknowledge Profes-
sor Martin Veller for his insightful contributions during the preparation of this manuscript and also Dr
Richard van Zyl-Smith for his assistance and review."
Author declarations "The sponsor of the Twisp e-cigarette had no role in the design and conduction; the collection, analysis
and interpretation of the study; or in the preparation, review or approval of the manuscript."
Notes Dropouts (N = 2) were due to illness (headache and fever) and undertaking a military course associated
with high stress and exposure to others smoking, making it difficult to abstain from cigarettes
The paper states that the EC cartridge contained 0.8 ml of solution with 0.0144 mg of nicotine. This
would be an unusually low concentration of nicotine and we have assumed an error in units where mil-
ligrams should have been grams (0.0144 grams of nicotine would make the concentration 18 mg/ml)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Prospective cohort
Allocation concealment
(selection bias)




Low risk 2/15 lost to follow-up
Selective reporting (re-
porting bias)





Methods Design: Randomized parallel-assignment double-blind trial
Setting: USA (2 sites)
Recruitment: Community advertisements
Veldheer 2019 
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Study start date: June 2015; Study end date: June 2018.
Participants Estimated enrolment: 520
Total N: 263 in this analysis (520 planned overall; THIS INCLUDES ONLY THOSE FOLLOWED UP AT 1 AND
3 MONTHS)
N per arm: sub: 72; EC: 191
Inclusion criteria:
• Age 21 - 65
• Smoke > 9 cigarettes per day for at least 1 year
• Smoke regular filtered cigarettes or machine-rolled cigarettes with a filter
• CO measurement > 9 ppm at baseline
• No serious quit attempt in the prior 1 month. This includes use of any FDA-approved smoking cessa-
tion medication (varenicline, bupropion (used specifically as a quitting aid), patch, gum, lozenge, in-
haler, and nasal spray) in the past 1 month as an indication of treatment-seeking
• Not planning to quit in the next 6 months
• Interested in reducing cigarette consumption
• Willing to attend visits weekly and monthly over a 9-month period (not planning to move, not planning
extended vacation, no planned surgeries)
• Read and write in English
• Able to understand and consent
Exclusion criteria:
• Pregnant and/or nursing women
• Unstable or significant medical condition in the past 12 months (recent heart attack or some other
heart conditions, stroke, severe angina including high blood pressure if systolic > 159 or diastolic > 99
observed during screening)
• Immune system disorders, respiratory diseases (exacerbations of asthma or COPD, require oxygen,
require oral prednisone), kidney (dialysis) or liver diseases (cirrhosis), or any medical disorder/med-
ication that may affect participant safety or biomarker data
• Use of any non-cigarette nicotine delivery product (pipe, cigar, dip, chew, snus, hookah, e-cigs, strips,
sticks) in the past 7 days
• Uncontrolled mental illness or substance abuse or inpatient treatment for these in the past 6 months
• History of difficulty providing or unwilling to provide blood samples (fainting, poor veins, anxiety)
• No surgery requiring general anesthesia in the past 6 weeks
• Use of an e-cig for 5 or more days in the past 28 days or any use in the past 7 days
• Use of marijuana or any illicit drug/prescription drugs for non-medical use daily/almost daily, or week-
ly in the past 3 months per NIDA Quick Screen
• Use of hand-rolled, roll-your-own cigarettes
• Known allergy to propylene glycol or vegetable glycerin
• Other member of household is currently participating/participated in the study
58% women; mean age 47; mean cpd 18; mean FTND: Not specified
Motivated to quit: Interested in reducing cigarette intake but not planning to quit in next 6 months
E-cigarette use at baseline: None
Interventions EC: Cig-a-like
For 24 weeks:
1) Cigarette substitute: QuitSmart cigarette substitute - plastic tube looks like a real cigarette, de-
signed to provide the same draw resistance as a smoker's usual cigarette. No drug delivery. 2 cigarette
substitutes and a product manual are provided to participants following randomization and replace-
Veldheer 2019  (Continued)
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ment products are provided throughout the intervention period (24 weeks). At baseline, associated
user manual, research staI explain how to use product. Reduction goal to 50% at weeks 0 and 1, 75% at
weeks 2 and 4, continue reducing onwards from there
2) EC with no nicotine: EGO e-cigarette. Cartomizers containing 0 mg/ml nicotine provided throughout
the intervention period (24 weeks) Associated user manual, research staI explain how to use product.
3) As (2) but 8 mg/ml nicotine
4) As (2) but 36 mg/ml nicotine
Outcomes Months 1, 3, 6, 9; (only 1 and 3 month available at time of extraction)
Cessation: Conventional tobacco product use measured but measures not clear
Adverse events and biomarkers:
• Adverse events
• Lung function
• Blood pressure, pulse
• CO, “exhaled breath condensate biomarkers of oxidative stress, glutathione and 8 Isoprostanes” – in-
cl. carcinogenic nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone [NNK; via its metabolite
NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol) in urine], expired air carbon monoxide (CO),





Study funding This study was funded by the National Institutes of Health (NIH) and the U.S. Food and Drug Adminis-
tration (FDA) under Award Number P50DA036105. The content is solely the responsibility of the authors
and does not necessarily represent the views of the NIH or FDA. The project [publication] was support-
ed by CTSA award No. UL1TR000058 from the National Center for Advancing Translational Sciences. Its
contents are solely the responsibility of the authors and do not necessarily represent official views of
the National Center for Advancing Translational Sciences or the National Institutes of Health.
Author declarations JF has done paid consulting for pharmaceutical companies involved in producing smoking cessation
medications, including GSK, Pfizer, Novartis, J&J, and Cypress Bioscience. TE is a paid consultant in lit-
igation against the tobacco industry and is named on a patent application for a device that measures
the puffing behavior of electronic cigarette users. There are no competing interests to declare for other
authors
Notes Preliminary data from RCT; full results not yet available
EC arms pooled in preliminary data available to us at time of writing
Authors provided outcome data; Study listed as ongoing study Lopez 2016 in the 2016 review update
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “the assignment codes are made from separate randomization lists cre-
ated in advance by the statistician for each site stratum.”
Allocation concealment
(selection bias)
Low risk Quote: “Once a participant has been confirmed eligible for randomization, a
computer procedure will assign the participant to the next condition on the list
automatically.”
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Low risk Not blinded for non-EC arms but given similar level of support/product, so per-
formance bias judged unlikely
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Not blinded for non-EC arms but given similar level of support/product, so dif-




Unclear risk Dataset only includes those followed up at 1 and 3 months, which excludes
140 participants; breakdown by arm not provided
Selective reporting (re-
porting bias)
High risk Results paper just preliminary results with all EC arms collapsed. Protocol and





Methods Design: Uncontrolled experimental study
Recruitment: Dental hospital staI were recruited – not specified how
Setting: Dental hospital, UK
Study start date: April 2015; Study end date: December 2015
Participants Total N: 20 (18 of the 20 attended the reassessment visit)
Inclusion criteria:
• 18 - 65 years old
• Systemically healthy
• Smoked at least 10 cigarettes per day for at least 5 years
• had at least 24 natural teeth (excluding third molars) and had no probing pocket depths over 4 mm
at any site
• did not wish to quit
Exclusion criteria:
• Participants were excluded if they had a systemic condition known to exacerbate or modulate peri-
odontitis (for example, diabetes)
• antibiotics had been taken in the previous 3 months
• anti-inflammatory drugs or other medication likely to affect the periodontal tissues were taken rou-
tinely
• if they were pregnant or a nursing mother
% women, age, cpd and FTND: not specified.
Motivated to quit: enrolled people who smoke who did not intend to quit smoking, but were prepared
to attempt to substitute smoking with the use of e-cigarettes for 2 weeks
E-cigarette use at baseline: not specified
Interventions EC: Refillable
Wadia 2016 
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Participants provided with a blu PROTM e-cigarette kit (Electric Tobacconist®), an extra bottle of blu
PRO Tobacco™ e-Liquid (Electric Tobacconist) and written instructions. The e-Liquid was Classic To-
bacco-flavoured and contained 18 mg of nicotine (medium strength). The participants agreed to sub-
stitute their regular smoking habits with the use of e-cigarettes for 2 weeks. They were asked to make a
note of any cigarette smoking during the 2 weeks if complete abstinence was unsuccessful
Outcomes 2 weeks




Study funding Not specified
Author declarations Not specified
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk No randomization
Allocation concealment
(selection bias)




Low risk 2 lost to follow-up
Selective reporting (re-
porting bias)





Methods Design: RCT (short-term, Cravo 2016) followed by cohort study (Walele 2018) in which all participants
were given nicotine EC
Recruitment: Community
Setting: 2 centres in the UK (Covance Clinical Research Unit Ltd, Leeds and Simbec Research Ltd, Wales)
Study start date: December 2013; Study end date: December 2016
Participants 420 participants
Inclusion criteria differ per study phase:
Cravo 2016 (short-term RCT):
• 21 - 65 years of age
Walele 2018 
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• BMI 18 - 35 kg/m2
• 5 - 30 cigarettes per day for at least 1 year (self-reported)
• in good health (determined by medical history, a physical examination, a 12-lead ECG, lung function
tests and clinical laboratory evaluations)
• Established people who smoke (urinary cotinine ≥ 3 and exhaled CO ≥ 6 ppm)
Additional criteria for Walele 2018 (participants from Cravo 2016):
• Participants assessed by PI as being compliant in Cravo 2016 (e.g. having attended outpatient visits
and having been compliant with study procedures)
• Participants had to be willing to use the study product as the only nicotine-containing product for the
duration of the study, and, as deemed by PI, had to have no clinically significant abnormalities in 12-
lead electrocardiogram, vital signs, spirometry and clinical laboratory assessments in the preceding
study
• In addition, participants who were assigned to the conventional cigarette (CC arm) in Cravo 2016 had
to be established people who smoke CCs, which was assessed by urinary cotinine levels (a score of
3 and above on a NicAlert™ test strip was considered positive), eCO levels (a readout > 6 ppm was
considered positive) and by review of a smoking history questionnaire
Exclusion criteria:
Cravo 2016:
• Use of NRT, snuI or chewing tobacco in 14 days previous, or intended to use during study
• Trying to stop smoking or considering quitting
• Clinically-significant illness or disorder, history of drug or alcohol abuse within 2 years prior to study
start
• Woman of “childbearing potential” unwilling to use “acceptable contraceptive measure” during study
Walele 2018 (participants from Cravo 2016):
• People who had taken or received any form of NRT, snuI or chewing tobacco during the previous study
or intended to use it during this study, were excluded
• People with relevant illness history
• People with history of drug or alcohol abuse
• People with lung function test or vital signs considered unsuitable
• People who are trying to stop smoking
• Women who are pregnant, or unwilling to use acceptable contraceptive method for the duration of
the study
Cravo 2016
Total N: 419 randomized, 408 analyzed (excludes 11 who were excluded prior to any product use)
N per arm: EVP: 306; Control: 102
45% women; mean age 34.6; Mean cpd: most 11 - 20 cpd (56% int, 62% control); Mean FTND: most mod-
erate (57% int, 54% cont)
Motivated to quit: No
E-cigarette use at baseline: Not excluded based on prior EC use
Walele 2018
Total N: 209 (147 pre-EVP group; 62 pre-CC group)
45% women; mean age 36.6; mean cpd 2.6 (data from figure): Not reported; FTND: Not reported
Motivated to quit: As reported for Cravo 2016
Walele 2018  (Continued)
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E-cigarette use at baseline: Not reported
Interventions EC: Cig-a-like
Cravo 2016
EC: EVP prototype (2.0% nicotine), developed by Fontem Ventures B.V. (Amsterdam, the Netherlands).
Instructed to only use EVP for study period. It consisted of a rechargeable battery (voltage range of
3.0e4.2 V), an atomiser and a capsule (small cartridge) containing e-liquid. The capsules were replace-
able and the battery and atomiser were reusable. Could choose between two different e-liquids, which
differed solely in their flavor: a menthol-flavored e-liquid with 2.0% nicotine (2.7 mg nicotine/capsule)
and a tobacco-flavored e-liquid with 2.0% nicotine (2.7 mg nicotine/capsule)
Control: Used their own usual conventional cigarette brand
Walele 2018
E-cigarette details: Commercially available Puritane™ (closed system EVP) consists of a lithium-ion
rechargeable battery and a replaceable cartomiser comprising of an e-liquid reservoir pre-filled by the
manufacturer, a heating element and a mouthpiece; 1.6% nicotine (16 mg/g) Available in tobacco or
menthol. 2 weeks before baseline, participants had a familiarization session with Puritane™, where
they could see and try the EVP
Outcomes Cravo 2016: Weeks 1, 2, 4, 6, 8, 10 and 12
Walele 2018: starting on the last day of the previous trial): Months 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24
Study centre visits for assessments
Adverse events and biomarkers:
• “adverse events” (coded using Medical Dictionary for Regulatory Activities version 16.1, 2013, collect-
ed via diary cards and questionnaires)
• vital signs (systolic and diastolic blood pressure, pulse rate and oral temperature)
• lung function (FEV, FEF, PEF, FEV)
• urine biomarkers (nicotine equivalents (NEQs: nicotine, cotinine, nicotine-N-glucuronide, coti-
nine-Nglucuronide, trans 3’-hydroxycotinine and trans 3’-hydroxycotinine glucuronide); S-PMA; 3-HP-
MA; PG; total NNAL (NNAL þ NNAL-glucuronide)); exhaled CO
• blood COHb
Other outcomes measured:
• Number of conventional cigarettes smoked
• EVP capsules used
• ECG (categorized them as normal, abnormal-not clinically significant (NCS) or abnormal-clinically sig-
nificant (CS))
• MWS-R (revised Minnesota Nicotine Withdrawal Scale)
• QSUBrief (Brief Questionnaire of Smoking Urges) questionnaires
• clinical chemistry (blood levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT),
alkaline phosphatase, gamma-glutamyl transferase (GGT), sodium, potassium, chloride, calcium, in-
organic phosphate, glucose, urea nitrogen (BUN), total bilirubin, creatinine, total protein, albumin,
cholesterol (HDL, LDL, and total));clinical haematology (white blood cell count (WBC), red blood cell
count (RBC), hemoglobin, hematocrit (PCV), mean cell volume (MCV), mean cell hemoglobin (MCH),
mean cell hemoglobin concentration (MCHC), platelet count, differential WBC);urinalysis (pH, protein,
glucose, ketones, urobilinogen, blood and specific gravity)
Study funding Cravo 2016
"This work was funded and supported by Fontem Ventures B.V. Imperial Brands plc is the parent com-
pany of Fontem Ventures B.V. the
Walele 2018  (Continued)
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manufacturer of the EVP prototype used in this study"
Walele 2018
"This work was funded and supported by Fontem Ventures B.V. Imperial Brands Group plc is the parent
company of Fontem Ventures B.V., the
manufacturer of the EVP used in this study"
Author declarations Cravo 2016
"Dr. Cravo has nothing to disclose. Mrs Martin reports personal fees from Fontem Ventures B.V. during
the conduct of the study; personal fees from Tobacco and pharmaceutical industries outside the sub-
mitted work. Dr. Sharma reports other from Fontem Ventures B.V. during the conduct of the study. Dr.
Bush reports other from Fontem Ventures B.V. during the conduct of the study. Mrs Savioz reports per-
sonal fees from Fontem Ventures B.V. during the conduct of the study; personal fees from Tobacco and
pharmaceutical industries outside the submitted work. Mr Craige has nothing to disclose. Mr Walele
has nothing to disclose."
Walele 2018 (copied from Transparency documents)
"Dr. Koch reports other from Fontem Ventures B.V., during the conduct of the study; Dr. Martin reports
personal fees from Fontem Ventures B.V., during the conduct of the study; personal fees from Tobacco
and pharmaceutical industries, outside the submitted work; Dr. O'Connell has nothing to disclose. Dr.
Bush reports other from Fontem Ventures B.V., during the conduct of the study; Dr. Savioz reports per-
sonal fees from Fontem Ventures B.V., during the conduct of the study; personal fees from Tobacco and
pharmaceutical industries, outside the submitted work; Dr. Walele has nothing to disclose."
Notes Sponsor: Imperial Tobacco Group PLC
Study listed as ongoing studies NCT02029196 and NCT02143310 in 2016 review update. Treated as sin-
gle study in this review due to including
the same participants, and no time lag between studies
"The same subjects who participated in our previous clinical trial (ClinicalTrials.gov, #NCT02029196)
conducted in the same centres, with another EVP (Cravo et al., 2016), were invited to participate the
study by Walele 2018. All volunteering subjects were assigned to switch to using Puritane™, a closed
system EVP, for two years, starting on the last day of the previous trial (End of Study [EoS] visit), which
corresponded to the baseline visit of Walele 2018."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “Randomisation was performed using an Interactive Web Response
System (IWRS; Almac Clinical Technologies)”
Allocation concealment
(selection bias)
Low risk Quote: "Randomisation was performed using an Interactive Web Response





High risk Open-label, no blinding, differential levels of support/product use so perfor-
mance bias cannot be ruled out
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Open-label, no blinding, with differential levels of support/product use and
subjective outcomes
Walele 2018  (Continued)
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Low risk Cravo: 286/306 int (4.5% ltfp) and 101/102 (1% ltfp) control completed study
but all who received product included in analysis. In EVP group, 14 withdrew
consent, 2 experienced AEs, 1 death, 3 “other”. CC group 1 AE
Walele 2018: High
209/387 enrolled for study Walele 2018. A total of 102 participants (48.8%; EVP:
75/145 (51%); CC: 27/61 (43.5%) completed the study
Selective reporting (re-
porting bias)
Low risk Cravo 2016: Low
All anticipated outcomes reported (study registered prior to study completion)
Walele 2018: Low






Recruitment: National media advertising
Setting: Community based, New Zealand
Study start date: Recruitment between March 2016; Study end date: Aug 2018
Participants N per arm: Patches-only group: 125; Patches plus nicotine e-cigarette group: 500; Patches plus nico-
tine-free e-cigarette group: 499
Inclusion criteria:
• Eligible if they were living in New Zealand
• 18 years or older
• smoked tobacco (amount not specified)
• Motivated to quit in the next 2 weeks
• Able to provide verbal consent
• Prepared to use any of the trial treatments
• Had access to a telephone
Exclusion criteria:
• Pregnant or breastfeeding women
• Had used an e-cigarette for smoking cessation for more than 1 week anytime in the past year
• Currently using smoking cessation medication
• Enrolled in another cessation program or study
• Self-reported a history of severe allergies
• Poorly-controlled asthma
• Cardiovascular event in the 2 weeks before enrolment
• Only 1 participant per household was permitted.
69% women; mean age 41.6; mean cpd 17.3; mean FTND 5.2
Motivated to quit: yes
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E-cigarette use at baseline: Not reported but use of an e-cigarette for smoking cessation for more than
1 week anytime in the past year was an exclusion criterion
Interventions EC: Refillable
Moderate-intensity behavioral support was available for all participants immediately after randomiza-
tion, then once a week for 6 weeks. This support consisted of 10 – 15 mins of withdrawal-oriented be-
havioral support and advice on using their allocated treatment, delivered proactively over the phone
by researchers who had received standardized training in delivery of such support. Assigned to:
1) Nicotine patch for 14 weeks including 2 week prequit. 21 mg, 24-hr nicotine patch (Habitrol)
2) Nicotine patch and nicotine-free EC for 14 weeks. As 1, plus 14-week supply at no cost. A 2nd gener-
ation eVOD (Kangertech, Shenzhen GuangDong, China) starter kit, with a choice of 1 of 2 tobacco e-liq-
uid flavors. Advised to start using the e-cigarette 2 weeks before their quit date, as and when necessary
or desired, and in accordance with the manufacturer’s written instructions, to become familiar with its
use Participants were instructed to stop smoking from their quit date and continue with their allocated
treatment for 12 weeks (ad libitum use of the e-cigarette), irrespective of any lapses to smoking
3) Nicotine patch and nicotine EC for 14 weeks. As above, but 18 mg/mL nicotine
Outcomes Quit date, 1, 3, 6 and 12 months
Continuous abstinence at 6 months with CO validation




• Self-reported treatment adherence
• Tobacco withdrawal symptoms and urge to smoke




• Use of other smoking cessation support or medication
• Continued use of allocated treatment past 14 weeks
• Changes in shortness of breath, cough, asthma, COPD, and mental health problems
• Belief in ability to quit and remain tobacco-free
• Smoking identity and views on their allocated treatment for smoking cessation and whether they
would recommend it to other people who smoke who want to quit
• In people still smoking at each follow-up call, outcomes were number of cigarettes smoked per day
and reduction in smoking
• Participants allocated e-cigarettes were asked about their urge to vape; whether they changed devices
or e-liquid, or both; whether they accessed any e-cigarette support
Study funding Funding: Health Research Council of New Zealand. "The sponsor of the study had no role in the study
design, data collection, data analysis, data interpretation, or writing of the report. The corresponding
author had full access to all the data in the study and had final responsibility for the decision to submit
for publication."
Author declarations NW, CB, MV, GL, ML, and VP report grants from the Health Research Council of New Zealand, during the
conduct of the study. NW, CB, MV, and VP report grants from Pfizer, outside of the submitted work. GL
chairs the organization End Smoking New Zealand, which advocates for harm reduction approach-
es to tobacco control. E-cigarettes were purchased from a New Zealand e-cigarette online retailer
(NZVAPOR, https://www.nzvapor.com/), e-liquid was purchased from Nicopharm, Australia (https://
www.nicopharm.com.au/), and nicotine patches were supplied by the New Zealand Government via
Walker 2020  (Continued)
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their contract with Novartis (Sydney, Australia). NZVAPOR also provided, at no cost to participants, on-
line and phone support regarding use of the e-cigarettes. Neither NZVAPOR nor Nicopharm have links
with the tobacco industry. None of the above parties had any role in the design, conduct, analysis, or
interpretation of the trial findings, or writing of this publication.
Notes Study listed as ongoing study NCT02521662 in the 2016 review update
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomization sequence
Allocation concealment
(selection bias)
Low risk Quote: “We ensured allocation concealment because the statistician who gen-





High risk Quote: “Participants and researchers collecting outcome data were masked to
the nicotine content of the e-liquid” but those allocated to patch only would
be aware they did not have an E-cigarette
Quote: “Third, while we attempted to minimise detection bias by masking the
nicotine content of the e-liquid, we were only 30% successful, and thus some
bias in favour of nicotine e-cigarettes could have occurred.”
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk < 50% lost to follow-up, similar rates of attrition between groups (within 20%)
Selective reporting (re-
porting bias)
Unclear risk CO-verified abstinence at 12 months stated as a secondary outcome but data
are not reported in the main text. However, state in the appendix that too few
people in each group were followed up to 12 months (36/1124) so no data are





Methods Design: Cross-over study
Recruitment: Participants were recruited from people living with HIV/AIDS (PLWHA) (who smoked)
seeking care at the Penn State Health HIV Comprehensive Care Program
Setting: USA
Study start date:Not reported
Participants Total N: 17; 41.2% female; mean age 49.1 (SD 8.8); mean cpd 16.9 (SD 7.9); mean CO 22.4 (13.1)
E-cigarettes use at baseline: not reported
Motivated to quit: No
Inclusion criteria:
Yingst 2020 
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• adult (age ≥ 18)
• smokers (≥ 10 cigarettes daily)
• not planning to quit smoking
• documented history of a positive HIV status
Exclusion criteria: not reported
Interventions EC: Cig-a-like; Refillable
Cig-a-like device (Blu), nicotine concentration 24 mg/ml. Propylene glycol/ vegetable glycerin ratio
70/30. Nicotine delivery 4.56 ng/ml after 20 puIs in 10 minutes
Button-operated device (eGO), nicotine concentration 36 mg/ml. Propylene glycol/ vegetable glycerin
ratio 70/30. Nicotine delivery 6.9 ng/ml after 10 puIs in 5 minutes (refillable)
Outcomes Visits: baseline, day 7, day 14, day 21
CO measured (day 0, 7, 14, 21); adverse events (nausea, dizziness)
Also: Number of tobacco cigarettes smoked per day (self-report); EC puIs per day (self-report)
Study funding This study was supported by the National Institute on Drug Abuse of the National Institutes of Health
under Award Number P50DA036107 and the Center for Tobacco Products of the U.S. Food and Drug Ad-
ministration. JY is also funded by the Penn State Cancer Institute (PSCI) and TE is also supported by
U54DA036105. The content is solely the responsibility of the authors and does not necessarily repre-
sent the official views of the National Institutes of Health or the Food and Drug Administration
Author declarations JF has done paid consulting for pharmaceutical companies involved in producing smoking cessation
medications, including GSK, Pfizer, Novartis, J&J, and Cypress Bioscience. TE is a paid consultant in lit-
igation against the tobacco industry and the electronic cigarette industry and is named on a patent ap-
plication for a device that measures the puffing behavior of electronic cigarette users
Notes New for 2021 update
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Used 2 ENDS in a random order – not enough information
Allocation concealment
(selection bias)





Low risk Unable to blind, but interventions judged equally intensive
Blinding of outcome as-
sessment (detection bias)
All outcomes




Low risk No loss to follow-up
Selective reporting (re-
porting bias)
Unclear risk Unclear what outcomes were prespecified
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AE: adverse event; BMI: body mass index; CO: carbon monoxide; COT: cotinine; cpd: cigarettes per day; EC: electronic cigarette; ENDS:
electronic nicotine delivery system; FTND: Fagerström Test for Nicotine Dependence; HRQoL: health-related quality of life; IQR: interquartile
range; ITT: intention-to-treat; LTFU: lost to follow-up; MMT: methadone maintenance treatment; NEC: nicotine electronic cigarette; NRT:
nicotine replacement therapy; PEC: placebo electronic cigarette; PP(A): point prevalence (abstinence); ppm: parts per million; SAE: serious
adverse event; SD: standard deviation; SMI: serious mental illness; TQD: target quit date; UC: usual care
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Adkison 2013 Although this study uses a prospective cohort design, no data on EC use were collected at baseline,
with EC use data only being available at follow-up
Al-Delaimy 2015 Observational study with no intervention provided - included in previous versions, but excluded
from 2020
Anonymous 2019 Commentary of included study (not primary study)
Battista 2013 Short-term EC use only
Bianco 2019 Ineligible intervention
Biener 2015 Cohort study, but EC use evaluated retrospectively only
Biondi-Zoccai 2019 Less than 1 week follow-up
Biondi-Zoccai 2020 Acute EC use only
Borderud 2014 Observational study with no EC intervention provided - included in previous versions, but excluded
from 2020
Brose 2015 Observational study with no EC intervention provided - included in previous versions, but excluded
from 2020
Brown 2014a Cross-sectional survey
Bullen 2010 Short-term EC use only
Bullen 2018 Withdrawn trial registry
Caponnetto 2019 Ineligible intervention
Cavarretta 2019 Less than 1 week follow-up
Chaumont 2018 Less than 1 week follow-up
Chaumont 2019 Ineligible intervention
Chausse 2015 Ineligible study design
Choi 2014 Observational study with no EC intervention provided - included in previous versions, but excluded
from 2020
Chorti 2012 Short-term EC use only
Collins 2019 Ineligible intervention
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Study Reason for exclusion
Cook 2019 Commentary of included study (not primary study)
Cox 2019a Short-term abstinence only (< 6 months)
Czogala 2012 Short-term EC use only
D'Ruiz 2017 Less than 1 week follow-up
Dawkins 2012 Short-term EC use only
Dawkins 2013a Short-term EC use only
Dawkins 2014 Short-term EC use only
Douptcheva 2013 Longitudinal study, but no data are reported for smoking cessation or reduction or for adverse
events
Dutra 2014 Cross-sectional survey
Eissenberg 2010 Short-term EC use only
Etter 2014 Observational study with no EC intervention provided - included in previous versions, but excluded
from 2020
Farsalinos 2012 Short-term EC use only
Farsalinos 2013a Included people that had already stopped smoking conventional cigarettes
Farsalinos 2013b Short-term EC use only
Farsalinos 2013c Short-term EC use only
Farsalinos 2013d Short-term EC use only
Flouris 2012 Short-term EC use only
Flouris 2013 Short-term EC use only
Gmel 2016 Cohort study, but EC use only evaluated retrospectively
Gottlieb 2019 Commentary of included study (not primary study)
Grana 2014b Observational study with no EC intervention provided - included in previous versions, but excluded
from 2020
James 2016 Follow-up at 12 weeks, AE data not collected
Kasza 2013 Longitudinal study, but no data are reported for smoking cessation or reduction or for adverse
events
Kouretas 2012 Short-term EC use only
Kousta 2019 Commentary of included study (not primary study)
Lechner 2015 Less than 1 week follow-up
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Study Reason for exclusion
Lee 2014 Cross-sectional survey
Manzoli 2015 Observational study with no EC intervention provided - included in previous versions, but excluded
from 2020
Marini 2014 Short-term EC use only
Mayor 2019 Commentary of included study (not primary study)
Meltzer 2017 Ineligible intervention
Miura 2015 Tests a device which is not an EC
NCT02487953 Withdrawn trial registry
NCT03036644 Less than 1 week follow-up
NCT03575468 Ineligible intervention
NCT04107779 Less than 1 week follow-up
Nolan 2016 Short-term abstinence only (< 6 months)
NTR6224 Study terminated early, no usable results. Previously listed as ongoing
Palamidas 2014 Short-term EC use only
Pearson 2012 Longitudinal study, but no data are reported for smoking cessation or reduction or for adverse
events
Pokhrel 2013 Cross-sectional survey
Polosa 2014a Observational study with no EC intervention provided - included in previous versions, but excluded
from 2020
Popova 2013 Cross-sectional survey
Prochaska 2014 RCT but no EC intervention provided - included in previous versions, but excluded from 2020
Russo 2018 Ineligible study design
Schober 2014 Short-term EC use only
Siegel 2011 Retrospective survey of 222 EC users that responded to a survey sent to 5000 new users of the 'Blu'
EC. Likely to be a self-selected sample
Song 2020 Ineligible patient population
St.Helen 2020 Wrong intervention
Stein 2019 Commentary of included study (not primary study)
Stower 2019 Ineligible study design
Tsikrika 2014 Short-term EC use only
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Study Reason for exclusion
Tucker 2018 Short-term abstinence only (< 6 months)
Tzatzarakis 2013 Short-term EC use only
Vakali 2014 Short-term EC use only
Valentine 2016 Less than 1 week follow-up
Van Heel 2017 Ineligible study design
Vansickel 2010 Short-term EC use only
Vansickel 2012 Short-term EC use only
Vansickel 2013 Short-term EC use only
Vardavas 2012 Short-term EC use only
Vickerman 2013 Cross-sectional survey
Voos 2019 Less than 1 week follow-up
Voos 2020 Ineligible study design
Wagener 2014 EC use for up to 1 week, but does not report on any adverse events
Walele 2016a RCT but follow-up too short
Walele 2016b RCT but follow-up too short
Yan 2015 Ineligible study design
Yuki 2017 Less than 1 week follow-up
Zhang 2019 Commentary of included study (not primary study)
EC: electronic cigarette
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name Vaporised nicotine products versus oral forms of nicotine replacement therapy (NRT) products for
tobacco smoking cessation among
low-socioeconomic status (low-SES) people who smoke
Methods Parallel, single-blinded, randomized controlled trial
Setting: Australia
Recruitment: Not stated.
Participants Target sample size: 868
Inclusion criteria:
ACTRN12617001324303 
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• At least 18 years of age
• Current daily smoker
• Motivated and willing to make a quit attempt using medications (NRT/VNP)
• Speak English
• Able to provide verbal informed consent
• Receipt of government pension or allowance (proxy for low-SES)
• Have a phone we contact them on;
• Willing to complete 2 telephone check-in calls and baseline and follow-up telephone interviews
The term “current smoker” in this trial will refer to those who use either factory-made or roll-own
cigarettes.
Exclusion criteria:
• Women who are pregnant, breastfeeding or planning to become pregnant in the next 12 months
• Current users of smoking cessation medications (i.e. NRT, bupropion [Zyban], clonidine, nortripty-
line, electronic nicotine cigarettes )
• Those who are participating in another smoking cessation program or study
People will also be excluded if they report any of the following medical conditions in the previous 3
months: serious chronic lung diseases, arrhythmia, heart attack, stroke, or severe angina
Interventions Vaporised nicotine product (VNP) arm:
• Innokin Endura T18 Personal Vaporizer
• e-liquid nicotine (18mg/ml nicotine) for 8 weeks
• Quitline behavioral support
• 3 flavors will be offered: tobacco, strawberry, menthol
• Permitted to use the study product ad libitum throughout the day and encouraged to stop smok-
ing completely, or reduce smoking if unable to stop completely
• Participants will be provided with detailed instructions on how to use the e-cigarette device ef-
fectively
Oral nicotine replacement therapy (NRT) arm:
• 2 mg or 4 mg nicotine gum/lozenge for 8 weeks
• Quitline behavioral support
• Those receiving the lozenge will be instructed to use 9 - 15 lozenges per day, approximately 1 every
2 hours or when they have an urge to smoke
• Those receiving the gum will be instructed to use 10 to 20 pieces per day for the 2 mg gum and 4
to 10 pieces per day for the 4 mg gum, approximately 1 every 2 hours or when they have an urge
to smoke
• Participants will be provided with detailed instructions on how to use the NRT effectively and
encouraged to stop smoking completely, or reduce smoking if unable to stop completely
Outcomes Primary outcome: Carbon monoxide-verified six-month continuous abstinence (smoking not more
than 5 cigarettes) from the quit date (8 months from baseline)
Secondary outcomes measured at 2-week and 6-week check-in calls and 8-month follow-up
• Self-reported 7-day point prevalence abstinence
• Self-reported continuous abstinence: defined as self-report of smoking not more than 5 cigarettes
from the designated quit date
• Self-reported number of cpd among people continuing to smoke
• Self-reported 30-day PPA at each follow-up (self-report of having smoked no cigarettes (not even
a puI))
• Mean reduction in number of cigarettes smoked per day based on participant self-report
ACTRN12617001324303  (Continued)
Electronic cigarettes for smoking cessation (Review)









Cochrane Database of Systematic Reviews
• Proportion of participants that achieved a 50% reduction of baseline cigarette consumption
based on participant self-report (8 months only)
• Self-reported continued use of nicotine products to assess maintenance use and dual use (8
months only)
Weekly text message surveys and check-in calls 2 weeks and 6 weeks into the treatment period.
These check-in calls will also assess smoking status, short-term outcomes, and adverse events at
these time points
Starting date Anticipated start date: 30 April 2019






Study name A pragmatic randomized partial cross-over clinical trial of nicotine vaporizers added to standard
care for smoking cessation and relapse prevention (CARP) among priority populations with comor-
bidities
Methods Randomized controlled trial
Setting: Australia
Recruitment: Not stated
Participants Target sample size: 810
Inclusion criteria:
• Diagnosed with or receiving treatment for a priority health conditions in the past 12 months
• Aged 18+ years
• Currently smoke 10+ cigarettes per day
• Has capacity to consent, able to understand participant materials and follow study instructions
and comply with study procedures (e.g. sufficient English language ability, able to operate the
vaporiser device)
• Willing to make a quit attempt at baseline according to randomized condition (Condition A to
make quit attempt with nicotine vaporizer; Condition B to make quit attempt without nicotine
vaporizer)
• Has a referral to Quitline counseling and smoking cessation support program (standard care) but
has not begun quit attempt (Note: Quitline referral can occur at time of study enrolment)
Exclusion criteria:
• Already begun quit attempt (i.e. post-quit day) at time of enrolment into trial or currently enrolled
in another smoking cessation clinical trial or using varenicline or bupropion or used a nicotine
vaporizer product in the last 30 days. NOTE: Use of nicotine replacement products not supplied
in the trial (e.g. as part of quitline support) is not an exclusion criterion
• Currently pregnant or breast-feeding or an intention to be during trial participation period;
* A urinary pregnancy test will be required where pregnancy is suspected
* Participants will be advised appropriate contraception should be used to avoid pregnancy dur-
ing the trial with ongoing contraception options discussed
• Has experienced cardiac-related chest pain, or another cardiovascular event or procedure in the
last month, such as heart attack, stroke, insertion of stent, bypass surgery
ACTRN12618000408280 
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• Hospitalized for a mental health condition in the last 30 days
• Currently being treated with oxygen therapy
• Diagnosed terminal illness (such as cancer) or debilitating condition that will limit ability to fully
participate as determined by preregistration responses from participant or opinion of enrolling
clinician
Interventions • Arm 1) Referral to Quitline telephone smoking cessation counseling + Nicotine patches (15
mg/16-hr) delivered at baseline + refillable nicotine vaporizer device (2 x kits) + nicotine vapor-
ising liquid (in high and low strength - high strength: nicotine 1.8% in Vegetable Glycerine and pu-
rified water; low strength: nicotine 0.6% in Vegetable Glycerine and purified water). 1 patch to be
applied daily to skin for up to 84 days. The vaporizer with nicotine liquid is to be used as needed
up to 3.5 mL per day to treat withdrawal symptoms for up to 2 years (concurrently with patches for
the first 84 days) to assist smoking cessation and relapse prevention. Participants start on high-
strength nicotine liquid and may decrease their dose to low strength to assist with dose reduction
prior to stopping use of the vaporizer.
• Arm 2) Referral to Quitline telephone smoking cessation counseling + Nicotine patches (15
mg/16-hr) + participant’s choice of either nicotine gum or nicotine lozenges (up to 800 x 4 mg
pieces to be used up to 8 per day) delivered at baseline. Between 6 - 9 months post-baseline -
participants in Arm 2 who are smoking (either failed to quit or relapsed) will be offered: refillable
nicotine vaporizer (2 x kits) + nicotine vaporizing liquid (in high and low strength - high strength:
nicotine 1.8% in Vegetable Glycerine and purified water; low strength: nicotine 0.6% in Vegetable
Glycerine and purified water) to make a second quit attempt. Participants start on high-strength
nicotine liquid and may decrease their dose to low strength to assist with dose reduction prior
to stopping use of the vaporizer at the discretion of the participant. Participants will have until 2
years from baseline to use the vaporizer for smoking cessation and relapse prevention
Outcomes Primary outcomes:
• Continuous abstinence from smoking from weeks 12 to 26 assessed at 26 weeks from baseline by
self-report. Participants that self-report abstinence from smoking will be asked for a urine speci-
men for bioconfirmation. Urine specimens will be batch-tested for anabasine and cotinine at 6,12
and 21 month time points from baseline
Secondary outcomes:
• Continuous abstinence from smoking from weeks 12 to 52, assessed at week 52 from baseline
• Continuous abstinence from smoking from weeks 12 to 104, assessed by self-report at week 104
from baseline
• Continuous abstinence from smoking from weeks 40 to 52, assessed by self-report at 52 weeks
from baseline
• Continuous abstinence from smoking from weeks 92 to 104, assessed by self-report at 104 weeks
from baseline
• Number of adverse events measured by self-report at 12 weeks and 26 weeks from baseline
Abstinence is assessed through study-specific survey questions in Module CS Combustible Smok-
ing Questions – administered through electronic survey or structured telephone interview. Partici-
pants that self-report abstinence from smoking will be asked for a urine specimen for bioconfirma-
tion. Urine specimens will be batch-tested for anabasine and cotinine at 6,12 and 21 month time
points
Starting date 5 June 2018
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Study name Project NEAT: nicotinE As Treatment for tobacco smoking following discharge from residential
withdrawal services
Methods RCT
Project NEAT: A randomized controlled trial to examine the efficacy of vaporised nicotine products
and telephone quit line support compared with nicotine replacement therapy and telephone quit
line support when used following discharge from a residential withdrawal services
Setting: Australia (New South Wales, Queensland, Victoria)
Recruitment 4 hospitals sites: Belmont Hospital, Belmont; St Vincent's Hospital, Darlinghurst; Turn-
ing Point Drug and Alcohol Centre, Richmond; Royal Brisbane & Womens Hospital, Herston
Participants Target sample size: 926
Inclusion criteria:
• Aged 18 or over
• Daily tobacco smoker (10 or more cigarettes) on entering withdrawal unit
• Accessing treatment from participating services
• Want to quit smoking in the next 30 days
• Has capacity to consent and able to understand the participant materials and follow the study in-
structions and procedure (e.g. sufficient English language ability and not too unwell as judged by
medical staI).
Exclusion criteria:
• Pregnant or breast-feeding
• Enrolled in another study
• Scheduled to be transferred to a long-term residential rehabilitation service following discharge
from the withdrawal unit
• Used VNP (containing nicotine) in the last 30 days
• Currently engaged in Quitline’s call-back services
• No ready access to a phone
Interventions Condition One: Vaporised Nicotine Products and Quitline
Condition Two: Current Best Practice Treatment for Tobacco Smoking (Combination Nicotine Re-
placement Therapy and Quitline)
Outcomes 9 months after inpatient withdrawal unit discharge:
Self-reported 7 months continuous abstinence from tobacco smoking
Biochemically-verified 7-month continuous abstinence from tobacco smoking
3 and 9 months after inpatient withdrawal unit discharge:
30-day point prevalence abstinence
7-day point prevalence abstinence
Abstinence from all nicotine/ tobacco products
Starting date Anticipated enrolment: 19 December 2019. Anticipated date last data collection 19 September 2022
Contact information Prof Billie Bonevski, Billie.Bonevski@newcastle.edu.au
ACTRN12619001787178 
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Study name Examining the effectiveness of general practitioner and nurse promotion of electronic cigarettes
versus standard care for smoking reduction and
abstinence in hardcore smokers with smoking-related chronic disease: protocol for a randomized
controlled trial
Methods Individually randomized, blinded, 2-arm trial
Setting: General practices, England
Recruitment: Primary care registries
Participants Target sample: 320 (160 per arm)
Inclusion criteria:
• Participant is willing and able to give informed consent for participation in the study
• Aged 18 years or above
• Current smoker with a value of at least 10 ppm for exhaled CO and smokes a minimum of 8 ciga-
rettes/8 g of tobacco per day (including pipe, cigars or tobacco roll-ups)
• Diagnosed with 1 or more of the following chronic conditions: ischaemic heart disease, peripher-
al vascular disease, hypertension, diabetes mellitus (type 1 and type 2), stroke, asthma, COPD,
chronic kidney disease, depression, schizophrenia, bipolar disorder or other psychoses
Exclusion criteria:
• GP believes that switching to e-cigarettes would not benefit the patient given their current med-
ical condition
• Currently using e-cigarettes, nicotine replacement therapy or other cessation therapies (e.g.
bupropion, nortriptyline or varenicline)
• Plans to stop smoking before or at the annual review
• Currently enrolled in another smoking-related study or other study where the aims of the studies
are incompatible
• Cannot consent due to mental incapacity
• Pregnant, breastfeeding or planning to become pregnant during the course of the study
Interventions • Control: No additional support beyond standard care
• Intervention: will receive GP- or nurse-led brief advice about e-cigarettes, an e-cigarette starter
pack with accompanying practical support booklet, and telephone support from experienced
vapers and online video tutorials
Outcomes Months 2, 8
Primary outcomes:
• 7-day PPA from smoked tobacco at 2 months; Self-reported abstinence from smoking—not even a
puI—in the past 7 days, accompanied by a salivary anabasine concentration of < 1 ng/ml; exhaled
CO as verification of abstinence (CO < 10 ppm) used, as necessary.
Secondary outcomes:
• Smoking reduction
• 7-day PPA and prolonged abstinence at 8 months;
Begh 2019 
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• Participant recruitment and follow-up,
• Participant uptake and use of e-cigarettes,
• Nicotine intake,
• Contamination of randomization and practitioner adherence to the delivery of the intervention
Starting date November 2016





Study name Randomized, placebo-controlled, double-blind, double-dummy, multicentre trial comparing elec-
tronic cigarettes with nicotine to varenicline and to electronic cigarettes without nicotine: the
ECSMOKE trial protocol
Methods 3-arm randomized, placebo-controlled, multicentre, double-blind, double-dummy, parallel
groups, phase III type trial
Setting: Smoking cessation clinics of both academic and community hospitals
Recruitment is either local (a) directly by the centres or centralized (b) using a web page and a cen-
tralized study-specific phone number and email address
• People who smoke intending to quit smoking are recruited by advertisement in pharmacies,
physicians’ offices situated in the catchment area of each investigator’s centre, by local newspa-
pers and in public places of the centres’ healthcare facilities
• Candidates to participate can register by the study’s website, unique email address and phone
number. Registration is followed by a phone screening before dispatching to the study centres.
Only 1 person by household will be recruited
Participants Estimated enrolment: 650 participants
Inclusion criteria:
• People who smoke, at least 10 cpd (factory-made or roll-your-own) in the past year
• Aged 18 – 70 years
• Motivated to quit, defined as a score > 5 on a visual rating scale ranging from 0 (not motivated at
all) to 10 (extremely motivated)
• Signed written informed consent
• Understanding and speaking French
• Women of childbearing age can be included if they use an effective contraceptive method: either
hormonal contraception or an intrauterine device started at least 1month before the first research
visit
• Individual affiliated to a health insurance system
• Previous failure of NRT for smoking cessation
Exclusion criteria:
• Any unstable disease condition within the last 3 months defined by the investigator as major
change in symptoms or treatments, such as recent myocardial infarction, unstable or worsening
angina, severe cardiac arrhythmia, unstable or uncontrolled arterial hypertension, recent stroke,
cerebrovascular disease, obliterative peripheral arterial disease, cardiac insufficiency, diabetes,
hyperthyroidism, pheochromocytoma, severe hepatic insufficiency, history of seizures, severe de-
pression, COPD
• Any life-threatening condition with life expectancy of < 3 months
Berlin 2019 
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• Alcohol use disorder defined as a score ≥ 10 on the Alcohol Use Disorders Identification Test (AU-
DIT)-C questionnaire (see below)
• Abuse of or dependence on illegal drugs in the last 6 months, revealed by medical history
• Regular use of tobacco products other than cigarettes




• Current or past 3 months participation in another interventional research
• Current or past 3 months use of smoking cessation medication such as varenicline, bupropion,
NRTs
• Known lactose intolerance (placebo tablets contain lactose)
• Hypersensitivity to the active substance or to any of the excipients
• Known severe renal failure
Interventions A) EC without nicotine (ECwoN) plus placebo tablets of varenicline (0.50mg) administered by oral
route: placebo condition;
B) EC with nicotine (ECwN) plus placebo tablets of varenicline: ECwN condition. V
C) Reference: ECwoN plus 0.5 mg varenicline tablets: varenicline condition. Varenicline adminis-
tered according to the marketing authorization
E-cigarette details:
• EC device Mini iStick kit (20 W) Eleaf, clearomiser: GS Air M with resistance of 1.5 ohm. To keep
the blinding, the clearomizer’s Pyrex window is of grey Colour not allowing to distinguish the col-
oration of the e-liquid containing nicotine. Liquid for EC is manufactured by GAIATREND SARL
(www.gaiatrend.fr/fr/)
• All participants will be delivered a short manual and a video specifically developed for this study
explaining the use of EC. At each visit, participants receive verbal counseling about the use of the
EC device and answers to their questions about handling the EC device
Behavioural support:
• Brief behavioral smoking cessation counseling for all participants is administered at all visits by
the investigators specialized in smoking cessation. It is based on the national guidelines for smok-
ing cessation
Treatment duration: 1 week + 3 months
Outcomes Week 2, 4, 8, 10, 12, 24 after target quit day
Primary outcome:
• Continuous smoking abstinence rate (CAR) (abstinence from conventional/combustible ciga-




• CAR confirmed by urinary anabasine concentration
• Changes in cpd consumption
• Craving for tobacco and withdrawal symptoms with respect to baseline
Starting date 17 October 2018
Contact information Ivan Berlin, ivan.berlin@aphp.fr
Berlin 2019  (Continued)
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Study name Smoking cessation and reduction In schizophrenia (the SCARIS study)
Methods 3-arm prospective 12-m randomized controlled trial investigating efficacy and safety of EC
Setting: psychiatric and smoking cessation centres, Italy
Recruitment: local newspapers and radio/television advertisements
Participants 153 participants
Inclusion criteria
• Schizophrenic in stable phase of illness
• Smoked at least 10 cpd over previous 5 years
• Aged 18 - 65
• In good general health
• Not currently attempting to quit smoke or wishing to do so in next 6m
Exclusion criteria
• Use smokeless tobacco or NRT
• Pregnant or breastfeeding
• Current or recent (1 yr) history of drug or alcohol abuse
• Other significant co-morbidities
Interventions 12-wk supply of:
• EC, high nicotine (24 mg)
• EC, no nicotine (0 mg, with tobacco aroma)
• PAIPO nicotine-free inhalator
Outcomes Follow-up visits at 4, 8, 12, 24 and 52 weeks
Outcome measures:
• Smoking cessation
• Smoking reduction (≥ 50% from baseline)
• Adverse events
• Quality of life
• Neurocognitive functioning
• Participant perceptions and satisfactions with products
Starting date September 2014
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Study name Non-inferiority trial comparing cigarette consumption, adoption rates, acceptability, tolerability,
and tobacco harm reduction potential in smokers switching to Heated Tobacco Products or elec-
tronic cigarettes: Study protocol for a randomized controlled trial
Methods RCT
12 weeks
Participants 220 healthy people who smoke tobacco cigarettes
Interventions Arm 1 - Heated Tobacco Products (HTPs)
Arm 2 - E-cigarettes (ECs)
Outcomes 12-week study. Follow-up 24 weeks
Biochemically-verified self-reported continuous abstinence at 12 weeks from the previous visit
Secondary outcomes will include: smoking reduction from baseline, adoption rates and product
acceptability, tolerability, changes in step test values and in the level of selected biomarkers of ex-
posure in exhaled breath (i.e. eCO) and in spot urine samples
A follow-up visit at 24 weeks to review product usage and smoking behavior under naturalistic con-
dition of use
Starting date Recruitment May 2019, enrolment is expected to be completed in November 2019
Results to be reported in 2020
Contact information Pasquale Caponnetto, p.caponnetto@unict.it
Notes NCT03569748




Study name An open-label randomized pragmatic policy trial examining effectiveness of short-term use of nico-
tine replacement therapy (NRT) vs short- or long-term use of NRT vs short- or long-term use of NRT
or electronic nicotine delivery systems for smoking cessation in cigarette smokers
Methods Phase 3 blinded RCT
Setting: Australia
Recruitment: commercial market research panel
Participants Target sample size: 1600
• Current daily smoking (at least 6 cpd)
• Can read and understand English
• Agree to try samples of nicotine products
• Willing to complete surveys
• 18 years or older
Exclusion criteria:
• If currently treated for serious medical condition,
Fraser 2015 
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• Pregnant or planning to become pregnant or breast-feed in next 12 m
Interventions • a) Factsheet explaining relative harm of NRT compared to smoking, free sample of NRT, partici-
pant chooses preferences, has free for 3 weeks then offered at subsidized rate for further 6 m
• b) As (a), but with additional information provided
• c) As (a), but additional information on electronic cigarettes and emphasis on cessation, and may
select electronic cigarettes as well as NRT
Outcomes 6 m and 12 m, self-report
• Continuous abstinence
• NRT and EC use
• Interest in quitting smoking and in quitting NRT
• Cigarette consumption
• Product orders and use
• Quit attempts
Starting date February 2014





Study name Can electronic cigarettes and nicotine replacement treatment help reduce smoking in smokers
who struggle to quit?
Methods Pilot single-centre randomized control trial
Setting: Queen Mary University of London, UK
Recruitment method not specified.
Participants Target sample size: 200
Inclusion criteria:
• 18 years or older
• Able to provide written informed consent
• History of failed quit attempts using stop-smoking medications or stop smoking services, or both
• Willing to use their allocated harm-reduction strategy for at least 4 weeks
Exclusion criteria:
• Women who are pregnant or breastfeeding
• Unable to read/write/understand English
• Currently using EC or any stop-smoking products
• Taking part in other interventional research
• Have a strong preference to use or not to use NRT or EC
Interventions 1) NRT arm:
• Will be shown and explained the NRT products available and encouraged to choose a product or
product combination that suits their needs
ISRCTN13288677 
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• Will receive a letter of recommendation as per standard practice and collect their chosen products
at local pharmacies
• Product use will be supervised and adjusted (if required) as part of the behavioral support pack-
age. As per local standard practice, NRT will be provided for up to 8 weeks
2) EC arm:
• Will be shown and explained different EC products commonly used and asked to obtain the prod-
uct of their choice, either using a voucher for up to GBP 35 to purchase EC at a local vape shop,
purchase from other suppliers and claim a refund of up to GBP 35 upon providing a valid receipt,
or choose from a limited selection at the smoking cessation clinic
• Will be encouraged to try different products and liquids if the first purchase does not meet their
needs, but after the initial purchase, participants will fund further supplies themselves (this is to
mimic the provision of starter packs, an approach that is most likely to be used by routine services)
Outcomes Participants contacted by phone at 1 week, 4 weeks and 24 weeks after the initial screening session
Primary outcomes:
• Cigarette consumption per day, assessed by self-report in the follow-up survey created for the
purpose of the study at 1, 4 and 24 weeks post-quit date/preparation date. Those who report ≥
50% smoking reduction will be validated with a CO reading in the clinic
Secondary outcomes:
• Use of allocated harm-reduction strategies
• Strategy ratings
• Changes in smoking behavior
• Proportion of people still using allocated strategy at 6 months
Starting date January 2017






Study name Do e-cigarettes help smokers quit when not accompanied by intensive behavioral support? A mul-
ti-center randomized controlled trial
Methods RCT
Setting: UK
Multicenter. Participants will be recruited mainly from hospitals and GP practices across the UK by
the Clinical Research Network. The study is being organized by Queen Mary University of London
(QMUL)
Researchers from QMUL will provide the study treatment and conduct follow-up calls
Participants 1170 people who smoke tobacco cigarettes
Inclusion criteria:
• Adult daily smokers who are motivated to stop smoking
ISRCTN61193406 
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• Must own a mobile phone and be willing to try either an online or texting treatment package, or
both, or an e-cigarette with or without telephone support.
• Be happy to receive follow-up calls
• Be able to read/write/understand English
Exclusion criteria:
• Women who are pregnant
• Currently using an e-cigarette
Interventions 1. Control: NHS Quit Now program (QN)
2. E-cigarette starter pack with no ongoing support (EC)
3. EC starter pack with helpline support (EC+)
The study will aim to use a refillable EC that is similar to the type used in a previous EC trial (One Kit
- Innokin, UK Ecig Store), and one that is compliant with UK regulations, and not produced by a to-
bacco company
Outcomes Follow-up at 4 weeks, 6 months and 12 months. CO at 6 and 12 months
Primary outcome measure:
Sustained smoking cessation at 6 months post-TQD. This is measured by asking participants if they
have smoked since their TQD at the 6-month follow-up. To be counted as a 'quitter', participants
must report smoking no more than 5 cigarettes since 2 weeks post-TQD with no smoking in the pre-
vious week, validated by carbon monoxide (CO) reading of < 8 ppm. Participants lost to follow-up
will be counted as smokers
Secondary outcome measures:
• Validated sustained abstinence rates measured by asking smoking status and taking a car-
bon-monoxide reading at 12 months post-TQD
• Validated sustained abstinence rates between 6 and 12 months, measured by asking smoking
status and taking a carbon-monoxide reading at 6 and 12 months
• Self-reported 7-day point-prevalence abstinence, measured by asking smoking status in last 7
days at 4 weeks, 6 months and 12 months post-TQD
• Cigarette consumption in non-abstainers by vaping status, measured by questionnaire at four
weeks, 6 and 12 months
• Frequency and severity of urges to smoke and withdrawal symptoms, measured by questionnaire
at 4 weeks post-TQD.
• Weight, measured by asking weight at 4 weeks, 6 months and 12 months post-TQD
• Respiratory symptoms, measured by questionnaire, at 4 weeks, 6 months and 12 months post-
TQD
• Treatment adherence and ratings, measured by questionnaire at 4 weeks (and 6 and 12 months
for EC arms)
• Adverse reactions to EC, measured by questionnaire at 4 weeks, 6 and 12 months post-TQD
• Cost-effectiveness of the interventions, measured by questionnaires at baseline, 6 and 12 months
• Smokers' and health-care professionals views and opinions of the helpline, measured by one-oI
qualitative interviews separate to the main trial.
Starting date Overall trial start date: 01 September 2020
Trial end date: 31 May 2024
Not yet recruiting. Last edited 12 August 2020
Contact information Dr Katie Myers Smith, katie.smith@qmul.ac.uk
ISRCTN61193406  (Continued)
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Study name Smokers making a quit attempt using e-cigarettes with or without nicotine or prescription nicotine
replacement therapy: impact on cardiovascular function (ISME-NRT) - a study protocol
Methods Pragmatic, 3-group, randomized, assessor-blinded, single-centre trial
Setting: Centre for Sport and Exercise Science (CSES) of Sheffield Hallam University, UK
Recruitment: From the community in the wider Sheffield area will be by: i) low-cost newspaper and
post-office advertisement, ii) posters in local pharmacies, libraries, mosques, churches, and clubs,
iii) social media or search engine advertisement (Facebook, Google ads) iv) notices in newsletters
or participation in outreach events of community organizations (such as Sheffield U3A and AGE
UK), iv) a study website, and v) out-reach events in local ethnic community centres or places of
worship
Participants Estimated enrolment: 258 participants (86 participants arm)
Inclusion Criteria:
• Age > 18 years of either sex
• People who smoke (at least 10 cpd for the past year)
• Willing (by declaration) to attempt quit smoking by using the NHS services or e-cigarettes
Exclusion Criteria:
• Inability to walk
• Recent (within 6 months) cardiovascular disease event (e.g. stroke, myocardial infarction) or car-
diac surgery
• Insulin-controlled diabetes mellitus or with co-existing skin conditions, leg ulcers, vasculitis or
deep venous occlusion (as these may affect their cardiovascular function)
• Pregnancy
• Requiring major surgery during the course of the study)
• Contra-indications/unsuitability for NRT
• Current daily use of e-cigarettes
• Currently undertaking a cessation attempt supported by a smoking cessation clinic
• Unable to give informed consent
Interventions • a) Complimentary e-cigarette equipment and refills (Tornado V5, Joyetech, Shenzhen, China)
at allocation stage, together with instructions on the correct usage of e-cigarettes. They will also
receive behavioral support for a 3-month period. The nicotine strength of Group A cartridges will
be up to 18 mg/ml nicotine strength
• b) As a), but with nicotine-free liquid
• c) Referral to NHS smoking cessation clinics and will receive NRT in conjunction with behavioral
support
Outcomes Follow-up: Within 3 days of “quit date”, 3 and 6 months past quit date
Outcome measures:
• Macro-vascular function (FMD assessment)
• Micro-vascular function
• Smoking status at 3 and 6 months, self-reported and biochemically validated by exhaled air mea-
surement of < 10 ppm CO
Klonizakis 2017 
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• Change in CVD risk using Q-risk assessment
• Health Economic effects using EQ5D-L
• Total cholesterol and High Density lipoprotein via fingerprick blood sample
• Participant experiences' assessment
Starting date 24 April 2017





Study name Yorkshire Enhanced Stop Smoking (YESS) study: a protocol for a randomized controlled trial to




Participants Anticipated recruitment: 1040 people who smoke tobacco cigarettes
Participants are aged 55 – 80, registered with a general practitioner (GP) in the Leeds Clinical Com-
missioning Group area and registered as a current or ex-smoker in primary care databases
Inclusion criteria:
• Attended an lung health check (LHC) and consent to participate in the Yorkshire Lung Screening
Trial (YLST)
• have smoked within the last month
• have an exhaled carbon monoxide (CO) reading ≥ 6 ppm
• have agreed to see an SCP on the mobile unit
Exclusion criteria:
• Any individual who does not have an LDCT scan
• or is unable to provide informed consent
Interventions Arm 1: enhanced, personalized smoking cessation (SC) support package, including CT scan images.
SC support over 4 weeks comprising behavioral support, pharmacotherapy and/or a commercial-
ly-available e-cigarette
Arm 2: continued standard best practice.
Outcomes Follow-up contact will be requested at 4 weeks, 3 months and 12 months, with a 2-week window to
accommodate participant availability
The primary objective is to measure 7-day point prevalent carbon monoxide (CO)-validated SC af-
ter 3 months
Secondary outcomes include CO-validated cessation at 4 weeks and 12 months, self-reported con-
tinuous cessation at 4 weeks, 3 months and 12 months, attempts to quit smoking and changes in
psychological variables, including perceived risk of lung cancer, motivation to quit smoking tobac-
co, confidence and efficacy beliefs (self and response) at all follow-up points
Starting date January 2019 and December 2020 with follow-up data collection ending December 2021
Murray 2020 
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Study name Spain-UK-Czech E-cigarette Study (SUKCES)
Methods Randomized controlled trial, open-label pilot study
Setting: smoking cessation clinics in London, Madrid and Prague
Recuitment: via smoking cessation clinics
Participants 220 people who smoke, seeking help to quit
Inclusion criteria:
• 18 or older
• Want help to quit
Exclusion criteria:
• Pregnant or breastfeeding;
• Enrolled in other research;
• Currently using EC
Interventions • Standard care plus 4 weeks EC supply
• Standard care only
Outcomes • CO-validated continuous abstinence at 4 and 24 weeks post-TQD
• Withdrawal symptoms at 1 and 4 weeks post-TQD
• EC use
• EC taste and satisfaction compared to conventional cigarettes
• Adverse events
Starting date December 2013





Study name Smoking cessation in women with gynecological conditions
Methods Randomized controlled trial, open-label feasibility study
Setting: hospital clinic, USA
Recruitment: in clinic
Participants 30 women who smoke with cervical dysplasia
NCT01989923 
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Inclusion criteria:
• Women who smoke at least 10 cpd over past year
• Diagnosis of cervical dysplasia, cervical cancer, and lower genital tract dysplasia and cancer
• Aged 18 - 65
Exclusion criteria:
• Previous diagnoses or treatment for cancer (except for non-melanoma skin cancer)
• Stroke, heart disease, heart attack, or irregular heart beat
• Pregnancy and lactation
• Plan to continue to use other nicotine as well as study products
• Uncontrolled hypertension
• Using other stop-smoking medication
• Taking prescription medicine for depression or asthma
Interventions • NRT patch (21 mg for first 3 weeks, 14 mg for 2nd 3 weeks) plus nicotine gum (2 mg) or lozenges
(2 mg) for 6 weeks
• EC device ('Blu' Cig) with refills to last 6 weeks, number provided based on packs smoked a day
x 1.5. Strength of EC reduced at 3 weeks
Both groups receive identical cessation counseling
Outcomes At 6 and 12 weeks via survey:
• Cpd
• PPA at 7 and 30 days
• Smoking cessation
• Participants' attitudes and beliefs towards treatments
• Adherence
Starting date June 2013





Study name Electronic cigarettes or nicotine inhaler for smoking cessation
Methods Randomized controlled trial, open-label safety/efficacy study
Setting and recruitment not specified, USA
Participants 40 participants
Inclusion criteria:
• 18 - 60 years old
• Meet DSM-IV criteria for nicotine dependence
• Seeking treatment for smoking cessation
• smoking at least 15 cpd
Exclusion criteria:
NCT02004171 
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• DSM-IV diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder
• Current diagnosis of major depressive disorder
• Current diagnosis for other psychiatric disorders that may require intervention over course of
study
• Receiving treatment for nicotine dependence
• Pregnancy, lactation, or chance of pregnancy
• Unstable medical condition
• Substance abuse diagnosis
• Use of cannabis or alcohol on more than 20 days in past 30 days
• Suicide risk
Interventions 4 weeks:
• ECs (2nd generation) with 24 mg nicotine cartridges, 1 - 2 cartridges daily
• Nicotine inhaler with 10 mg cartridges, max 16 cartridges per day
Outcomes Over 4 weeks:
• cpd
• Withdrawal
• Benefits from smoking cessation (breathing, sense of taste and smell, physical fitness)
• Adverse events
• BMI
Starting date December 2013





Study name Smoking cessation and reduction in depression (SCARID)
Methods 3-arm prospective 12-m randomized controlled trial investigating efficacy and safety of ECs
Participants 129 participants
Inclusion criteria:
• Diagnosis of major depressive disorder (MDD) (according to DSM-5 criteria)
• Smoke ≥ 10 cpd (for at least the past 5 years)
• age 18 - 65 years
• In good general health
• Unwilling to quit smoking in the next 30 days
Exclusion criteria:
• Use of smokeless tobacco or NRT or other smoking cessation therapies 
• Pregnancy or breastfeeding 
• Current or recent (< 1 yr) past history of alcohol or drug abuse or both 
• Active suicidal intention
NCT02124187 
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• Other significant co-morbidities according to the Investigator's clinical assessment (e.g. cancer,
acute myocardial infarction, unstable angina, severe cardiac arrhythmia, recent cerebrovascular
incident, or severe atherosclerosis)
Interventions 12-wk supply of:
• EC 24 mg nicotine
• EC 0 mg nicotine
• Nicotine-free inhalator
Outcomes Follow-up visits at 4, 8, 12, 24 and 52 weeks
Outcome measures:
• Smoking cessation
• Smoking reduction (≥ 50% from baseline)
• Adverse events
• Quality of life
• Neurocognitive functioning
• Participant perceptions and satisfaction with products
Starting date February 2015





Study name Head-to-head comparison of personal vaporizers versus cig-a-like: prospective 6-month random-
ized control design study (VAPECIG 2)
Methods Randomized parallel-assignment open-label trial
Setting: Italy, community
Participants Estimated enrolment: 200
Inclusion criteria:
• (People who smoke) in good general health
• Committed to follow trial procedures
Exclude if:
• Recent vaping history (stopped vaping < 3 months ago)
• Use of any other form of non-combustible nicotine-containing products (chewable tobacco or
nicotine replacement therapy)
• Symptomatic cardiovascular disease
• Clinical history of asthma and COPD
• Regular psychotropic medication use
• Current or past history of alcohol abuse
• Use of smokeless tobacco or nicotine replacement therapy
• Pregnancy or breastfeeding.
NCT02398487 
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Starting date October 2014





Study name E-cigarettes: dynamic patterns of use and health effects
Methods Prospective observational study
Setting: community, USA
Recruitment: People who smoke and dual EC and cigarette users
Participants Estimated enrolment: 450
Inclusion criteria:
• ≥ 18 years old
• No plans to quit smoking and/or EC use in the next 30 days
• Not currently taking smoking cessation medication
• Not currently in treatment for psychosis or bipolar disorder
• Participants must report either that they have: smoked at least 5 cpd for the past 6 months and
not used EC within the last 3 months ("exclusive smokers") or used nicotine-containing EC at least
once a week for the past month and have smoked at least 5 cpd for the last 3 months ("dual users")
Interventions "We will conduct a 2-year longitudinal cohort study comprising participants who smoke exclusively
CCs (n = 175) and dual users of e-cigs and CCs (n = 275)"
Outcomes "We will use state-of-the-art ecological momentary assessments to determine:
1) dynamic patterns of e-cig and CC use and related outcomes (e.g. dependence, withdrawal symp-
toms, CC quit attempts and quitting success);
2) episodic (affective, contextual, social) and stable person-factor (lifestyle factors, demographics)
variables that covary meaningfully with e-cig and CC use and related outcomes;
3) biomarkers of tobacco and carcinogen exposure as well as other health-related outcomes (e.g.
reduced pulmonary function)."
Starting date September 2015
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Study name The role of nicotine and non-nicotine alkaloids in e-cigarette use and dependence
Methods Randomized parallel-assignment double-blind trial
Setting: Smoking research clinic, USA
Recruitment: volunteers
Participants Estimated enrolment: 375
Inclusion criteria:
• Have no known serious medical conditions
• Are 18 - 65 years old
• Smoke an average of at least 10 cpd
• Have smoked at least 1 cumulative year
• Have an expired air CO reading of at least 10 ppm
• Are able to read and understand English
Exclude if: multiple, related to baseline health status
Interventions • Switch to standard nicotine EC use for 8 weeks
• Switch to ECs with same nicotine but very low non-nicotine alkaloid levels
• Switch to ECs with very low nicotine and non-nicotine alkaloids
Outcomes Primary:
• CO levels at 8 weeks
Secondary:
• EC use
• EC solution use
• cigarette use, at 8 weeks
Starting date May 2016
Contact information Jed Rose
Notes "This is not a smoking cessation study; People who smoke will not be asked to quit smoking, and e-





Study name Changes in lung function parameters, bronchial reactivity, state of health and smoking behavior as-
sociated with changing from conventional
smoking to electronic cigarettes
Methods Prospective observational study
Setting: Community, Germany
Recruitment: Vape shops and smoking cessation clinics
NCT02635620 
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Participants Estimated enrolment: 80
Inclusion criteria:
• Smoking ≥ 5 years
• Smoking ≥ 10 cpd
• No intention to stop smoking within the last 3 months
• Using EC with nicotine
• No infection of airways at the time of measurements
• EC group: intending to use EC
• Control group: smoking cessation in the framework of a clinical conducted program
Exclude if:
• pregnancy or breastfeeding
• not speaking German
• known allergy
• acute psychiatric diseases, suicidal tendency
• drug/substance/alcohol abuse
• severe internal diseases
Interventions Comparison between:
• People who smoke who intend to start EC use for the first time





• Respiratory tract inflammation
Starting date October 2015





Study name The ESTxENDS Trial- Electronic Nicotine Delivery Systems (ENDS/Vaporizer/E-cigarette) as an aid
for smoking cessation. (ESTxENDS)
Methods Randomized, parallel-assignment, open-label trial
Setting: Switzerland
Recruitment: Not specified
Participants Estimated Enrolment: 1172
Inclusion criteria:
• Informed consent as documented by signature
• Persons aged 18 or older
• Currently smoking 5 or more cigarettes a day for at least 12 months
NCT03589989 
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• Willing to try to quit smoking within the next 3 months
• Persons providing a valid phone number, a valid email address and/or a valid postal address.
Exclusion criteria:
• Known hypersensitivity or allergy to contents of the e-liquid
• Participation in another study with investigational drug within the 30 days preceding the baseline
visit and during the present study where interactions are to be expected
• Women who are pregnant or breastfeeding
• Intention to become pregnant during the course of the scheduled study intervention, i.e. within
the first 6 months of the study
• Persons having used ENDS regularly in the 3 months preceding the baseline visit
• Persons having used nicotine replacement therapy (NRT) or other medications with demonstrat-
ed efficacy as an aid for smoking cessation such as varenicline or bupropion within the 3 months
preceding the baseline visit
• Persons who cannot attend the 6-month follow-up visit for any reason
• Cannot understand instructions delivered in person or by phone, or otherwise unable to partici-
pate in study procedures
Interventions • a) ENDS (vaporizer/e-cig) and smoking cessation counseling will receive:
• ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum
• Smoking cessation counseling: provided in person at the first clinical visit and then over the
phone at the target quit date 1 week later and again at weeks 2, 4 and 8 after the target quit
date. After 6 months, participants will be asked to come to a final clinical visit
• Participants will be allowed to additionally use nicotine replacement therapy
• b) Control group will receive smoking cessation counseling only as provided for a). Participants
will be allowed to additionally use nicotine replacement therapy
Outcomes Primary outcome: Continuous smoking abstinence at 6 months post-quit date measured by:
• Self-report of having smoked no cigarettes from quit date, validated by urinary levels of anaba-
sine. If anabasine is missing, validation by exhaled carbon monoxide (CO).
Seconday outcomes:
• Continuous smoking abstinence at 6 months post-quit date
* Self-report of having smoked no cigarettes from quit date, validated by urinary levels of NNAL
(4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol). If NNAL is missing, validation by urinary lev-
els of anabasine or exhaled carbon monoxide (CO)
• Self-reported smoking abstinence allowing a 2-week`grace period' at 4, 8 weeks and 6 months
post quit date
• Validated smoking abstinence allowing a 2-week`grace period at 6 months post quit date
* validated by urinary levels of anabasine. If anabasine is missing validation by exhaled CO
* validated by urinary levels of NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol). If NNAL is
missing, validation by urinary levels of anabasine or exhaled CO
• Self-reported smoking abstinence allowing up to 5 cigarettes at 1, 2, 4, 8 weeks and 6 months
post-quit date
• Validated smoking abstinence allowing up to 5 cigarettes at 6 months post-quit date:
* validated by urinary levels of anabasine. If anabasine is missing validation by exhaled CO
* validated by urinary levels of NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol). If NNAL is
missing, validation by urinary levels of anabasine or exhaled CO
• Self-reported 7-day PPA at 1, 2, 4, 8 weeks and 6 months post-quit date
• Validated 7-day PPA at 6 months post-quit date
* Confirmation of having smoked no cigarettes in the past 7 days, validated by urinary levels of
anabasine. If anabasine is missing validation by exhaled CO
* Confirmation of having smoked no cigarettes in the past 7 days, validated by urinary levels
of NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol). If NNAL is missing, validation by uri-
nary levels of anabasine or exhaled CO
NCT03589989  (Continued)
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• Number of cpd at baseline, target quit date, 1, 2, 4, 8 weeks and 6 months post-quit date, self-
reported
• Change in number of cpd at baseline, 6 months post-quit date, self-reported. Successful reduction
defined as 50% reduction in cpd
• Use of any other smoking cessation products (NRT) at 1, 2, 4, 8 weeks and 6 months post-quit date,
self-reported
• Withdrawal at baseline and 6 months
• Fagerström Test for Nicotine Dependence at baseline and 6 months
• Swiss EQ-5D at baseline and 6 months
• Use of any ENDS at 1, 2, 4, 8 weeks and 6 months post-quit date, self-reported
• Most common adverse events using ENDS at 1, 2, 4, 8 weeks and 6 months post-quit date
Starting date 16 July 2018
Contact information Reto Auer, reto.auer@biham.unibe.ch
Anna Schöni, anna.schoeni@biham.unibe.ch





Study name An open-label, randomized cross-over study comparing nicotine pharmacokinetics of seven elec-
tronic cigarette products and one traditional cigarette across two delivery (10 puI and ad-libitum)
conditions, in healthy adult smokers.
Methods Open-label, randomized cross-over trial
Setting and recruitment not specified, New Zealand
Participants Estimated enrolment: 24
Inclusion criteria:
• Male or female aged 18 to 60 years of age inclusive
• BMI between 18 to 35 kg/m2 inclusive
• Healthy based on medical history and screening assessments, in the opinion of the Investigator
• Current smoker of at least 8 cigarettes per day on average
• Has been smoking for at least 12 months prior to screening. Brief periods of non-smoking (e.g. up
to ~7 consecutive days due to illness, trying to quit, participation in a study where smoking was
prohibited) are permitted at the discretion of the Investigator
• Able to participate, and willing to give written informed consent and comply with study restric-
tions
Exclusion criteria:
• Clinically-relevant medical or psychiatric disorder, in the opinion of the Investigator
• Clinically-significant abnormality on screening ECG
• Sustained blood pressure recordings at screening of < 90 mmHg or > 150 mmHg for systolic blood
pressure, or < 50 mmHg or > 90 mmHg for diastolic blood pressure
• Sustained resting heart rate of > 100 or < 40 beats per minute at screening
• Positive result for urine drugs of abuse test or alcohol breath test at screening. If a positive urine
drug test is observed, and it is believed the positive urine test is due to prescription drugs, the PI
should obtain documentation that a) confirms the person's use of the prescribed medication, and
b) the prescribed medication will cause a false positive drug test
NCT03700112 
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• Clinically-significant abnormality in laboratory test results at screening, in the opinion of the In-
vestigator
• Exposure to an investigational drug in a clinical trial within 1 month prior to Assessment Day 1
• Blood or plasma donation of > 500 mL within 1 month prior to Assessment Day 1
• Positive urine pregnancy test at screening or Assessment Day 1 in women
• Any clinically-significant concomitant disease or condition that could interfere with, or for which
the treatment of might interfere with, the conduct of the study, or that would, in the opinion of
the investigator, pose an unacceptable risk to the participant in this study
Interventions • JUUL Virginia Tobacco flavored 5.0% ENDS; consumed using 10 puIs delivery method, ad-libitum
• PMI iQOS Heat sticks - Regular consumed using 10 puIs delivery method, ad-libitum
• Reynolds VUSE Solo ENDS - Original consumed using 10 puIs delivery method, ad-libitum
• Imperial MyBlu ENDS - Original consumed using 10 puIs delivery method, ad-libitum
• Altria MarkTen ENDS - Bold Classic consuming using 10 puIs delivery method, ad-libitum
• MLV PHIX ENDS - Original Tobacco consumed using 10 puIs delivery method, ad-libitum
• NJOY Daily EXTRA ENDS - Rich Tobacco consumed using 10 puIs delivery method, ad-libitum
• Altria Marlboro combustible cigarette - Red consumed using 10 puIs delivery method, ad-libitum
Outcomes Day 48
Outcomes:
• Nicotine PK parameters calculated from the individual plasma concentrations
• Exhaled CO
• Level of user satisfaction measured by Modified Product Evaluation Scale
• Characterize consumption of 8 x E-cigarettes/cigarettes products by collecting total number of
puIs for each e-cigarette
Starting date 7 December 2018
Contact information Study director: Concetta Carbonaro





Study name Harm reduction for tobacco smoking with support of tobacco-replacing electronic nicotine deliv-
ery systems (HaRTS-TRENDS)
Methods Parallel, randomized controlled trial
Setting: USA
Recruitment: from prominent Housing First programs serving chronically homeless people who are
often multiply affected by psychiatric, medical and substance-use disorders. The proposed sample
will be recruited from a highly vulnerable and marginalized population in a tight-knit urban com-
munity
Participants Estimated enrolment: 94
Inclusion criteria:
• Having a history of chronic homelessness according to the widely-accepted federal definition
NCT03962660 
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• Being a current DESC client living in 1 of DESC's participating permanent supportive housing
projects
• Being between 21 - 65 years of age
• Being a daily smoker (> 4 cigarettes/day in the past year with a breath CO ≥ 6 ppm or salivary
cotinine test at level 1 if CO < 6 ppm)
• Having adequate English language skills to understand verbal information and communicate in
the study
Exclusion Criteria:
• Use of other tobacco products besides cigarettes ≥ 9 days in the past month
• Refusal or inability to consent to participation in research
• Constituting a risk to the safety and security of other clients or staI.
Interventions • Intervention: HaRTS-TRENDS: 4 individual sessions delivered in the context of the intervention-
ist's pragmatic harm-reduction mindset paired with a compassionate, advocacy-oriented "heart-
set" or style. It comprises the delivery of 4 manualized components, including
* a) participant-led tracking of preferred smoking outcomes,
* b) elicitation of participants' harm-reduction goals and their progress toward achieving them,
* c) discussion of the relative risks of various nicotine delivery systems,
* d) instruction in using ENDS. Additionally, HaRTS-TRENDS entails provision of commercially
available ENDS.
• Standard care: The 4-session, individual standard care control condition entails the well-docu-
mented and evidence-based 5 As intervention (i.e. Ask about nicotine use, Assess use, Advise
to quit smoking, Assist with exploring current smoking/planning smoking cessation, Arrange fol-
low-up). Part of arranging follow-up is the recommendation to call the smoking quit line, which
can supply additional counseling and nicotine replacement therapy
Outcomes Primary outcomes, measured across the 12-month follow-up:
• Biologically-verified nonsmoking (i.e. self-reported nonsmoking if corresponding CO measure is
< 8) in the past 7 days
• Urinary concentration of a tobacco-specific nitrosamine
Secondary outcomes, measured across the 12-month follow-up:
• Self-reported smoking intensity is the mean number of cigarettes participants report smoking per
day in the 7 days prior to the assessment
• Self-reported smoking frequency is the number of days participants report smoking in the 7 days








• Side effects of ENDS
Starting date 9 May 2019
Contact information Tatiana M Ubay, tatiubay@uw.edu
Notes  
NCT03962660  (Continued)
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Study name Electronic cigarettes as a harm reduction strategy in individuals with substance use disorder
Methods Parallel, randomized trial
Recruitment/Setting: Not specified
Participants Estimated enrolment: 240
Inclusion criteria:
• Smokes at least 10 cpd
• Meet DSM-V AUD and/or OUD within the past year, interested in reducing cpd
• Able to provide consent
• Use a cell phone, are willing/able to receive and respond to daily text messages about their ciga-
rette use and e-cigarette use on their cell phone
• Provide 1 additional contact, and are willing to use an e-cigarette for 3 weeks
Exclusion criteria:
• Pregnant and/or breast feeding (self-reported)
• Currently using smoking cessation medications (including other forms of NRT, bupropion, or
varenicline)
• enrolled in a smoking cessation program or another cessation trial
• Have used an e-cigarette in the past 14 days
• Have used any other tobacco products (pipe, cigar, cigarillos, snuI, chewing tobacco, rolling to-
bacco, or hookah/shisha) in the past 30 days
• Report having a history of asthma, other airways diseases, or heart disease
Interventions E-cigarettes arm:
• Participants will be encouraged to substitute e-cigarettes for combustible cigarettes in order to
reduce nicotine withdrawal symptoms
Nicotine Replacement Therapy arm:
• Nicotine patches and gum to last them the first week based on their baseline recorded smoking.
Participants will be advised to use both a 21 mg nicotine patch and 4 mg nicotine for cravings
Outcomes Proportion of participants who achieve 50% reduction in cpd at 3 weeks
Starting date 15 September 2019





Study name A randomized controlled international multicentre study evaluating changes in metabolic syn-
drome in smokers with type 2 diabetes mellitus after switching from tobacco cigarettes to combus-
tion-free nicotine delivery systems: DIASMOKE Study
Short title: Metabolic syndrome in diabetic smokers using cigarettes & combustion-free nicotine
delivery systems (DIASMOKE)
NCT04231838 
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Participants will be required to satisfy all of the following criteria at the screening visit, unless oth-
erwise stated:
• Participants will be: 1.1. over 23 years of age
• T2DM Patients will have: 2.1. body mass index (BMI) between 17.6 and 32.0 kg/m2, inclusive 2.2.
body weight exceeding 50 kg (men) or 40 kg women 2.3 6.5 < HbA1C < 10 3.2. completion of profor-
ma (CRF) 3.3. lab assessment as outlined in the CRF
• Participants will be willing to refrain from eating/drinking prior to screening and check-in at each
study visit.
• Participants will be regular smokers of at least 10 cigarettes/day (max 30 cigarette/day)
• Participants will have smoked for at least 5 consecutive years prior to screening
• Participants must have a saliva cotinine level > 10 ng/mL or an exhaled breath CO (eCO) level >
7 ppm at screening
• Participants in Arm A who continue to smoke will be willing to use their own brand/type cigarettes
• Participants in Arm B will be willing to use the study products (THP product or e-cigarette) pro-
vided to them during the study
Exclusion Criteria:
Participants will be excluded at the screening visit based on the following criteria:
• Women who are pregnant or breastfeeding. This will be confirmed at screening and at visit 1. Any
woman who becomes pregnant during this study will be withdrawn
• People with a history of recent acute decompensation of their disease requiring treatment within
4 weeks prior to visit 1
• People who have a significant history of alcoholism or drug/chemical abuse within 24 months
prior to screening, as determined by the investigator
• People who are still participating in another clinical study (e.g. attending follow-up visits) or
who have participated in a clinical study involving administration of an investigational drug (new
chemical entity) in the past 3 months prior to first product use
• People who have, or who have a history of, any clinically-significant neurological, gastrointesti-
nal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, hematological
or other major disorder that, in the opinion of the investigator or their appropriately qualified de-
signee, would jeopardize the safety of the person or impact on the validity of the study results
• People who regularly use any nicotine (e.g. e-cigarettes, NRT) or tobacco product (e.g. HTPs, oral
smokeless) other than their own cigarettes within 14 days of screening
At screening and prior to enrolment, all patients will be offered a locally-available free smoking
cessation program as per local guidelines. Those who express the intention of booking for the ces-
sation program together with those who, at screening, are planning to quit smoking in the next 6
months, will not be recruited into the study. Patients taking part in the study will be informed that
they are free to quit smoking and withdraw from the study at any time. Any person who decides to
quit smoking will be directed to local stop smoking services.
Interventions Arm A: tobacco cigarettes (continuing smoking their own tobacco cigarette brand)
Arm B: switching to using combustion-free nicotine delivery systems (C-F NDS)
Outcomes Time frame: 3 months, 6 months, 1 year and 2 years
NCT04231838  (Continued)
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Change in metabolic syndrome prevalence
Change in plasma glucose
Change in triglycerides
Change in high-density lipoprotein (HDL)
Change in waist circumference
Starting date Estimated start date: 17 September 2020. Estimated primary completion September 2021. Estimat-
ed study completion March 2025
Contact information Daniela Saitta, PhD, daniela.saitta@eclatrbc.it





Study name Impact of non-cigarette tobacco product formulation on reinforcement value and use in current
smokers
Short title: Salt-Based E-cigarette
Methods RCT
Setting: USA, South Carolina
Participants 30 participants
Inclusion criteria:
• daily cigarette smoker
• interested in using non-cigarette tobacco product
• have a smartphone that can receive text messages and has access to the internet or have an e-
mail account they check daily (necessary for daily diary completion)
Exclusion criteria:
• additional tobacco use criteria
• additional medical criteria
Interventions Salt base nicotine
Free base nicotine
Outcomes Most preferred product [ Time Frame: Lab Visit 2, occurring approximately 1 week after the initial
screening/baseline visit ]
Participants complete a preference assessment in which they choose between the salt liquid, free-
base liquid, or a traditional cigarette in a series of trials. The outcome of this assessment is the
product chosen most often by each participant
Cigarettes per day [ Time Frame: Week 2 of study ]
The average number of cigarettes smoked per day during the 1 week sampling period.
Biomarkers (i.e. expired CO, cotinine) will corroborate self-reported indices of use
NCT04238832 
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Starting date 23 June 2020. Estimated completion August 2021





Study name Official title: Cigarette consumption after switchinG to high or low Nicotine strENght E-cigaretteS In
Smokers with Schizophrenia spectrum disorders: a 12-month randomized, double-blind multicen-
tre trial
Brief title: Cigarette consumption after switchinG to high or low nicotine strENght E-cigaretteS In
Smokers with Schizophrenia (GENESIS)
Methods RCT
Multicenter: Italy, Russia, Ukraine, UK
Collaborators:
• Juul Labs, Inc.
• St. Petersburg State Pavlov Medical University
• Bashkir State Medical University
• Ukrainian Institute on Public Health Policy
• University of Surrey
• Eclat Srl
Participants Estimated enrolment: 260
Inclusion criteria:
• Adult (> 18 yrs)
• Regular smoking (> 10 cigarettes a day; for at least 1 year)
• Exhaled breath CO (eCO) level > 7 ppm
• Not currently attempting to quit smoking or wishing to do so in the next 30 days; this will be veri-
fied at screening by the answer ''NO'' to the question ''Do you intend to quit in the next 30 days?''
• Schizophrenia spectrum disorder diagnosis (schizophrenia, delusional disorder, schizoaffective
disorder, personality disorder, schizoid personality disorder, etc) by DSM-V criteria
• Understand and provide informed consent
• Able to comply with all study procedures
Exclusion criteria:
• Institutionalized patients
• Acute decompensation of Schizophrenia spectrum disorder symptoms within the past month
• Change in antipsychotic treatment within the past month
• No recent history of hospitalization for any serious medical condition within 3 months prior to
screening, as determined by the investigator
• Myocardial infarction or angina pectoris within 3 months prior to screening, as determined by the
investigator
• Current poorly-controlled asthma or COPD
• Pregnancy, planned pregnancy or breastfeeding. Any female participant who becomes pregnant
during this study will be withdrawn
• People who have a significant history of alcoholism or drug/chemical abuse within 12 months
prior to screening, as determined by the investigator.
NCT04452175 
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• Accepting to take part in a smoking cessation program
• People who regularly use any recreational nicotine (e.g. e-cigarettes,) or tobacco product (e.g. to-
bacco heated products, oral smokeless) other than their own cigarettes within 30 days of screen-
ing
• People who have used smoking cessation therapies (e.g. varenicline, bupropion, or NRT) within
30 days of screening
• People who are still participating in another clinical study (e.g. attending follow-up visits) or who
have recently participated in a clinical study involving administration of an investigational drug
(new chemical entity) within the past 3 months
• People who have, or who have a history of, any clinically-significant neurological, gastrointesti-
nal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, hematological
or other major disorder that, in the opinion of the investigator or their appropriately qualified de-
signee, would jeopardize the safety of the participant or impact on the validity of the study results
Interventions • Experimental: HIGH 5%. Intervention: JUUL E-CIGARETTE
• Active Comparator: LOW 1.7%. Intervention: JUUL E-CIGARETTE
Outcomes Primary outcomes:
• Rates of participants with continuous smoking abstinence at 6 months; Time Frame: 24 weeks
• Self-reported continuous smoking abstinence at 6 months from the previous visit, biochemical-
ly-verified by exhaled CO measurements of ≤ 7 ppm
Secondary outcomes
• Rates of participants with continuous smoking abstinence at 12-month [ Time Frame: 52 weeks ]
• Rates of participants with continuous smoking reduction at 6-month [ Time Frame: 24 weeks]
• Rates of participants with continuous smoking reduction at 12-month [ Time Frame: 52 weeks]
• Proportion of AEs [ Time Frame: 24 weeks]
• Absolute change in PANSS [ Time Frame: 24 weeks]
• Absolute change in mCEQ [ Time Frame: 24 weeks]
• Absolute change in Chester Step Test-derived values [ Time Frame: 24 weeks]
• Change in App-derived endpoints (self-rated mental health -SRMH). [ Time Frame: 24 weeks]
Starting date October 2020. Estimated completion date March 2022





Study name International randomized controlled trial evaluating changes in oral health in smokers after switch-
ing to combustion-free nicotine delivery systems (SMILE)
Methods RCT
Setting: multicenter: Italy, Moldova, Poland, UK and Indonesia
Participants Estimated enrolment 606 participants
Inclusion criteria:
• Demonstrate understanding of the study and willingness to participate in the study by providing
a signed written informed consent
• Healthy, not taking regular medications for chronic medical conditions
NCT04649645 
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• Adults, age at least 18 years old
• Presence of at least 10 natural anterior teeth in total (cuspid to cuspid, lower and upper jaw)
• Presence of at least 18 'scorable' teeth with scorable facial and lingual surfaces. Teeth that are
grossly carious, orthodontically banded, exhibiting general cervical abrasion and/or enamel abra-
sion, and third molars will not be included in the tooth count
• Willingness and ability to comply with the requirements of the study including installing an APP
on their digital device, e.g. smart phone or tablet
For Arms A and B, participants have to be:
• Regular smokers, defined as: smoked for at least 5 consecutive years prior to screening. Smoked
> 10 and < 30 cigarettes per day (cpd).with an exhaled breath carbon monoxide (CO) level ≥ 7 ppm
at screening
• willing to regularly use any nicotine or tobacco product other than their own conventional ciga-
rettes brand within 14 days prior to screening
• willing to change to use of study products or if randomized to Arm A continuing to use their own
brand of conventional cigarettes for the whole duration of the study
For Arm C, participants have to be:
• Never-smokers, defined as:never smoked or who have smoked < 100 cigarettes in their lifetime
and none in the 30 days prior to screening.with an exhaled breath CO level < 7 ppm at screening
• willing to not smoke or use any form of tobacco or nicotine-containing products for the whole
duration of the study
Exclusion criteria:
• Pregnancy
• Presence of extensive crown or bridge work, dental implants, and/or rampant decay (per Investi-
gator/Examiner discretion)
• Significant oral soO tissue pathology or any type of gingival overgrowth, other than plaque-in-
duced gingivitis and mild periodontitis (Stage I)
• Moderate-to-severe periodontitis (Stage II, III and IV) based on 2017 World Workshop on the Clas-
sification of Periodontal and Peri-Implant Diseases and Conditions, which require:Detectable In-
terdental Clinical Attachment Loss (CAL) ≥ 3 mm at ≥ 2 non-adjacent teeth. Buccal or Oral CAL ≥ 3
mm with pocketing ≥ 5 mm detectable at ≥ 2 teeth
• Removable dentures or fixed and removable orthodontic appliance (except fixed lingual wires)
• Significant history of alcoholism or drug abuse (other than tobacco/nicotine) within 24 months
prior to screening, as determined by the Investigator
• A course of treatment with any medications or substances (other than tobacco/nicotine) which:in-
terfere with the cyclo-oxygenase pathway (e.g. anti-inflammatory drugs including aspirin and
ibuprofen) within 3 days prior to each visit.are known to have antibacterial activity (e.g. antibi-
otics) within 7 days prior to each visit
Interventions Standard Arm (Arm A): own tobacco cigarette brand
Intervention Arm (Arm B): combustion-free nicotine delivery system (C-F NDS)
Control Arm (Arm C): no smoking or use of any nicotine/tobacco products
Outcomes Oral health parameters and teeth appearance, comparing short- and long-term impact on peri-
odontal health between smokers continuing with conventional cigarette smoking, those switching
to combustion-free nicotine delivery systems (C-F NDS), and never-smokers over 18 months
Starting date Not yet recruiting (last updated February 2021)
Estimated study start date Feb 2021. Primary completion date Feb 2023. Completion April 2023
Contact information Principal investigator: Antonio Pacino, DDS, Addendo srl, Catania, Italy
NCT04649645  (Continued)
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BMI: body mass index; CAR: continuous abstinence rate; CO: carbon monoxide; COPD: chronic obstructive pulmonary disease; cpd:
cigarettes per day; CVD: cardiovascular disease; EC: electronic cigarette; ECG: electrocardiogram; FTND: Fagerström Test for Nicotine
Dependence; NNAL: carcinogen found in tobacco smoke; NRT: nicotine replacement therapy; PP(A): point prevalence (abstinence); QoL:
quality of life; TQD: target quit date; wk: week; yr: year
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Nicotine EC versus NRT
Outcome or subgroup
title
No. of studies No. of partici-
pants
Statistical method Effect size
1.1 Smoking cessation 3 1498 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [1.25, 2.27]
1.2 Adverse events 2 485 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.80, 1.19]
1.2.1 4 weeks 1 29 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.31, 1.73]
1.2.2 6 months 1 456 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.81, 1.22]
1.3 Serious adverse
events
2 727 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [0.77, 2.41]
1.3.1 4 weeks 1 29 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
1.3.2 1 year 1 698 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [0.77, 2.41]
1.4 Carbon monoxide
(ppm)
2   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.4.1 8 weeks 2 136 Mean Difference (IV, Fixed, 95% CI) -0.66 [-1.94, 0.62]
1.5 Heart rate (bpm) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.5.1 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.6 Systolic blood pres-
sure
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.6.1 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.7 Blood oxygen satu-
ration
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.7.1 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.8 3-HPMA (pmol/mg
creatinine)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.8.1 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Outcome or subgroup
title
No. of studies No. of partici-
pants
Statistical method Effect size
1.9 NNAL (pmol/mg cre-
atinine))
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.9.1 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.10 2-HPMA (pmol/mg
creatinine)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.10.1 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.11 HMPMA (pmol/mg
creatinine)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.11.1 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.12 PheT (pmol/mg
creatinine)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.12.1 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.13 CEMA (pmol/mg
creatinine)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.13.1 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.14 AAMA (pmol/mg
creatinine)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.14.1 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.15 FEV1 (ml) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.15.1 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.16 FEV1/FVC (%) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.16.1 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Heterogeneity: Chi² = 1.21, df = 2 (P = 0.55); I² = 0%
Test for overall effect: Z = 3.46 (P = 0.0005)





























M-H, Fixed, 95% CI
1.26 [0.68 , 2.34]
1.83 [1.30 , 2.58]
2.50 [0.34 , 18.63]
1.69 [1.25 , 2.27]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours NRT Favours EC
 
 













Test for overall effect: Z = 0.05 (P = 0.96)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 0.45, df = 1 (P = 0.50); I² = 0%
Test for overall effect: Z = 0.21 (P = 0.83)


































M-H, Fixed, 95% CI
0.74 [0.31 , 1.73]
0.74 [0.31 , 1.73]
0.99 [0.81 , 1.22]
0.99 [0.81 , 1.22]
0.98 [0.80 , 1.19]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours EC Favours NRT
Footnotes
(1) Data at 4 weeks post-operation; time from baseline not defined and likely to differ between participants
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Test for overall effect: Z = 1.07 (P = 0.28)
































M-H, Fixed, 95% CI
Not estimable
Not estimable
1.37 [0.77 , 2.41]
1.37 [0.77 , 2.41]
1.37 [0.77 , 2.41]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours EC Favours NRT
Footnotes
(1) Data at 4 weeks post-operation; time from baseline not defined and likely to differ between participants
 
 






Heterogeneity: Chi² = 3.18, df = 1 (P = 0.07); I² = 69%
Test for overall effect: Z = 1.01 (P = 0.31)




























IV, Fixed, 95% CI
-0.50 [-1.80 , 0.80]
-9.20 [-18.68 , 0.28]
-0.66 [-1.94 , 0.62]
Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours EC Favours NRT
 
 



















IV, Fixed, 95% CI
-1.40 [-2.74 , -0.06]
Mean Difference
IV, Fixed, 95% CI
-4 -2 0 2 4
Favours EC Favours NRT
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IV, Fixed, 95% CI
0.30 [-1.41 , 2.01]
Mean Difference
IV, Fixed, 95% CI
-4 -2 0 2 4
Favours EC Favours NRT
 
 



















IV, Fixed, 95% CI
-0.10 [-0.29 , 0.09]
Mean Difference
IV, Fixed, 95% CI
-0.5 -0.25 0 0.25 0.5
Favours NRT Favours EC
 
 



















IV, Fixed, 95% CI
-374.00 [-994.76 , 246.76]
Mean Difference
IV, Fixed, 95% CI
-1000 -500 0 500 1000
Favours EC Favours NRT
 
 



















IV, Fixed, 95% CI
0.30 [0.09 , 0.51]
Mean Difference
IV, Fixed, 95% CI
-1 -0.5 0 0.5 1
Favours EC Favours NRT
 
 



















IV, Fixed, 95% CI
-143.00 [-300.83 , 14.83]
Mean Difference
IV, Fixed, 95% CI
-200-100 0 100 200
Favours EC Favours NRT
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IV, Fixed, 95% CI
-67.00 [-550.76 , 416.76]
Mean Difference
IV, Fixed, 95% CI
-1000 -500 0 500 1000
Favours EC Favours NRT
 
 



















IV, Fixed, 95% CI
-0.57 [-0.94 , -0.20]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours EC Favours NRT
 
 



















IV, Fixed, 95% CI
-3.90 [-55.93 , 48.13]
Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
Favours EC Favours NRT
 
 



















IV, Fixed, 95% CI
103.00 [55.95 , 150.05]
Mean Difference
IV, Fixed, 95% CI
-500 -250 0 250 500
Favours EC Favours NRT
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IV, Fixed, 95% CI
592.00 [146.22 , 1037.78]
Mean Difference
IV, Fixed, 95% CI
-1000 -500 0 500 1000
Favours NRT Favours nicotine EC
 
 



















IV, Fixed, 95% CI
40.10 [-15.00 , 95.20]
Mean Difference
IV, Fixed, 95% CI
-1000 -500 0 500 1000
Favours NRT Favours nicotine EC
 
 
Comparison 2.   Nicotine EC versus varenicline
Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
2.1 Smoking cessation 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.2 Serious adverse events 1 54 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2.2.1 12 weeks 1 54 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
 
 














M-H, Fixed, 95% CI
0.31 [0.11 , 0.82]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours varenicline Favours nicotine EC
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Test for overall effect: Not applicable


























M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours EC Favours varenicline
Footnotes
(1) n followed up not reported; n randomised used as denominators
 
 
Comparison 3.   Nicotine EC versus non-nicotine EC
Outcome or sub-
group title
No. of studies No. of partici-
pants
Statistical method Effect size
3.1 Smoking cessa-
tion
4 1057 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [1.03, 2.81]
3.2 Adverse events 3 601 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.91, 1.11]
3.2.1 1 week 1 48 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.27, 8.19]
3.2.2 6 months 1 298 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.71, 1.34]
3.2.3 12 weeks 1 255 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.94, 1.08]
3.3 Serious adverse
events
4 494 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.15, 2.44]
3.3.1 1 week 1 48 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3.3.2 4 weeks 1 74 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3.3.3 24 weeks 1 255 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.15, 2.44]
3.3.4 1 year 1 117 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3.4 Carbon monoxide
(ppm)
2 171 Mean Difference (IV, Fixed, 95% CI) -2.44 [-3.91, -0.97]
3.4.1 2 weeks 1 25 Mean Difference (IV, Fixed, 95% CI) -0.40 [-3.00, 2.20]
3.4.2 12 weeks 1 146 Mean Difference (IV, Fixed, 95% CI) -3.40 [-5.18, -1.62]
3.5 Heart rate 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Outcome or sub-
group title
No. of studies No. of partici-
pants
Statistical method Effect size
3.5.1 12 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.6 Systolic blood
pressure
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.6.1 12 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.7 FeNO (ppb) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.7.1 12 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.8 FEV1 (l) 1   Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.8.1 12 weeks 1   Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.9 FVC (l) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.9.1 12 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.10 FEV1/FVC 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.10.1 12 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
 
 








Heterogeneity: Chi² = 1.78, df = 3 (P = 0.62); I² = 0%
Test for overall effect: Z = 2.09 (P = 0.04)


































M-H, Fixed, 95% CI
1.77 [0.54 , 5.77]
2.75 [0.97 , 7.76]
1.65 [0.40 , 6.77]
1.18 [0.57 , 2.46]
1.70 [1.03 , 2.81]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours non-nicotine EC Favours nicotine EC
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Test for overall effect: Z = 0.27 (P = 0.79)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 0.26, df = 2 (P = 0.88); I² = 0%
Test for overall effect: Z = 0.12 (P = 0.91)












































M-H, Fixed, 95% CI
1.50 [0.27 , 8.19]
1.50 [0.27 , 8.19]
0.97 [0.71 , 1.34]
0.97 [0.71 , 1.34]
1.01 [0.94 , 1.08]
1.01 [0.94 , 1.08]
1.01 [0.91 , 1.11]
Risk Ratio
M-H, Fixed, 95% CI
0.05 0.2 1 5 20
Favours non-nicotine EC Favours nicotine EC
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Test for overall effect: Z = 0.72 (P = 0.47)





















































0.60 [0.15 , 2.44]
0.60 [0.15 , 2.44]
Not estimable
Not estimable
0.60 [0.15 , 2.44]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours nicotine EC Favours non-nicotine EC
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Test for overall effect: Z = 3.74 (P = 0.0002)
Total (95% CI)
Heterogeneity: Chi² = 3.48, df = 1 (P = 0.06); I² = 71%
Test for overall effect: Z = 3.25 (P = 0.001)


































IV, Fixed, 95% CI
-0.40 [-3.00 , 2.20]
-0.40 [-3.00 , 2.20]
-3.40 [-5.18 , -1.62]
-3.40 [-5.18 , -1.62]
-2.44 [-3.91 , -0.97]
Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours nicotine EC Favours non-nicotine EC
Footnotes
(1) Data is 2.4% nicotine compared to no-nicotine; 1.8% nicotine arm reported elsewhere
 
 



















IV, Fixed, 95% CI
-2.80 [-3.86 , -1.74]
Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours nicotine EC Favours non-nicotine ECFootnotes
(1) Data is 2.4% nicotine compared to no-nicotine; 1.8% nicotine arm reported elsewhere
 
 



















IV, Fixed, 95% CI
0.60 [-0.99 , 2.19]
Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours nicotine EC Favours non-nicotine ECFootnotes
(1) Data is 2.4% nicotine compared to no-nicotine; 1.8% nicotine arm reported elsewhere
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IV, Fixed, 95% CI
2.35 [1.78 , 2.92]
Mean Difference
IV, Fixed, 95% CI
-4 -2 0 2 4
Favours nicotine EC Favours non-nicotine ECFootnotes
(1) Data is 2.4% nicotine compared to no-nicotine; 1.8% nicotine arm reported elsewhere
 
 



















IV, Fixed, 95% CI
0.04 [-0.38 , 0.46]
Std. Mean Difference
IV, Fixed, 95% CI
-1 -0.5 0 0.5 1
Favours non-nicotine EC Favours nicotine ECFootnotes
(1) Data is 2.4% nicotine compared to no-nicotine; 1.8% nicotine arm reported elsewhere
 
 



















IV, Fixed, 95% CI
0.05 [-0.08 , 0.18]
Mean Difference
IV, Fixed, 95% CI
-0.2 -0.1 0 0.1 0.2
Favours non-nicotine EC Favours nicotine ECFootnotes
(1) Data is 2.4% nicotine compared to no-nicotine; 1.8% nicotine arm reported elsewhere
 
 



















IV, Fixed, 95% CI
0.06 [-0.69 , 0.81]
Mean Difference
IV, Fixed, 95% CI
-4 -2 0 2 4
Favours non-nicotine EC Favours nicotine ECFootnotes
(1) Data is 2.4% nicotine compared to no-nicotine; 1.8% nicotine arm reported elsewhere
 
 
Comparison 4.   Nicotine EC versus behavioural support only/no support
Outcome or sub-
group title
No. of studies No. of partici-
pants
Statistical method Effect size
4.1 Smoking cessation 5 2561 Risk Ratio (M-H, Fixed, 95% CI) 2.70 [1.39, 5.26]
Electronic cigarettes for smoking cessation (Review)









Cochrane Database of Systematic Reviews
Outcome or sub-
group title
No. of studies No. of partici-
pants
Statistical method Effect size
4.2 Adverse events 4 765 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [1.12, 1.32]
4.2.1 12 weeks 2 657 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [1.11, 1.30]
4.2.2 16 weeks 1 50 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.67, 2.07]
4.2.3 6 months 1 58 Risk Ratio (M-H, Fixed, 95% CI) 11.00 [0.64, 190.26]
4.3 Serious adverse
events
6 1011 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.33, 4.09]
4.3.1 4 to 6 weeks 2 246 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4.3.2 12 weeks 1 408 Risk Ratio (M-H, Fixed, 95% CI) 3.69 [0.21, 66.17]
4.3.3 16 weeks 1 50 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4.3.4 6 months 2 307 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.16, 3.10]
4.4 Carbon monoxide
(ppm)
8   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.4.1 3 to 4 weeks 3   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.4.2 6 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.4.3 8 weeks 2   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.4.4 4 months 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.4.5 6 months 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.5 Heart rate (bpm) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.5.1 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.6 Systolic blood
pressure
3   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.6.1 6 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.6.2 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.6.3 4 months 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.7 Blood oxygen satu-
ration
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.7.1 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.8 3-HPMA (SMD) 2   Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.8.1 8 weeks 1   Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Outcome or sub-
group title
No. of studies No. of partici-
pants
Statistical method Effect size
4.8.2 12 weeks 1   Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.9 NNAL (SMD) 4   Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.9.1 3 weeks 1   Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.9.2 8 weeks 1   Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.9.3 12 weeks 1   Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.9.4 6 weeks 1   Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.10 2-HPMA (pmol/
mg creatinine)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.10.1 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.11 HMPMA (pmol/
mg creatinine)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.11.1 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.12 PheT (pmol/mg
creatinine)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.12.1 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.13 CEMA (pmol/mg
creatinine)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.13.1 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.14 AAMA (pmol/mg
creatinine)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.14.1 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.15 S-PMA
(nanograms)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.15.1 12 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.16 FVC (litres) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.16.1 12 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.17 FEV1 (litres) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.17.1 12 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.18 FEF 25-75 (litres/
second))
2 555 Mean Difference (IV, Fixed, 95% CI) -0.06 [-0.18, 0.06]
4.18.1 6 weeks 1 168 Mean Difference (IV, Fixed, 95% CI) -0.14 [-0.28, 0.00]
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Outcome or sub-
group title
No. of studies No. of partici-
pants
Statistical method Effect size
4.18.2 12 weeks 1 387 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.10, 0.30]
4.19 PEF 25-75 (litres/
minute)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.19.1 12 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
 
 
Analysis 4.1.   Comparison 4: Nicotine EC versus behavioural









Heterogeneity: Chi² = 1.45, df = 4 (P = 0.83); I² = 0%
Test for overall effect: Z = 2.92 (P = 0.003)







































M-H, Fixed, 95% CI
4.71 [0.25 , 88.30]
4.73 [0.56 , 39.88]
6.11 [0.33 , 113.24]
3.00 [0.64 , 13.98]
1.86 [0.79 , 4.38]
2.70 [1.39 , 5.26]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours usual care Favours nicotine EC
Footnotes
(1) Although participants were given a choice of nicotine concentration including 0 mg, none of the participants chose the non-nicotine e-liquid
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Heterogeneity: Chi² = 2.61, df = 1 (P = 0.11); I² = 62%












Test for overall effect: Z = 1.65 (P = 0.10)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 5.04, df = 3 (P = 0.17); I² = 41%
Test for overall effect: Z = 4.70 (P < 0.00001)

















































M-H, Fixed, 95% CI
1.29 [1.15 , 1.45]
1.13 [1.01 , 1.26]
1.20 [1.11 , 1.30]
1.18 [0.67 , 2.07]
1.18 [0.67 , 2.07]
11.00 [0.64 , 190.26]
11.00 [0.64 , 190.26]
1.22 [1.12 , 1.32]
Risk Ratio
M-H, Fixed, 95% CI
0.001 0.1 1 10 1000
Favours nicotine EC Favours usual care
Footnotes
(1) 24mg EC arm included here; 16mg data reported elsewhere
(2) Participants offered choice of nicotine or no-nicotine EC; all chose nicotine-containing EC
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Analysis 4.3.   Comparison 4: Nicotine EC versus behavioural
support only/no support, Outcome 3: Serious adverse events
Study or Subgroup

























Test for overall effect: Z = 0.46 (P = 0.65)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 1.05, df = 1 (P = 0.31); I² = 5%
Test for overall effect: Z = 0.24 (P = 0.81)






























































3.69 [0.21 , 66.17]
3.69 [0.21 , 66.17]
Not estimable
Not estimable
0.71 [0.16 , 3.10]
Not estimable
0.71 [0.16 , 3.10]
1.17 [0.33 , 4.09]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours nicotine EC Favours usual care
Footnotes
(1) Data from 24mg arm (0 events in 16mg arm as well)
(2) Participants offered choice of nicotine or no-nicotine EC; all chose nicotine-containing EC
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Analysis 4.4.   Comparison 4: Nicotine EC versus behavioural
support only/no support, Outcome 4: Carbon monoxide (ppm)
Study or Subgroup






































































IV, Fixed, 95% CI
-7.17 [-9.87 , -4.47]
0.40 [-1.43 , 2.23]
-2.94 [-6.05 , 0.17]
-7.76 [-8.84 , -6.68]
-5.70 [-6.93 , -4.47]
-8.50 [-9.95 , -7.05]
-4.30 [-5.18 , -3.42]
-6.20 [-12.21 , -0.19]
Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours EC Favours usual care
 
 



















IV, Fixed, 95% CI
-2.70 [-4.25 , -1.15]
Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours EC Favours usual care
 
 
Analysis 4.6.   Comparison 4: Nicotine EC versus behavioural



































IV, Fixed, 95% CI
-2.68 [-4.38 , -0.98]
1.35 [-0.29 , 2.99]
0.20 [-3.49 , 3.89]
Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours EC Favours usual care
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Analysis 4.7.   Comparison 4: Nicotine EC versus behavioural



















IV, Fixed, 95% CI
0.50 [0.31 , 0.69]
Mean Difference
IV, Fixed, 95% CI
-0.5 -0.25 0 0.25 0.5
Favours usual care Favours EC
 
 



























IV, Fixed, 95% CI
-2.31 [-2.86 , -1.75]
-0.50 [-0.73 , -0.27]
Std. Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
Favours EC Favours usual careFootnotes
(1) measured as pmol/mg creatinine
(2) Measured as micrograms
 
 











































IV, Fixed, 95% CI
0.27 [-0.28 , 0.81]
-0.90 [-1.36 , -0.44]
-0.45 [-0.68 , -0.22]
-2.02 [-2.41 , -1.63]
Std. Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
Favours EC Favours usual careFootnotes
(1) Measured as pg/ml
(2) Measured as pmol/mg creatinine
(3) Measured as nanograms
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Analysis 4.10.   Comparison 4: Nicotine EC versus behavioural



















IV, Fixed, 95% CI
-513.00 [-1024.55 , -1.45]
Mean Difference
IV, Fixed, 95% CI
-1000 -500 0 500 1000
Favours EC Favours usual care
 
 
Analysis 4.11.   Comparison 4: Nicotine EC versus behavioural



















IV, Fixed, 95% CI
-3458.00 [-4498.43 , -2417.57]
Mean Difference
IV, Fixed, 95% CI
-1000 -500 0 500 1000
Favours EC Favours usual care
 
 
Analysis 4.12.   Comparison 4: Nicotine EC versus behavioural



















IV, Fixed, 95% CI
-2.76 [-5.10 , -0.42]
Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours EC Favours usual care
 
 
Analysis 4.13.   Comparison 4: Nicotine EC versus behavioural



















IV, Fixed, 95% CI
-290.20 [-340.91 , -239.49]
Mean Difference
IV, Fixed, 95% CI
-500 -250 0 250 500
Favours EC Favours usual care
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Analysis 4.14.   Comparison 4: Nicotine EC versus behavioural



















IV, Fixed, 95% CI
-139.60 [-192.49 , -86.71]
Mean Difference
IV, Fixed, 95% CI
-500 -250 0 250 500
Favours EC Favours usual care
 
 
Analysis 4.15.   Comparison 4: Nicotine EC versus behavioural



















IV, Fixed, 95% CI
-1371.00 [-1995.23 , -746.77]
Mean Difference
IV, Fixed, 95% CI
-1000 -500 0 500 1000
Favours EC Favours usual care
 
 



















IV, Fixed, 95% CI
0.10 [0.03 , 0.17]
Mean Difference
IV, Fixed, 95% CI
-1 -0.5 0 0.5 1
Favours usual care Favours nicotine EC
 
 



















IV, Fixed, 95% CI
0.00 [-0.19 , 0.19]
Mean Difference
IV, Fixed, 95% CI
-0.5 -0.25 0 0.25 0.5
Favours usual care Favours nicotine EC
 
 
Electronic cigarettes for smoking cessation (Review)









Cochrane Database of Systematic Reviews
Analysis 4.18.   Comparison 4: Nicotine EC versus behavioural











Test for overall effect: Z = 0.98 (P = 0.33)
Total (95% CI)
Heterogeneity: Chi² = 3.68, df = 1 (P = 0.06); I² = 73%
Test for overall effect: Z = 1.02 (P = 0.31)


































IV, Fixed, 95% CI
-0.14 [-0.28 , 0.00]
-0.14 [-0.28 , 0.00]
0.10 [-0.10 , 0.30]
0.10 [-0.10 , 0.30]
-0.06 [-0.18 , 0.06]
Mean Difference
IV, Fixed, 95% CI
-4 -2 0 2 4
Favours usual care Favours nicotine EC
 
 
Analysis 4.19.   Comparison 4: Nicotine EC versus behavioural



















IV, Fixed, 95% CI
-7.10 [-29.14 , 14.94]
Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
Favours usual care Favours nicotine EC
 
 
Comparison 5.   Nicotine EC + NRT versus non-nicotine EC + NRT
Outcome or sub-
group title
No. of studies No. of partici-
pants
Statistical method Effect size
5.1 Smoking cessation 2 1039 Risk Ratio (M-H, Fixed, 95% CI) 1.77 [1.07, 2.94]
5.2 Adverse events 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.2.1 12 weeks 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.3 Serious adverse
events
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.3.1 6 months 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.4 Carbon monoxide
(ppm)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.4.1 8 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.5 FeNO (ppb) 1 30 Mean Difference (IV, Fixed, 95% CI) -0.36 [-7.23, 6.51]
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Outcome or sub-
group title
No. of studies No. of partici-
pants
Statistical method Effect size
5.5.1 6 months 1 30 Mean Difference (IV, Fixed, 95% CI) -0.36 [-7.23, 6.51]
5.6 FEV1 (%) 1 32 Mean Difference (IV, Fixed, 95% CI) 0.05 [-0.01, 0.10]
5.6.1 6 months 1 32 Mean Difference (IV, Fixed, 95% CI) 0.05 [-0.01, 0.10]
5.7 FVC (%) 1 32 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.03, 0.09]
5.7.1 6 months 1 32 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.03, 0.09]
 
 






Heterogeneity: Chi² = 0.03, df = 1 (P = 0.87); I² = 0%
Test for overall effect: Z = 2.21 (P = 0.03)
Test for subgroup differences: Not applicable























M-H, Fixed, 95% CI
2.00 [0.41 , 9.71]
1.75 [1.02 , 2.98]
1.77 [1.07 , 2.94]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours non-nicotine EC Favours nicotine EC
 
 















M-H, Fixed, 95% CI
1.09 [0.90 , 1.31]
Risk Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours nicotine EC Favours non-nicotine EC
 
 















M-H, Fixed, 95% CI
0.67 [0.37 , 1.19]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours nicotine EC Favours non-nicotine EC
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IV, Fixed, 95% CI
-1.40 [-4.26 , 1.46]
Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours nicotine EC Favours non-nicotine EC
 
 






Test for overall effect: Z = 0.10 (P = 0.92)
Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
























IV, Fixed, 95% CI
-0.36 [-7.23 , 6.51]
-0.36 [-7.23 , 6.51]
-0.36 [-7.23 , 6.51]
Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours nicotine EC Favours non-nicotine EC
 
 






Test for overall effect: Z = 1.67 (P = 0.10)
Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.67 (P = 0.10)
























IV, Fixed, 95% CI
0.05 [-0.01 , 0.10]
0.05 [-0.01 , 0.10]
0.05 [-0.01 , 0.10]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours non-nicotine EC Favours nicotine EC
 
 






Test for overall effect: Z = 1.09 (P = 0.28)
Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
























IV, Fixed, 95% CI
0.03 [-0.03 , 0.09]
0.03 [-0.03 , 0.09]
0.03 [-0.03 , 0.09]
Mean Difference
IV, Fixed, 95% CI
-4 -2 0 2 4
Favours non-nicotine EC Favours nicotine EC
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Comparison 6.   Nicotine EC + NRT versus NRT
Outcome or subgroup
title
No. of studies No. of partici-
pants
Statistical method Effect size
6.1 Smoking cessation 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.2 Adverse events 2   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.2.1 12 weeks 2   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.3 Serious adverse
events
3 682 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.46, 3.42]
6.3.1 5 weeks 1 7 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6.3.2 12 weeks 1 50 Risk Ratio (M-H, Fixed, 95% CI) 3.00 [0.13, 70.30]
6.3.3 6 months 1 625 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.39, 3.27]
 
 
Analysis 6.1.   Comparison 6: Nicotine EC + NRT versus NRT, Outcome 1: Smoking cessation
Study or Subgroup
Walker 2020











M-H, Fixed, 95% CI
2.92 [0.91 , 9.33]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours NRT Favours nicotine EC + NRT
 
 




















M-H, Fixed, 95% CI
1.50 [0.84 , 2.67]
0.76 [0.58 , 0.99]
Risk Ratio
M-H, Fixed, 95% CI
0.2 0.5 1 2 5
Favours EC + NRT Favours NRTFootnotes
(1) NRT not matched between arms
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Test for overall effect: Z = 0.22 (P = 0.83)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 0.33, df = 1 (P = 0.56); I² = 0%
Test for overall effect: Z = 0.46 (P = 0.65)
Test for subgroup differences: Chi² = 0.33, df = 1 (P = 0.56), I² = 0%









































M-H, Fixed, 95% CI
Not estimable
Not estimable
3.00 [0.13 , 70.30]
3.00 [0.13 , 70.30]
1.13 [0.39 , 3.27]
1.13 [0.39 , 3.27]
1.26 [0.46 , 3.42]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours EC+NRT Favours NRT
Footnotes
(1) NRT not matched between arms
 
 
Comparison 7.   Higher versus lower nicotine content
Outcome or sub-
group title
No. of studies No. of partici-
pants
Statistical method Effect size
7.1 Serious adverse
events
1 72 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7.1.1 1 year 1 72 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7.2 Carbon monoxide
(ppm)
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.2.1 12 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.3 Heart rate 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.3.1 12 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.4 Systolic blood
pressure
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Outcome or sub-
group title
No. of studies No. of partici-
pants
Statistical method Effect size
7.4.1 12 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.5 FeNO (ppb) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.5.1 12 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.6 FEV1 (l) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.6.1 12 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.7 FVC (l) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.7.1 12 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.8 FEV1/FVC 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.8.1 12 weeks 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
 
 











Test for overall effect: Not applicable


























M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours higher Favours lower
 
 



















IV, Fixed, 95% CI
-0.20 [-1.82 , 1.42]
Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours higher dose Favours lower dose
 
 
Electronic cigarettes for smoking cessation (Review)









Cochrane Database of Systematic Reviews



















IV, Fixed, 95% CI
-0.50 [-1.63 , 0.63]
Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours higher dose Favours lower dose
 
 



















IV, Fixed, 95% CI
0.80 [-0.99 , 2.59]
Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours higher dose Favours lower dose
 
 



















IV, Fixed, 95% CI
0.30 [-0.37 , 0.97]
Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours higher dose Favours lower dose
 
 



















IV, Fixed, 95% CI
-0.01 [-0.11 , 0.09]
Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
Favours lower dose Favours higher dose
 
 



















IV, Fixed, 95% CI
-0.03 [-0.15 , 0.09]
Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
Favours lower dose Favours higher dose
Electronic cigarettes for smoking cessation (Review)









Cochrane Database of Systematic Reviews
 
 



















IV, Fixed, 95% CI
0.91 [0.15 , 1.67]
Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
Favours lower dose Favours higher dose
 
 
Comparison 8.   Non-nicotine EC versus behavioural support only/no support
Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
8.1 Smoking cessation 2 388 Risk Ratio (M-H, Fixed, 95% CI) 1.74 [0.76, 3.96]
8.2 Adverse events at 12 weeks 1   Risk Ratio (M-H, Random, 95%
CI)
Totals not selected
8.3 Serious adverse events at 24
weeks





Analysis 8.1.   Comparison 8: Non-nicotine EC versus behavioural






Heterogeneity: Chi² = 0.24, df = 1 (P = 0.63); I² = 0%
Test for overall effect: Z = 1.31 (P = 0.19)
























M-H, Fixed, 95% CI
2.86 [0.30 , 27.10]
1.57 [0.65 , 3.82]
1.74 [0.76 , 3.96]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours usual care Favours non-nicotine EC
 
 
Analysis 8.2.   Comparison 8: Non-nicotine EC versus behavioural














M-H, Random, 95% CI
1.28 [1.13 , 1.44]
Risk Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours non-nicotine Favours behavioural
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Analysis 8.3.   Comparison 8: Non-nicotine EC versus behavioural support














M-H, Random, 95% CI
1.19 [0.33 , 4.33]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours non-nicotine Favours behavioural
 
 
Comparison 9.   Non-nicotine EC + NRT versus NRT
Outcome or subgroup ti-
tle
No. of studies No. of partici-
pants
Statistical method Effect size
9.1 Smoking cessation 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
9.2 Adverse events 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
9.3 Serious adverse events 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
9.3.1 6 months 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
 
 
Analysis 9.1.   Comparison 9: Non-nicotine EC + NRT versus NRT, Outcome 1: Smoking cessation
Study or Subgroup
Walker 2020











M-H, Fixed, 95% CI
1.67 [0.50 , 5.53]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours NRT alone Favours EC + NRT
 
 
Analysis 9.2.   Comparison 9: Non-nicotine EC + NRT versus NRT, Outcome 2: Adverse events
Study or Subgroup
Walker 2020











M-H, Fixed, 95% CI
0.70 [0.53 , 0.91]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours EC + NRT Favours NRT
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M-H, Fixed, 95% CI
1.69 [0.60 , 4.74]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours EC+NRT Favours NRT
 
 
Comparison 10.   Non-nicotine EC versus NRT
Outcome or subgroup ti-
tle
No. of studies No. of partici-
pants
Statistical method Effect size
10.1 Smoking cessation 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
10.2 Adverse events 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
10.2.1 6 months 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
10.3 Serious adverse
events
1 132 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
10.3.1 6 months 1 132 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
 
 














M-H, Fixed, 95% CI
0.76 [0.43 , 1.34]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours NRT Favours non-nicotine ECFootnotes
(1) 0.01 mg/ml of nicotine in e-liquid
 
 















M-H, Fixed, 95% CI
0.33 [0.12 , 0.87]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours non-nicotine EC Favours NRTFootnotes
(1) 0.01 mg/ml of nicotine in e-liquid; length of follow-up not defined but presumably over study period
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Test for overall effect: Not applicable


























M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours non-nicotine EC Favours NRT
Footnotes
(1) 0.01 mg/ml of nicotine in e-liquid; length of follow-up not defined but presumably over study period
 
 
A D D I T I O N A L   T A B L E S
 
Study Motivated or unmotivated to
quit smoking?
% abstinent
Cohort studies 6-month 12-month 18-month 24-month Notes
Adriaens 2014 a Unmotivated to quit 19.6% (10/51) - - - Data from
8-month
follow-up
Bell 2017 "Willing to attempt to quit" 26.6% (8/30) - - - -
Caponnetto
2013b
Unmotivated to quit - 14% (2/14) - - -
Ely 2013 b Motivated to quit 44% (21/48) - - - -
Pacifici 2015 Unmotivated to quit - 53% (18/34) - - -
Polosa 2011 Unmotivated to quit 23% (9/40) - 15% (6/40) 13% (5/40) -
Polosa 2014b Unmotivated to quit 36% (18/50) - - - -
Polosa 2015 Not defined 42% (30/71) 41% (29/71) - - -
Table 1.   Summary of proportion of participants abstinent from smoking at 6+ months follow-up: cohort studies of
nicotine EC 
aTechnically an RCT but observational for purposes of EC analysis.
bAll participants (N = 48) used an EC, but 16 also used bupropion and 2 used varenicline.
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A P P E N D I C E S
Appendix 1. Protocol for living systematic review
Justification for ‘Living Review’ status
Living systematic reviews (LSRs) oIer a new approach to updating reviews, in which the review is continually updated by incorporating
relevant new evidence as it becomes available (Brooker 2019). Previous versions of this Cochrane Review of electronic cigarettes (ECs)
for smoking cessation have informed policy worldwide (Hartmann-Boyce 2016; McRobbie 2014). This update has found high degrees of
uncertainty (low- and very low-certainty evidence) for most outcomes, due to the small number of included randomized controlled trials,
and the resulting imprecision in eIect estimates. This means that some conclusions are likely to change substantially as new evidence
emerges.
On average, Cochrane Reviews are updated every three to four years. For EC, where the evidence base is rapidly evolving, this schedule
impedes the ability of the review to provide the most up-to-date evidence to decision-makers. As EC use, availability, and design changes,
policymakers are frequently drawing on this review to inform decisions, so it is imperative that it is up-to-date to ensure decisions are
being made on the basis of the entirety of the evidence. Regular updates have the potential to strengthen the existing conclusions of the
review or to change conclusions where conflicting evidence or evidence on new outcomes emerges (e.g. comparisons between EC and
other interventions; longer-term safety data).
Objective of the change to ‘Living Review’ status
To implement approved Cochrane LSR methods to provide an up-to-date, accessible, engaging and unbiased review of the evidence on
the eIect and safety of using EC to quit smoking.
LSR methodological considerations
The methods outlined below are specific to maintaining this review of Electronic cigarettes for smoking cessation as an LSR on the
Cochrane Library. These methods will be ‘active’ immediately upon publication of this update. Core review methods, such as the criteria
for considering studies in the review and assessment of risks of bias, are unchanged and are detailed in the main body of the review. Below
we outline the methods for which specific considerations apply as a result of the change to ‘living’ status.
Search methods for identification of studies
We will conduct database searches monthly, beginning December 2020. These searches will be of the Cochrane Central Register of
Controlled Trials (CENTRAL), MEDLINE, Embase, PsycINFO, and clinical trial registries, as detailed in the main body of the review. The
funders of this LSR – Cancer Research UK (CRUK) - already run monthly searches of the EC evidence and so we will work alongside their
health information oIicer to ensure that we are identifying all the relevant literature with our searches. We will review our search strategies
on an ongoing basis every 12 months, as indexing terms and keywords may change, and new search filters may be published. Such changes
will be managed by input from experienced information specialists.
Selection of studies
We will immediately screen any new citations retrieved by the monthly searches using Covidence, undertaking dual screening of title and
abstract, and then full text, by independent review authors. Where we find multiple citations of the same study we will group them into one
study record with a single study ID. One review author (AB) will contact corresponding authors of potentially relevant ongoing studies as
they are identified and ask them to advise when results are available, or to share early or unpublished data. Based on the information and
projected timescales shared, we will contact corresponding authors on an ongoing basis to retrieve new evidence as it becomes available.
Data synthesis
Whenever we identify new studies relevant to the review, we will extract the relevant data and assess risks of bias as detailed in the main
body of the review. We will highlight availability of this new evidence on both the Cochrane Library and on our own dedicated website.
We will incorporate the new data into meta-analyses and tables in the Revman (Review Manager 2020) and supplementary data files, and
carry out GRADE assessments (GRADEpro GDT). We will conduct a full update of the review (full incorporation and interpretation of all new
data within the review and re-publishing) when the accumulating evidence leads to changes in any one of:
• The direction of eIect or clinical significance of the findings for one or more outcomes;
• The certainty (e.g. GRADE rating) of one or more outcomes;
• The availability of studies investigating new settings, populations, interventions, comparisons or outcomes.
Formal sequential meta-analysis approaches will not be used for updated meta-analyses, in line with Cochrane guidance for LSRs.
Future updates of review methods
The LSR approach acknowledges that reviews may cease to need to be ‘living’ over time, as the review findings become stable, or the
question is no longer a priority for decision-makers (Brooker 2019). Eighteen months into this review’s ‘living’ status (March 2022) we will
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evaluate the LSR approach, including the likely benefits of and challenges to continuing this methodology for this evidence base, and
whether such an approach remains warranted. If the evidence is high certainty for all outcomes and all comparisons at that point, meaning
further studies are judged very unlikely to impact the eIect estimate, we would consider ceasing living mode for this review. If, as is more
likely, some or all outcomes are not yet certain, we will facilitate discussions within the author team and Cochrane, as well as engaging
with a wider PPI panel and key decision-makers, e.g. policymakers, in order to determine next steps. If the decision is made to continue in
living mode, we will review, and if necessary revise, the living review methods described in this Appendix before continuing.













AAMA N-acetyl-S-(carbamoylethyl)-L-cysteine (synonym: 2-carbamoylethylmercapturic acid)
CEMA/CNEMA 2-cyanoethylmercapturic acid; referred to as 'acrylonitrile' in Pulvers 2018
- Formic acid
HEMA 2-hydroxyethylmercapturic acid
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Appendix 3. MEDLINE search strategy - 2020 update
1. exp case control studies/ or exp cohort studies/ or Case control.tw. or (cohort adj (study or studies)).tw. or Cohort analy$.tw. or (Follow
up adj (study or studies)).tw. or (observational adj (study or studies)).tw. or Longitudinal.tw.
2. (e-cig$ or ecig$ or electr$ cigar$ or electronic nicotine).mp. or (vape or vapes or vaporizer or vapourizer or vaporiser or vapouriser or
vaper or vapers or vaping).ti,ab. or exp Electronic Nicotine Delivery Systems/
3. (randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or clinical trials as topic.sh. or randomly.ab.
or trial.ti.
4. exp animals/ not humans.sh.
5. 3 not 4
6. 2 and 5
7. 1 and 2
8. 6 or 7
9. smoking cessation.mp. or exp Smoking Cessation/
10. tobacco cessation.mp. or "Tobacco-Use-Cessation"/
11. (nicotine dependence or tobacco dependence).mp.
12. exp Smoking/th
13. "Tobacco-Use-Disorder"/
14. Smoking reduction/ or Smoking reduction.mp.
15. exp Pipe smoking/ or exp Tobacco smoking/ or exp Tobacco Products/
16. ((quit$ or stop$ or ceas$ or giv$ or abstain* or abstinen*) adj5 (smoking or smoke* or tobacco)).ti,ab.
17. exp Tobacco/ or exp Nicotine/
18. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19. 8 and 18
Appendix 4. MEDLINE search strategy - pre-2020
1. e-cig$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare
disease supplementary concept, unique identifier]
2. electr$ cigar$.mp.
3. electronic nicotine.mp.
4. (vape or vaper or vapers or vaping).ti,ab.
5. 1 OR 2 OR 3 OR 4
Identical terms used for other databases.
Line 4 added to search strategy for 2016 update.
W H A T ' S   N E W
 
Date Event Description
15 April 2021 New search has been performed Updated with six new included studies and new data from one
previously included study. Most recent search 1 Feb 2021. 
15 April 2021 New citation required and conclusions
have changed
6 new included studies added (Czoli 2019; Ikonomidis 2020; Oz-
ga-Hess 2019; Pulvers 2020; Scheibein 2020; Yingst 2020), cer-
Electronic cigarettes for smoking cessation (Review)









Cochrane Database of Systematic Reviews
Date Event Description
tainty in finding of no difference in adverse events between nico-
tine EC and non-nicotine EC updated to moderate (from low).
First study of pod EC device included.
 
H I S T O R Y
Protocol first published: Issue 11, 2012
Review first published: Issue 12, 2014
 
Date Event Description
1 April 2021 Amended This is a Living Systematic Review. We run and screen searches
monthly. Last search date 1st April 2021. In addition to the stud-
ies identified from March 2021 we found two new ongoing stud-
ies and one paper linked to a study already included in the re-
view. We will incorporate these into the review as part of a future
update. 
17 March 2021 Amended This is a Living Systematic Review. We run and screen search-
es monthly. Last search date 1st March 2021. Studies identified
in March are not included in this version of the review, but will
be incorporated into a subsequent version. We found four new
included studies, five new ongoing studies and five papers
linked to studies already included in the review. The four new
included studies were all conference abstracts; three of which
were identified from the SRNT 2021 abstract book (SYM2A,
SYM2B, PH-353; www.srnt.org/page/2021_Meeting). The fourth is
available here: dx.doi.org/10.1016/j.drugalcdep.2015.07.1091.
4 February 2021 Amended This is a Living Systematic Review. We run and screen searches
monthly. Last search date 1st February 2021. In addition to the
studies identified from our December 2020 and January 2021
searches we found one paper linked to a study already included
in the review (Lucchiari 2020), and have preliminary results from
a study listed as ongoing (Begh 2019). We will incorporate this
paper and data into the review as part of a future update.
20 January 2021 Amended This is a Living Systematic Review. Searches are run and
screened monthly. Last search date 4th January 2021. In addi-
tion to the studies identified from our December 2020 searches
we found four new completed studies, one new ongoing study
and one paper linked to a study already included in the review.
These studies and papers will be incorporated into the review
at the next update. DOIs for the four new included studies are as
follows: Ozga-Hess et al. 2019: 10.1016/j.addbeh.2019.106105;
Pulvers et al. 2020: 10.1001/jamanetworkopen.2020.26324;
Scheibein 2020: 10.1186/s12954-020-00406-y; Yingst et al. 2020:
10.1080/09540121.2019.1687835
15 December 2020 Amended This is a Living Systematic Review. Searches are run and
screened monthly. Last search date 1st December 2020. Search-
es found 3 new completed studies, 11 new ongoing studies and
9 papers linked to studies already included in the review. These
studies and papers will be incorporated into the review at the
next update. DOIs for the three new included studies are as fol-
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Date Event Description
lows: Czoli et al:10.1093/ntr/nty174; Bonevski et al: 10.1093/ntr/
ntaa143; Eisenberg et al: 10.1001/jama.2020.18889 .
20 July 2020 New citation required and conclusions
have changed
Strength of evidence increased for existing comparisons; new
comparisons added
20 July 2020 New search has been performed New searches run January 2020. 35 new studies added. Living
systematic review protocol incorporated
14 December 2016 Amended Clarification on outcome data from Adriaens - no changes to con-
clusions
23 June 2016 New search has been performed Update search run January 2016, 11 new included studies added.
Reduction removed as outcome, now covered in Harm Reduc-
tion review.
23 June 2016 New citation required but conclusions
have not changed
11 new included studies added; no changes to conclusions.
 
C O N T R I B U T I O N S   O F   A U T H O R S
All authors contributed to the writing of this review.
For this update, JHB, NL, CN, RB, PH, NR, ARB, HMR screened studies and/or extracted data.
JHB and ARB entered data for analysis.
D E C L A R A T I O N S   O F   I N T E R E S T
RB holds an NIHR grant, however this did not directly fund this current work. She is principal investigator of an ongoing study listed in
this review.
CB was principal investigator on the ASCEND e-cigarette trial reported in the Cochrane review and a co-investigator on the ASCEND II trial
and several other studies included in the review. CB has provided consultancy for J&J KK (Japan) on NRT products. CB reports research
grants from the Health Research Council of NZ, the Heart Foundation of NZ and the NZ Ministry of Health. He has recently led a project
funded by Pfizer (NZ) on chronic disease management.
ARB's work on this review has been supported by Cancer Research UK Project Award funding. This is not deemed a conflict of interest.
PH provided consultancy for and received research funding from Pfizer, a manufacturer of stop-smoking medications. He was principal
investigator on one of the trials included in this review and co-investigator on other relevant studies.
JHB has received support for this work from the Cochrane Review Support Programme and the University of Oxford's Returning Carer's
Fund. Neither of these are deemed conflicts of interest.
NL has received payment for lectures on systematic review methodology, and has been an applicant on project funding to carry out priority
setting and systematic reviews in the area of tobacco control (NIHR funded). None of this is deemed a conflict of interest.
HM has received honoraria for speaking at smoking cessation educational events and sitting on an advisory board organized by Pfizer.
CN has no known conflicts of interest.
NR has received royalties from UpToDate, Inc., for chapters on electronic cigarettes and occasional fees from academic hospitals or
professional medical societies for lectures on smoking cessation that include discussion of electronic cigarettes. Dr. Rigotti was an member
of the committee that produced the 2018 National Academies of Science, Engineering, and Medicine's Consensus Study Report on the
Public Health Benefits of E-cigarettes. She was unpaid for this work. Outside the topic of e-cigarettes, Dr. Rigotti has received honoraria
from Achieve Life Sciences for consulting about cytisine. NR is a consultant for Achieve LifeSciences, which is developing an investigational
smoking cessation medication for FDA approval (cytisine) and her institution (MGH) receives a grant from the company as a site for a clinical
trial testing the safety and eIicacy of cytisine. NR has received travel reimbursement (but no honoraria) from Pfizer for attending advisory
boards regarding varenicline. NR holds grants from NIH for research work.
Electronic cigarettes for smoking cessation (Review)









Cochrane Database of Systematic Reviews
AT's work on this review has been supported by the Cochrane Review Support Programme and the University of Oxford's Returning Carer's
Fund. Neither of these are deemed conflicts of interest.
TT has no known conflicts of interest.
S O U R C E S   O F   S U P P O R T
Internal sources
• Queen Mary University of London, UK
provides salary, oIice space and library resources for HM and PH
• The University of Auckland, New Zealand
provides salary, oIice space and library resources for CB
• University of Oxford, UK
Support from Returning Carers' Fund
External sources
• NIHR, UK
Infrastructure award for Cochrane Tobacco Addiction Group and Cochrane Incentive Award
• Cancer Research UK, UK
Cancer Research UK project award funding to support living systematic review
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
The protocol did not specify a minimum follow-up period for data on adverse events. As of the 2016 update, we have changed the Methods
section to clarify that we will exclude follow-up data at less than a week.
The original version of this review included reduction as a secondary outcome. The 2016 update removed reduction as an outcome, to
bring the review into line with other reviews of cessation treatments produced by the Cochrane Tobacco Addiction Group and to prevent
substantial overlap with the update of the Group's review of interventions for harm reduction.
As prespecified in the 2016 update, in the 2020 update we excluded non-intervention studies. In the 2020 update, we also added in an
appendix with a protocol setting out our plans to convert this review into a living systematic review in the future.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Bias;  Cohort Studies;  *Electronic Nicotine Delivery Systems;  *Nicotine  [administration & dosage];  *Nicotinic Agonists  [administration &
dosage];  Publication Bias;  Randomized Controlled Trials as Topic;  Smoking  [epidemiology];  Smoking Cessation  [*methods]  [statistics
& numerical data];  *Smoking Prevention;  Tobacco Use Cessation Devices;  Vaping
MeSH check words
Humans; Middle Aged
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